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Abstract 
The hypothalamic arcuate and paraventricular nuclei play important roles in the 
neuroendocrine regulation of systemic thyroid hormone homeostasis. However, the roles of 
other hypothalamic regions are poorly understood. Triiodothyronine (T3) is the active form 
of thyroid hormone. T3 administration to the hypothalamic ventromedial nucleus (VMN) of 
rats stimulates feeding, although the mechanism remains unclear. 
Activation and inactivation of thyroid hormones is mediated by the iodothyonine deiodinases, 
where D2 is the activating enzyme and D3 the inactivating enzyme. Recombinant adeno-
associated virus (rAAV) vectors were designed to modulate the local activity of thyroid 
hormones by over-expressing D2 (rAAV-D2) or D3 (rAAV-D3). 
Two initial investigations were carried out employing these viruses in vivo. Initially, rats 
received bilateral injections of either rAAV-D2 or rAAV-GFP into the VMN. Cumulative 
food intake and body weight were unaffected, despite a significant increase D2 enzyme 
activity. However, fasted rAAV-D2 treated rats consumed significantly more food than 
controls over the initial 2 hours of refeeding following a 12 fast. In the second investigation, 
rats received bilateral injections of either rAAV-D3 or rAAV-GFP into the VMN. 
Hypothalamic D3 mRNA and brown adipose tissue activity were both significantly increased 
in the rAAV-D3 group, which was not associated with any change in systemic thyroid 
hormone levels. This suggested that sympathetic activity had been increased, independent of 
peripheral thyroid status. 
In a final investigation, rats were challenged with a high fat diet (HFD) 17 days after iVMN 
injection of either rAAV-D3 or rAAV-GFP. The rAAV-D3 treated group gained significantly 
more weight and consumed significantly more energy than controls, per day of HFD 
treatment. The increased HFD consumption was matched with a significant increase in 
hypothalamic fatty acid synthase mRNA. 
This thesis highlights putative mechanisms by which thyroid hormones affect peripheral 
metabolism and appetite via the VMN, through interplay with neuronal fatty acid 
homeostasis. 
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Chapter 1 
Introduction 
22 
 
1.1 Energy Homeostasis 
Energy homeostasis is the process of balancing energy input with energy expenditure. 
Imbalances in the process result in either obesity or weight loss. An essential component of 
this system is the hypothalamus, which responds to circulating hormones to control energy 
consumption and utilisation via a complex network of neural circuits. 
Hormones exist within the circulation in order for the central nervous system (CNS) to 
appropriately respond to changes in the peripheral state. Compelling evidence implicates at 
least two peripheral hormones as afferent signalling molecules to the CNS which circulate in 
relation to the level of adiposity. 
1.1.1 Insulin 
Insulin is produced by pancreatic islets in response to elevated blood glucose levels. Its 
primary function is to coordinate efficient utilisation and storage of nutritional constituents 
following a meal. Levels of plasma insulin have been shown to directly correlate with body 
weight and adiposity (Bagdade, 1967). Obese animals have higher basal insulin levels and 
secrete more insulin in response to a meal than lean subjects (Woods et al., 1974). Insulin 
levels increase during periods of positive energy balance, such as during meals, and decrease 
in states of negative energy balance, such as fasting. Insulin receptor mRNA (messenger)  
and protein is found in CNS regions involved in the regulation of appetite and energy 
homeostasis (Schwartz et al., 2000). 
1.1.2 Leptin 
Since its discovery leptin has proven to be a key metabolic hormone with actions throughout 
the body. Leptin is secreted from adipocytes and circulates in plasma in proportion to the 
level of adiposity (Maffei et al., 1995). This is conveyed to the brain via leptin receptors 
(LEPR) which are expressed in the hypothalamus, where leptin acts to decrease appetite and 
increase energy (Wang, 1997). A lack of leptin in circulation signals a state of starvation to 
the hypothalamus to instigate feeding. Disruption of leptin signalling either by knock-out 
(KO) of its gene (Ob) or LEPR results in hyperphagia and extreme obesity (Chua Jr et al., 
1996, Zhang et al., 1994). 
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1.2 The Hypothalamus 
The hypothalamus links the nervous and endocrine systems by responding to plasma 
hormones that reflect the metabolic state.  It is present in the brain of all mammals including 
humans, where it lies inferior to the thalamus and superior to the brainstem in the ventral 
diencephalon. It can be anatomically divided into functional regions (nuclei), as illustrated in 
figure 1.1, which interact to modulate various processes, including food intake and energy 
expenditure. The hypothalamic area containing both the ventromedial and arcuate nuclei is an 
important area for energy homeostasis that may be referred to as the mediobasal 
hypothalamus (MBH).  
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Figure 1.1: Three dimensional diagrammatic representation of the relative positioning of the 
hypothalamic nuclei in the rat as viewed from the dorsal and caudal hypothalamus in the 
right hemisphere.  Abbreviations:  AHA, anterior hypothalamic area; ARC, arcuate nucleus; 
AV3V, anteroventral area of third ventricle; CI, capsula interna; DP, dorsal parvocellular 
subnucleus of paraventricular nucleus (PVN); DMH, dorsomedial nucleus; F, fornix; LHA, 
lateral hypothalamic area; LM, lateral magnocellular subnucleus of paraventricular nucleus; 
LPOA, lateral preoptic area; ME, median eminence; MP, medial parvocellular PVN; MPO, 
medial preoptic area; OT, optic tract; SCh, suprachiasmatic nucleus; SON, supraoptic 
nucleus; SI, substantia inomminata; ST, subthalamic nucleus; VMN, ventromedial nucleus; 
VP, ventral parvocellular subnucleus of paraventricular nucleus (Berthoud, 2002). 
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1.2.1 Arcuate Nucleus 
The arcuate nucleus (ARC) encircles the third ventricle and lies superior to the median 
eminence. It extends anterior from the optic chiasm and posterior to the mamillary bodies. 
The ARC has a semi-permeable blood brain barrier, which allows the passage of signalling 
molecules from the circulation, including leptin, insulin and ghrelin (Cone et al., 2001). In 
terms of energy homeostasis, the two most studied neuronal populations in the ARC are 
neurones co-expressing anorectic peptides cocaine-and amphetamine-related transcript 
(CART) and pro-opiomelanocortin (POMC), in addition to neurones co-expressing 
orexigenic peptides agouti related peptide (AgRP) and neuropeptide Y (NPY). 
1.2.2 Paraventricular Nucleus 
The paraventricular nucleus (PVN) is a discrete triangular cluster of neurones surrounding the 
third ventricle in the anterior hypothalamus. A large amount of evidence suggests that the 
PVN is important in the regulation of appetite control, lesions to the area result in 
hyperphagia and obesity (Fukushima et al., 1987).  Microinjection studies have shown that 
administration of orexigenic peptides to the area, including NPY (Stanley et al., 1985) and 
AgRP (Kim et al., 2000), stimulates food intake whilst anorexigenic peptide administration 
inhibits fast-induced feeding. Intracerebroventricular (ICV) administration of NPY into the 
third or fourth ventricle induces the expression of the immediate early gene c-fos in the PVN, 
indicating neuronal activation in this area (Xu et al., 1995). 
1.2.3 Ventromedial Nucleus 
The ventromedial nucleus (VMN) lies medial to the third ventricle. The VMN has been 
considered an important nucleus in energy homeostasis since the finding that lesioning the 
VMN of rats resulted in marked hyperphagia and obesity (Albert et al., 1971) which has later 
been associated with hypertriglyceridemia, hyperglycaemia and hyperleptinemia (Satoh et al., 
1997). This led to its initial definition as a „satiety centre‟, although its functional role in 
energy homeostasis has since shown to be more complex. 
The VMN is an important nucleus in the control of glucose homeostasis. A widely 
documented feature of the VMN is the presence of glucose-sensitive neurones which exhibit 
altered action potential frequency in response to glucose exposure. As extracellular glucose 
increases from 0.1 to 2.5 mM, the action potential frequency of glucose-excited neurons 
increases, whereas for glucose-inhibited neurons it decreases (Song et al., 2001). 
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The VMN is associated with several CNS regions important in energy homeostasis 
regulation. It receives input from the ARC, lateral hypothalamus, and amygdala (Elias et al., 
1998, Luiten et al., 1983, Saper et al., 1976). The VMN also contains efferent projections to 
ARC, PVN, lateral hypothalamus, DMN, amygdala, ventral tegmental area, nucleus 
accumbens, and nucleus of the solitary tract (Ter Horst and Luiten, 1987, Mcclellan et al., 
2006, Saper et al., 1976, Canteras et al., 1994, Krieger et al., 1979). It has been reported that 
ARC POMC neurones receive strong excitatory input from VMN neurones, which is 
diminished during fasting (Sternson et al., 2005). 
The VMN contains neuronal populations which differ in their biochemical properties and 
functional identities. It contains hormone receptors and neurones regulating energy 
homeostasis, including those of leptin, insulin, and melanocortins (Dhillon et al., 2006, Kang 
et al., 2004). The VMN is also marked by expression of the receptor for pituitary adenylate 
cyclase-activating peptide (PACAP) (Hawke et al., 2009), brain-derived neurotrophic factor 
(BDNF) (Wang et al., 2007), and steroidogenic fator-1 (SF-1) (Ikeda et al., 1995). 
SF-1 is a member of the nuclear hormone receptor family of transcriptional regulators, which 
demonstrates activity at multiple levels of the hypothalamo-pituitary-steroidogenic axis 
(Ikeda et al., 1995, Lynch et al., 1993). CNS expression of SF-1 is limited to and essential for 
the development of the VMN (Ikeda et al., 1995). Homozygous SF-1 KO models produce 
normal litter sizes, but die by eight days due to acute glucocorticoid deficiency and exhibit 
developmental abnormalities such as the absence of adrenal glands, gonads, and VMN 
structure (Dellovade et al., 2000, Luo et al., 1994). The effects of SF1 may be partly mediated 
by altered BDNF expression, which is colocalised with SF-1 in mouse ventrolateral VMN 
neurones (Tran et al., 2006). 
BDNF is a neurotrophin that demonstrates an essential role in hypothalamic control of energy 
homeostasis. Heterozygotic and homozygotic BDNF KO models are associated with reduced 
BDNF protein in the PVN and VMN with a concomitant increase in body weight and plasma 
leptin (Kernie et al., 2000). The BDNF receptor TrkB is also expressed in the VMN (Yan et 
al., 1997) and human patients with a de novo mutation in the TrkB gene exhibit hyperphagia 
and obesity (Yeo et al., 2004), whilst chronic overexpression of BDNF in the MBH 
stimulates energy expenditure in adult rats without affecting food intake (Cao et al., 2009). 
Recent studies have suggested that BDNF expression in the VMN is regulated by leptin and 
the melanocortins (Komori et al., 2006, Xu et al., 2003). 
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1.3 The Hypothalamopituitary Axes 
The hypothalamus interacts with the pituitary gland to regulate several physiological 
processes. Stimulation of the pituitary by hypothalamic afferents stimulates pituitary 
secretion of hormones that regulate major organ function. Two important targets regulated in 
this way are the adrenal gland and the thyroid gland, via the hypothalamo-pituitary adrenal 
(HPA) and the hypothalamo-pituitary thyroid (HPT) axes, respectively. These endocrine 
pathways regulate metabolic function both independently and synergistically. 
1.3.1 The Pituitary Gland 
The pituitary is anatomically divided into anterior and posterior sections and also the 
intermediate lobe whose function is unclear. The posterior pituitary is innervated by 
hypophyseal neurones whose cell bodies originate in the PVN and supra optic nucleus 
(SON). In contrast, the anterior pituitary is composed of a number of different endocrine cells 
including, thyrotrophs, gonadotrophs, and somatotrophs. The secretory activity of these cells 
is principally controlled by peptide-releasing hormones, which are secreted from the 
hypothalamus into the adenohypophyseal portal vasculature, which flows into the pituitary 
via the pituitary stalk. 
1.3.2 The Hypothalamo-Pituitary Thyroid Axis 
Thyrotropin-releasing hormone (TRH) is a tripeptide (Glu-His-Pro) synthesised in the 
parvicellular PVN. Following synthesis, TRH is transported to the median eminence en route 
to the anterior pituitary via the portal capillary plexus. Interaction of TRH with its receptor on 
pituitary thyrotropes induces an intracellular cascade, which triggers the synthesis, and 
release of thyroid-stimulating hormone (TSH) into the circulation. 
TSH is a 28kDa glycoprotein consisting of α and β subunits. The α subunit is common to 
other pituitary hormones, such as luteinising hormone (LH), and follicle stimulating hormone 
(FSH). Plasma TSH exerts effects in a number of tissues, although its primary action is on 
thyroid follicles, which express the TSH receptor. Upon TSH interaction with its receptor, 
intracellular cyclic adenosine monophosphate (cAMP) levels and protein kinase A activity 
are elevated. This stimulates the expression of genes involved in thyroid hormone synthesis 
and release. 
Thyroid hormones regulate pituitary TSH synthesis and release by direct and indirect 
mechanisms, with the latter being through TRH expressing hypophysiotropic neurones of the 
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parvicelular PVN (Kakucska et al., 1992). Thyroid hormones may also influence the 
synthesis of other pituitary hormones, such as growth hormone (GH) and prolactin, by 
modulating transcription of their common glycoprotein α-subunit (Madison et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Diagrammatic representation of the HPT Axis. TRH is released from the 
hypothalamus and stimulates pituitary secretion of TSH, which increases thyroidal 
production and secretion of thyroid hormones (T3 and T4). Plasma T3 and T4 form a 
negative feedback loop to the hypothalamus and pituitary where they inhibit expression of 
TRH and TSH, respectively. The hypothalamopituitary axis is subject to an additional 
negative feedback pathway, whereby TSH inhibits TRH production. 
 
T3 T4 
Thyroid 
TSH 
TSH 
TRH 
Hypothalamus 
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1.4 The Thyroid Gland 
The thyroid gland is essential to endocrine function on a number of levels. In addition to its 
primary effect on the basal metabolic rate (BMR), it is permissive for multiple hormonal 
pathways, particularly the adrenal axis, and is becoming increasingly recognised as an 
essential molecule for brain function. 
1.4.1 Anatomy 
The thyroid gland lies caudal to the larynx and adheres to the trachea. Its functional unit is the 
follicle, whose lumen is colloidal, composed almost entirely of thyroglobulin. The major 
products of the thyroid are thyroxine and triiodothyronine, which are synthesised and 
released following hypothalamo-pituitary stimulation. It is these products which feedback to 
the hypothalamus and pituitary gland to regulate their own circulating levels. 
1.4.2 Hormone Synthesis 
Inorganic iodine (I
-
) is transported into follicle cells via a basolateral membrane Na
+
 
symporter and oxidised (I
+
) by thyroperoxidase at the lumen, in the presence of H202. I
+
 is 
used to iodinate tyrosine residues of colloidal thyroglobulin. Monoiodotyrosine (MIT) and 
diiodotyrosine (DIT) are formed after single or double iodination respectively. These residues 
are then coupled to yield precursors of biologically active thyroid hormone. Thyroid 
hormones are then liberated from thyroglobulin following lysosomal hydrolysis. T4 is 
generated from DIT-DIT coupling, and MIT-DIT formation yields T3. 
1.4.3 Plasma Thyroid Hormone 
Thyroid hormones have widespread importance in early life, being critical for differentiation, 
growth, and development. In adulthood, these hormones are major regulators of the BMR, 
oxygen consumption and modification of adenosine triphosphate (ATP) turnover. 
Thyroxine (T4) was first isolated in 1915. Thirty-seven years later, triiodo-L-thyronine (T3) 
was detected in human plasma (Gross and Pitt-Rivers, 1952). Its ability to control goitre in 
thiouracil-treated rats brought thyroid hormone into focus and in the subsequent years, the 
roles of thyroid hormone in energy homeostasis and development were discovered with its 
functional significance receiving greater appreciation. 
In peripheral tissues, thyroid hormone activity is regulated by local enzymatic conversion, 
and exerted via interaction with nuclear receptor complexes. The most physiologically 
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significant thyroid hormone molecules are T4 and T3. Both consist of two covalently linked 
tyrosine molecules giving a double aromatic ring structure to which iodide (I
-
) ions are added. 
Thyroid hormone nomenclature depends on the number of iodine atoms present on the 
iodothyronine molecule, i.e. the possesion of four I
-
 is what defines the T4 molecule. 
In the circulation, thyroid hormone is bound to serum proteins. Approximately 0.015% of T4 
and 0.33% of T3 are free in plasma, with the majority bound to thyroxine-binding globulin 
(TBG). Healthy (euthyroid) plasma concentrations range from 2.5 – 5.3 pmol/L free T3 
(fT3), and 10-23 pmol/L free T4 (fT4). The euthyroid range of plasma TSH is 0.27 - 4.2 
mU/L. Disease of the thyroid gland is generally indicated when circulating levels of these 
hormones lie outside of their respective euthyroid range. 
1.4.4 Thyroid Gland Pathophysiology 
Elevation of plasma thyroid hormone above the euthyroid range is termed as thyrotoxicosis. 
Over-production of thyroid hormone by the thyroid gland denotes hyperthyroidism, where 
patients often present with heat intolerance, tachycardia, hyperphagia and weight loss. 
Hypothyroidism, conversely, is caused by thyroid under-activity and is principally associated 
with weight gain, cold intolerance, and fatigue.  
Thyroid disease states are generally associated with disruption of HPT feedback regulation. 
Primary thyroid disease defines improper activation of the thyroid gland, secondary thyroid 
disease concerns pituitary release of TSH, and tertiary thyroid disease describes inappropriate 
signalling by the thyroid hormone-responsive hypothalamus. 
Thyroid hormone resistance is a syndrome of hyposensitivity to thyroid hormone. Plasma 
TSH, T3, and T4 are normally elevated, although patients present symptoms of both 
hypothyroidism and hyperthyroidism. The level of thyroid hormone resistance may vary 
across tissues. Pituitary resistance to thyroid hormone induces signs of hyperthyroidism in 
peripheral tissues, suggesting that the impairment of thyroid hormone signalling is limited to 
the pituitary gland (Refetoff et al., 1993), which inappropriately stimulates thyroid gland 
activity.  
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1.5 Intracellular Thyroid Hormone 
Steroid hormones are known to exert their effects via interactions with intracellular receptors. 
The classical steroid hormone receptors include the glucocorticoid, mineralocorticoid, 
oestrogen, androgen, and progesterone receptors. The resulting receptor-ligand complexes 
either translocate to the nucleus to exert slow, genomic effects or mediate rapid, non-genomic 
effects via intracellular signalling pathways. 
The primary intracellular effect of thyroid hormone occurs in a similar fashion to that of the 
steroid hormones, whereby it is achieved through the interaction of T3 with the intracellular 
thyroid hormone receptor (TR). 
1.5.1 Thyroid Hormone Receptors 
Two major TR isoforms, encoded on separate genes, were identified and designated as TRα 
and TRβ. Additional heterogeneity of TRs occurs due to alternative splicing. 
Splicing of the initial TRα mRNA transcript generates two mature mRNAs which code for 
two distinct proteins: TRα1 and TRα2. This splice variation is critical to thyroid hormone 
function as it renders c-erbAα2 unable to bind its T3 ligand, despite maintaining affinity for 
target genes (Lazar et al., 1988). This highlights a mechanism of antagonism in TR arising 
from the same genetic locus and is an important physiological feature of this system. 
TRβ1 and TRβ2 are both derived from the TRβ gene. This gene contains two promoter 
regions whose activation dictates whether either or both receptor variants are synthesised. 
Both receptors bind T3 and target genes with equal affinity and are regulated by pituitary-
specific transcription factors (Wood et al., 1996). 
All forms of thyroid hormone receptor are ubiquitously expressed in rat tissues (Hodin et al., 
1990). TRα-1 has highest expression levels in skeletal muscle and adipose tissue, whereas 
TRβ-1 is dominant in the brain, liver, and kidney. TRβ-2 has tissue specific expression in the 
anterior pituitary and specific areas of the hypothalamus (Cook et al., 1992). 
1.5.2 Genomic Actions of Thyroid Hormone 
Thyroid hormone enters the cell before translocating to the nucleus to interact with its nuclear 
receptor. Active TR is found in the nucleus either as a homodimer or as a heterodimer, bound 
to the retinoid X receptor (RXR). T3 efficaciously binds to this heterodimer complex which 
sheds corepressor factors and recruits coactivators following ligand binding. This TR-T3 
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complex (holoTR) then interacts with the thyroid-response element (TRE) which is present in 
the promoter of genes targeted by thyroid hormone (Brent, 1994). 
HoloTR functions like other steroid hormone receptors by stimulating or suppressing the 
transcription of target genes, however, the TR mechanism is unique in that unliganded TR 
(apoTR) also interacts with TRE to modulate transcription of T3-responsive genes. It has 
been reported that holoTR and apoTR modulate transcription in opposite fashions to enable 
differential regulation of gene expression, depending on the temporal level of T3 activity 
(Brent et al., 1989). 
1.5.3 Non-Genomic Actions of Thyroid Hormone 
In addition to its well characterised effects on gene expression, thyroid hormone also elicits a 
number of non-genomic effects to rapidly alter cellular BMR. The non-genomic roles for 
thyroid hormone are concerned with modulation of cellular basal activity and are mediated 
through its interactions with plasma membrane receptors and signal transduction pathways. 
The cell surface receptor, integrin αVβ3, is a heterodimeric protein which, following its 
stimulation by T3, activates mitogen-activated protein kinase (MAPK). Activated MAPK 
then translocates to the nucleus to dissociate TRβ1 from its co-repressors (Bergh et al., 2005). 
Optimal activation of TRβ1 requires its T3 ligand, however, evidence of this MAPK 
interaction suggests that nuclear thyroid hormone is not always required to elicit a response 
(Davis et al., 2008). 
Further to its phosphorylation and activation of TRβ1, this T3-activated MAPK pathway also 
leads to the phosphorylation and nuclear translocation of other nuclear proteins (Davis et al., 
2008). In this manner, it is hypothesised that thyroid hormone acts permissively in preparing 
other nuclear hormone receptors for interactions with their natural ligands. 
Another important non-genomic effect of T3 is its modulation of Na
+
/K
+
 ATPase insertion 
into the plasma membrane, which has been highlighted in rat alveolar cells (Lei et al., 2003). 
This is particularly important in the case of neurophysiology as these proton pumps are the 
point of regulation in generation of the axonal action potential. 
1.5.4 Other RXR Partners 
Cholesterol, fatty acids, fat-soluble vitamins and various lipids are absorbed from the diet and 
serve as precursors for nuclear receptor ligands. These lipids require activation by enzymes in 
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the gastrointestinal tract before being transported to tissues where they mediate their effects 
(Chawla et al., 2001). 
The receptors for these ligands constitute a nuclear receptor paradigm whereby adopted 
orphan nuclear receptors heterodimerise with RXR to modulate cellular function. Peroxisome 
proliferator-activated receptors (PPAR) interact with fatty acids, liver-X-receptors (LXR) 
interact with oxysterols, farsenoid-X-receptors (FXR) interact with bile acids and steroid 
xenobiotic receptors (SXR) interact with xenobiotics (Chawla et al., 2001). Increased activity 
of these RXR partners has been linked with impaired thyroid hormone signalling, owing to 
competition for the RXR heterodimer, genomic binding sites and transcriptional cofactors 
(Liu and Brent, 2010). 
1.5.5 Iodothyronine Deiodinases 
Although one would assume that thyroid hormone effect should be relative to its plasma 
concentration, such potent molecules require strict regulation in order to control metabolic 
rate. Plasma levels of thyroid hormones do not exhibit diurnal patterns of secretion like other 
essential hormones. Instead, a physiological mechanism exists to control the metabolic 
activity of specific tissues, without the need to drastically increase thyroid gland output. 
The thyroid hormone T4 requires a molecular modification before it can efficiently interact 
with its receptor. An iodide molecule can be removed from specific sites on the aromatic 
rings of T4 with the targeted site dictating the biological activity of the product. Outer ring 
deiodination of T4 molecule yields biologically active T3, whereas inner ring deiodination 
produces reverse T3 (rT3) molecule, which exhibits lower affinity for TR (Braverman, 1990). 
These catabolic reactions are mediated by a group of selenoenzymes, known as the 
iodothyronine deiodinases, which may be up or down-regulated in specific tissues in response 
to metabolic requirements, such as cold exposure and fasting (Alkemade, 2010). Further to 
their transcriptional regulation, the deiodinases undergo post-translational modifications. 
There are three classes of deiodinases, all of which have unique genetic origins (Dio1, Dio2, 
Dio3) and vary in their iodide targets and kinetic properties (Figure 1.3). 
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Figure 1.3:  The products of iodothyronine deiodination. Removal of iodide from the outer 
phenolic ring by D2 produces active T3 (A), whereas removal of iodide from the inner 
phenolic ring by D3 produces inactive rT3 (B). Rings highlighted blue indicate those which 
have been deiodinated. 
1.5.5.1 Iodothyronine Deiodinase I 
Iodothyronine deiodinase I (D1) can deiodinate either the inner or outer ring of 
iodothyronines and is thought to be responsible for the majority of T4 to T3 conversion in 
circulation. Tissues with a high level of D1 expression include the liver, kidney, lung, 
pituitary gland and thyroid gland. The preferential substrates for D1 are rT3 and conjugated 
thyroid hormone, which highlights its important role in the degradation of circulating thyroid 
hormone metabolites (Chopra, 1996). D1-generated T3 in the liver and kidney rapidly 
equilibrates with plasma levels, which is primarily due to residence of D1 at the cell 
membrane (Toyoda et al., 1995). D1 is expressed in the rat, but not human CNS. 
D1 is sensitive
 
to inhibition by high concentrations of iodothyronine substrates (of which rT3 
is the most potent), polythiouracil (PTU), catecholamine agonists and several other 
polyphenol molecules, including flavonols, isoflavones, aurones and calcones. 
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D1 KO models exhibit elevated plasma T4 and rT3 with euthyroid levels of plasma TSH and 
T3. This suggests compensatory mechanisms exist for the regulation of plasma thyroid 
hormone. Notable features of these models include increased faecal excretion of 
iodothyronines, indicating impaired clearance of thyroid hormone metabolites for which D1 
is principally responsible (Schneider et al., 2006). 
1.5.5.2 Iodothyronine Deiodinase II 
The metabolically active T3 molecular structure is 3,3‟5 triiodo-L-thyronine, which is formed 
following  deiodination of T4 at the C5‟ position of its outer ring. This reaction is catalysed 
by iodothyronine deiodinase II (D2) which is expressed across a range of tissues to regulate 
intracellular T3 levels. Where D1 is important in producing T3 for export into the plasma, D2 
is considered responsible for maintaining specific tissue levels given that its affinity for T4 is 
approximately 3 fold higher than that of D1 (Richard et al., 1998). 
D2 is retained in the ER and does not reach the golgo apparatus during its trafficking This 
provides an ideal locus for T3 roduction where it is in close proximity to the nucleus (Zeöld 
et al., 2006). D2-generated T3 has a much longer cellular residence time than T3 generated 
by D1, which highlights its importance to intracellular thyroid hormone activity. This is 
illustrated by the finding that almost total thyroid hormone receptor saturation is witnessed in 
cells of the cerebral cortex that express D2 (Burmeister et al., 1997). 
1.5.5.3 Iodothyronine Deiodinase III 
Iodothyronine deiodinase III (D3) selectively dehalogenates the inner ring at its C5 position 
to produce inert hormones rT3 and T2 from T4 and T3, respectively. D3 displays 3 orders of 
magnitude higher affinity for thyroid hormones than D1 underlining its role as the principal 
thyroid hormone inactivator (Richard et al., 1998). It has been reported that D3 functions as a 
homodimer (Sagar et al., 2008). Following its translation, D3 is internalised at the plasma 
membrane and integrates with endosomal vesicles in a process of constant recycling between 
endosomal storage and membrane-association (Baqui et al., 2003). 
D3 is highly expressed in the CNS in adulthood, in addition to the skin, ear, eye, placenta and 
foetal tissues. During early postnatal life, alterations in the expression of D3 are critical for 
maturation of the HPT axis (Hernandez et al., 2006a). D3 activity is affected by substrate 
inhibition in the rat brain (Tu et al., 1999), where it is up-regulated in response to thyrotoxic 
doses of T3 (Esfandiari et al., 1992). D3 is resistant to PTU inhibition and exhibits higher 
affinity for T3 than for T4. 
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1.5.5.4 Physiological Regulation of Iodothyronine Deiodinases 
It is not surprising that the activities of the deiodinases are subject to tight physiological 
regulation given the profound effects of their thyroid hormone products. The substrate 
affinities of D2 and D3 are approximately three-fold higher than that of D1, which underlines 
the instrumental role that these deiodinases play in regulating TH activity and the efficiency 
by which they achieve this. 
Static retention of D2 at the endoplasmic reticulum (ER) enables T3 to be generated in the 
cytosol with optimal access to the nucleus, where it mediates many of its effects. It has been 
reported that homodimerisation of D2 is critical for catalytic activity (Sagar et al., 2008). 
Conversely, the  subcellular localisation of D3 at the plasma membrane allows instant 
deiodination and consequential inactivation of thyroid hormone upon its entry into the cell 
(Baqui et al., 2003). These respective cellular localisations provide an efficient mechanism in 
which incoming thyroid hormones are readily inactivated by the cell in cases of D3 
upregulation, whilst D2 is in adequate proximity to the nucleus to offer its T3 product to its 
receptor and allow entry of the heterodimeric complex. 
The half-lives of D1 and D3 have been reported as being several hours  whereas the D2 half-
life is much less at around twently minutes (Gereben et al., 2000). This highlights a key 
feature of the D2 pathway as being strict physiological regulation of its activity. This is 
mediated by a variety of factors, such as feedback from thyroid hormones themselves (Sagar 
et al., 2007). Whilst D1 and D3 are primarily regulated by thyroid hormones at the 
transcriptional level, D2 is subject to post-translational regulation by ubiquitination (Tu et al., 
1999, Koenig, 2005, Gereben et al., 2000). This ubiquitination pathway involves complex 
interplay between a number of elements, such as the hypoxic cascade and the hedgehog 
family of transcription factors, as outlined in figure 1.4 which summarises the key features of 
the iodothyronine deiodinases. 
In addition to thyroid hormones, the expression of the deiodinases is regulated by numerous 
factors. Catecholamines and glucocorticoids are known modulators of D2 and D3 (Araki et 
al., 2003, Coppola et al., 2005, Song and Oka, 2003, Darras et al., 1996, Van der Geyten and 
Darras, 2005, Van der Geyten et al., 1999), which highlights an important and deep 
association between the thyroid pathway and other steroidogenic factors. The deiodinases are 
also regulated by the physiological state, where D2 is upregulated by cold exposure and food 
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consumption, whilst D3 is upregulated by inflammatory pathways and the hypoxic response 
(Simonides et al., 2008, Boelen et al., 2005, Boelen et al., 2008). 
 
Parameter D1 D2 D3 
Molecular Weight (Da) 29000 30500 31500 
Preferred Substrates rT3, T3 T4, rT3 T3, T4 
Km 10-7 - 10-6 10-9 10-9 
Half-life Hours ~20 minutes Hours 
Sub-cellular Location Plasma membrane Endoplasmic reticulum Plasma membrane 
Response 
to T3 
Transcriptional ↑↑ ↓ ↑↑ 
Post-translational ? ↓↓↓ ? 
 Induced by: T3 
Cold, hyperphagia, 
catecholamines, bile 
acids, cAMP 
Tissue injury, 
infection, growth 
factors, MAPK 
activators, HIF-1α 
Repressed by: Fasting, illness 
T3, hedgehog family, 
WSB1 
Growth hormone, 
glucocorticoids, 
Physiological Role 
Clearance of 
metabolites 
Thermogenesis, 
development, intracellular 
and plasma T3 source 
Development, T3 and 
T4 clearance, 
avaoidance of 
intracellular T3 
production 
 
Figure 1.4: Summary of features of the iodothyronine deiodinases, adapted from (Bianco and 
Kim, 2006). T3, triiodothyronine; rT3, reverse T3; T4, thyroxine; cAMP, cyclic adenosine-
monophosphate; MAPK, mitogen-activated protein kinase; HIF-1α, hypoxia-inducible factor 
1 alpha; WSB1, WD repeat and SOCS box-containing protein 1 
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1.5.5.4 Selenocysteine Insertion 
 The deiodinases are all selenozymes, which means that they require selenium at their active 
sites for efficacy. Selenium is an essential trace element that is incorporated into proteins as 
selenocysteine (Sec), the 21st amino acid. Selenocysteine is similar to cysteine in terms of its 
structure, where the principal difference is the replacement of a thiol group with a selenol 
group. This selenol group is advantageous in offering greater catalytic activity to 
selenoenzymes by virtue of its higher ionisation state at physiological pH. 
Sec is encoded by a UGA codon, which would normally signal the termination of translation. 
In order to translate Sec from this codon, rather than a termination signal, the selonocysteine 
insertion sequence (SECIS), an RNA element of around sixty nucleotides in length, is 
required to decode UGA with Sec-tRNA (Hoffmann and Berry, 2005). In the iodothyronine 
deiodinases genes, this element is found in the 3‟ untranslated region (UTR) where it forms 
the secondary hairpin-loop structure which interacts with the selenocysteine insertion 
machinery (Buettner et al., 1998). The advantage of having SECIS in the 3‟ UTR is that this 
avoids the need to create such a structure in the mRNA itself. 
Mammalian Sec incorporation requires a Sec-specific translation elongation factor 
(eEFSec/eSelB) which specifically binds to the Sec-tRNA only (Fagegaltier et al., 2000). 
Two binding proteins have also been identified as being important for Sec insertion, which 
are SECIS-binding protein 2 (SBP2) and ribosomal protein L 30 (rpl30) (Kinzy et al., 2005, 
Copeland et al., 2000). It has been proposed that the Sec-insertion machinery involves a 
complex of Sec-tRNA, the SECIS element, eEFSec and SBP2 (Driscoll and Copeland, 2003). 
The precise model for selenocysteine insertion remains to be elucidated, although a basic 
representation is illustrated in figure 1.5. 
Selenoprotein synthesis in vivo is highly selenium-dependent, which can limit deiodinase 
overexpression when selenium availability is limited (Driscoll and Copeland, 2003, Hawkes 
and Keim, 2003). Selenocysteine incorporation is not an efficient process and the 
replacement of the UGA codon in D1 with a cysteine codon yields up to 400 fold more D1 
protein (Berry et al., 1992). Mutations in the SECIS machinery have been reported in humans 
who display abnormal thyroid hormone metabolism owing to reduced D2 activity 
(Dumitrescu et al., 2005). 
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Figure 1.5: The selenocystein insertion machine. The SECIS element in the 3‟UTR forms a 
hairpin-loop structure containing a „core‟ of four quarternary non Watson-Crick base 
pairings, which is bound by SBP2. The eEFSec-associated Sec-tRNA interacts with this 
complex and its insertion at the UGA site is chaperoned by this complex. Adapted from 
(Driscoll and Copeland, 2003). 
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1.5.5.5 Deiodinase Polymorphisms 
Two D1 polymorphisms (D1-C785T and D1-A1814G), affecting serum T3:rT3 ratio in 
healthy subjects, have been identified (Peeters et al., 2003). Both polymorphisms occur in the 
3‟ UTR which indicates that the diseases result from impaired mRNA stability. Opposing 
clinical presentations have been observed in these polymorphisms where D1-C785T results in 
decreased serum T3:rT3 ratio, whilst the opposite has been noted with D1-A1814G (Peeters 
et al., 2003). This suggests that D1-C785T results in decreased D1 activity and D1-A1814G 
results in increased D1 activity. The involvement of the SECIS has been implicated here, 
which lies downstream of the Dio1 coding region (Bianco et al., 2002). 
An interesting observation has been noted in studies of deiodinase polymorphisms, regarding 
the varying contributions of D1 and D2 to serum T3 with age. The D1-C785T polymorphism 
has been associated with reduced serum T3:rT3 ratio in the aged, but is not as effective in 
younger patients (Peeters et al., 2006). Conversely, a D2-ORFa-Gly3Asp polymorphism in 
the Dio2 gene affects serum T3:T4 ratio young, but not elderly patients (Peeters et al., 2005). 
This indicates that, in addition to its important role in maintaining local T3 concentrations, 
D2 is also important for maintain serum T3 concentrations in early life, but D1 becomes more 
important with age. 
The first D2 polymorphism to be detected was D2-Thr92Ala which is associated with insulin 
resistance rather than plasma thyroid hormone levels (Mentuccia et al., 2002). The 
mechanism is not well established, but is thought to involve D2 activity in skeletal muscle 
and brown adipocytes in humans (Bianco et al., 2002). The pathways proposed to be involved 
include the regulation of T3-stimulated lipolysis and sympathetic innervation of white 
adipose tissue, originating from hypothalamic D2 (Viguerie et al., 2002, Romijn and Fliers, 
2005). 
The only D3 polymorphism to be identified, D3-T1546G, is located in the 3‟ UTR of Dio3 
(Peeters et al., 2003). This does not appear to manifest in thyroid hormone homeostasis and 
the specific effects are not well characterised. 
1.5.6 Thyroid Hormone Transporters 
Thyroid hormone must be transported across the plasma membrane before it may interact 
with deiodinases in the cytosol and receptors of the nucleus. The hydrophobic nature of 
thyroid hormone molecules may account for some of its entry into the cell by passive 
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diffusion, although specific carriers belonging to organic anion and amino acid transporter 
families have been identified as significant mediators of thyroid hormone entry into the cell. 
1.5.6.1 Organic Anion Transporters 
Organic anion transporters (OAT) mediate the uptake of iodothyronines and their 
sulphonated derivatives. OATs are members of the Na+/tauchlorate cotransporting 
polypeptide and Na
+
 independent organic anion transporting polypeptide (OATP) families. 
Since other NTCP members are exclusively expressed in the liver, it is OATP transporters 
that have a prominent role in the transport of thyroid hormone. The particularly interesting 
OATP members with respect to thyroid hormone transport are OATP14 and OATP1C1, the 
latter of which is highly expressed in human brain (Pizzagalli et al., 2002). It is thought to 
preferentially transport the T4 molecule and based on its wide expression in CNS capillaries, 
it is assumed to play an important role in T4 penetration of the blood-brain barrier (BBB) 
(Jansen et al., 2005). 
1.5.6.2 Amino acid Transporters 
With thyroid hormone being composed of covalently bound amino acids it is logical that 
amino acid transporters facilitate their membrane passage. The monocarboxylate transporter 
(MCT) family comprise 14 identified members, with MCT8 being important in thyroid 
hormone transport. MCT8 is predominantly expressed in neuronal cells and T3 appears to be 
its preferential ligand (Friesema et al., 2008). 
In humans, mutations of the MCT8 gene result in resistance to thyroid hormone and impaired 
CNS development due to central hypothyroidism (Schwartz et al., 2005). This X-linked 
condition is termed Allan-Herndon-Dudley Syndrome with which six large families have 
been identified (Allan et al., 1944, Bialer et al., 1992, Friesema et al., 2004). The abnormal 
transport of thyroid hormones in these patients is highlighted by the presence of elevated 
plasma fT3 levels with reduced plasma fT4 levels. This underlines the importance of MCT8 
for T3 transport and the extent of its preference for this iodothyronine molecule. 
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Figure 1.6: The process of thyroid hormone entry into the cell, subsequent deiodination and 
eventual genomic interaction within the nucleus. Thyroid hormones T4 and T3 enter the cell 
via their respective transporters OATP1C1 and MCT8. D3 is localised to the plasma 
membrane and readily inactivates entering iodothyronines upon entry into the cell. D2 is 
localised to the endoplasmic reticulum, which allows it to produce active T3 ligand in close 
proximity to the nucleus. T3 enters the nucleus, where it binds either TR or TR-RXR 
heterodimer. The T3-TR-RXR heterotrimeric complex efficaciously mediates its effects on 
thyroid-responsive genes through interaction with the thyroid response element. T4, 
Thyroxine; T3, triiodothyronine; T2, diiodothyronine; D2, iodothyronine deiodinase II; D3, 
iodothyronine deiodinase III; OATP1C1, organic anion transporter 1C1; MCT8, 
monocarboxylate transporter 8; ER, endoplasmic reticulum; TR, thyroid hormone receptor; 
RXR, retinoid X receptor; TRE, thyroid response element. 
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1.6 Thyroid Hormone and the Metabolic Rate 
In a fully relaxed subject at room temperature, energy expenditure equals the basal metabolic 
rate. The BMR is the amount of energy expended while at rest in a neutrally temperate 
environment with the resultant heat defined as obligatory thermogenesis. In states of thyroid 
dysfunction, alterations in energy homeostasis occur. It has long been accepted that thyroid 
hormone affects the BMR by modulating cellular metabolic cycles, through targets such as 
Na
+
/K
+
 symporters and permissive interactions with steroid hormone receptors. However, in 
addition to this well defined metabolic role in peripheral organs, there is growing interest in 
how thyroid hormone regulates energy homeostasis via the CNS, with much focus on the 
hypothalamus. 
1.6.1 Metabolic Pathways 
T3 is an essential regulator of metabolic pathways with varying effects across peripheral 
tissues. The iodothyronine deiodinases locally control thyroid hormone effects by influencing 
its intracellular concentration, whilst expression of specific TR isoforms may vary across 
tissues. These features enable the metabolic rate in specific tissues to be modulated 
independent of plasma thyroid hormone levels. Two important metabolic pathways affected 
by thyroid hormone include fatty acid metabolism and glucose metabolism, which culminate 
in the synthesis of ATP. 
1.6.1.1 Glucose Metabolism 
Glucose homeostasis is influenced by thyroid hormone where an excess of T3 stimulates 
glucose uptake in muscle, glucose production in the liver and impairs glucose-stimulated 
insulin secretion. 
T3 principally affects muscle glucose metabolism by stimulating glycolysis and the insertion 
of glucose transporter 4 (GLUT4) into the plasma membrane of myocytes (Leijendekker et 
al., 1987), although ATP production remains constant due to upregulation of UCP2 and 
UCP3 (Short et al., 2001). T3 is further linked to glucose metabolism through its regulation 
of carbohydrate response element binding protein, a basic helix-loop-helix leucine zipper 
transcription factor, which upregulates glycolytic and lipolytic enzymes in response to 
glucose and insulin. The net effect of these processes is a potent increase in oxygen 
consumption and thermogenesis. 
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The hyperthyroid state is generally associated with impaired glucose tolerance despite the 
characteristic reduction in body fat increased fuel oxidation. This may be, in part, due to the 
effect of holoTR on pancreatric islets, which impairs glucose-stimulated insulin secretion. T3 
enhances hepatic glucose production by promoting glycogenolysis and gluconeogenesis. In 
thyrotoxic rats, endogenous glucose production was increased by 45%, with concomitant 
upregulation of hepatic phosphoenol pyruvate carboxykinase (PEPCK), a rate-limiting 
enzyme of hepatic gluconeogenesis (Klieverik et al., 2008). 
1.6.1.1 Fatty Acid Metabolism 
T3 treatment in rats stimulates lipolysis as a result of increased fatty acid ß oxidation, where 
it augments catecholamine stimulation of lipolysis. T3 upregulates hormone-sensitive lipase 
(HSL) and inhibits the expression of cAMP phosphodiesterase, thereby increasing intracellular 
cAMP signalling to lipolytic pathways (Conti et al., 1995, Oppenheimer et al., 1991). 
Lipogenesis is also stimulated by T3, which is important in the control of cholesterol 
homeostasis. T3 treatment stimulates the expression of the low density lipoprotein receptor 
and sterol regulatory element binding proteins (SREBPs), which interact with a number of 
lipogenic enzymes (Brenta et al., 2007, Baxter and Webb, 2009). Hypercholesterolaemia is a 
common symptom of hypothyroidism, marked by elevated serum LDLs and decreased 
hepatic lipase activity, which can be ameliorated by thyroid hormone replacement therapy 
(Brent, 1994, Packard et al., 1993). 
Fatty acid metabolism is modulated by thyroid hormone, where the expression of several 
enzymes of this metabolic pathway is affected, including malic enzyme, glucose-6-phosphate 
dehydrogenase (G6PDH), acetyl CoA carboxylase (ACC) and fatty acid synthase (FAS) 
(Oppenheimer et al., 1995). 
The expression of the SREBP enzymes is regulated by thyroid hormones, where SREBP-1c is 
repressed and SREBP2 is induced by holoTR signalling (Shin and Osborne, 2003, Hashimoto 
et al., 2006). The SREBPs affect the expression of a range of enzymes involved in cholesterol 
and fatty acid synthesis, including FAS and ACC. SREBP function is also regulated by 
thyroid hormone in an indirect manner. SREBP homodimers recognise the sterol-response 
element (SRE) on target genes, some of which have tandem arrangement of the SRE and 
TRE, which positions them in close proximity (Bengoechea-Alonso and Ericsson, 2007). 
This is an important feature in ACCA expression, which is enhanced by the formation of a 
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tetrameric complex between SREBP-1 and TR-RXR, which stabilises SREBP-1 on the SRE 
(Zhang et al., 2003). 
Thyroid hormone signalling has been implicated in the negative regulation of PPAR 
signalling. T3 and PPARs combine to modulate a variety of processes in fatty acid 
metabolism, such as the stimulation of β oxidation by carnitine palmitoyl transferase 1 alpha 
(CPT-1α) (Liu et al., 2007). Unliganded TR can inhibit the effects of PPAR by competing for 
RXR and occupying the PPAR-response element (PPRE) present on its target genes 
(Lemberger et al., 1996). Furthermore, treatment with a PPARα agonist can ameliorate the 
impaired glucose-stimulated insulin secretion associated with the hyperthyroid state, which 
highlights the complex interplay between thyroid hormone, fatty acid signalling and glucose 
homeostasis (Holness et al., 2008). 
1.6.1.3 Adenylate Charge 
T3 modulates cellular adenylate charge through the stimulation of ATP consuming proteins, 
such as the Na
+
/K
+
 or Ca
2+ 
ATPases (Davis and Blas, 1981), and also stimulation of ATP 
synthesising machinery. Oxidation of fuels, such as glucose and fatty acids, yields electrons 
in the form of reduced nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2). These molecules serves as carriers for electrons to enter the 
mitochondria, where they feed into the electron transport chain a series of protein complexes 
located in the mitochondrial inner-membrane. The movement of electrons along the electron 
transport chain produces the proton motive force. This electrochemical proton gradient is 
harnessed by ATP synthase to drive ATP synthesis (Lehninger et al., 2005). 
1.6.2 Brown Adipocyte Thermogenesis 
Thyroid hormone also plays a fundamental role in „adaptive‟ thermogenesis (Lowell and 
Spiegelman, 2000). Adaptive thermogenesis in larger mammals was historically thought to be 
mediated by muscle-shivering and responses to dietary intake, with smaller mammals 
demonstrating a higher level of dependence on a specialised fat cell lineage, known as brown 
adipose tissue (BAT). However, recent evidence has suggested that BAT thermogenesis is 
also physiologically significant to humans and may protect against obesity (van Marken 
Lichtenbelt et al., 2009, Cypess et al., 2009, Virtanen et al., 2009). 
The net effect of BAT thermogenesis is a decline in metabolic efficiency, causing cellular 
respiration to produce heat rather than replenish energy supplies. This serves a physiological 
46 
 
purpose to provide thermal energy to distant tissues via the circulatory system. BAT activity 
depends on nutrient supply and its activation by the sympathetic nervous system. 
The uncoupling proteins (UCPs) are members of the mitochondrial anion-carrier proteins. 
There are five UCP homologues (UCP1-5) of which UCP2 and UCP3 share high sequence 
identity with UCP1. Whilst UCP1 is unique to BAT, UCP2 and UCP3 demonstrate a diverse 
expression pattern. The physiological role of UCP1 in adaptive thermogenesis is well 
defined, however, the specific roles of the other UCP homologues is not entirely clear. 
Uncoupling protein 1 (UCP1) can be upregulated, to interfere with ATP synthesis, by 
peroxisome proliferator-activated receptor γ (PPARγ), co-activator 1 (PGC1), noradrenaline-
stimulated cAMP response element-binding protein (CREB) phosphorylation (Thonberg et 
al., 2002, Puigserver et al., 1998) and thyroid hormone. Transcribed UCP1 translocates to the 
mitochondrial membrane, where it allows protons to re-enter the matrix for further respiration 
as opposed to driving ATP synthase activity. This dissociates the electron transport chain 
from ATP synthesis, which dissipates electrochemical energy as heat. 
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1.7 Hypothalamic Thyroid Hormone 
Thyroid hormone has major effects on the developing brain in utero and during neonatal 
development. Studies in hypothyroid rats have shown that absence of thyroid hormone causes 
diminished axon and dendritic growth in various the neocortex, hippocampus, and cochlea . 
However, in adult mammals the central role of thyroid hormone is primarily concerned with 
the control of energy homeostasis owing to its variety of interactions with the hypothalamus. 
Hypothalamic thyroid hormone is critical to the regulation of energy homeostasis, for which 
it provides important regulatory signals across a number of pathways. D2 is highly expressed 
in specialised glial cells, known as tanycytes, which line the floor and intralateral walls of the 
third ventricle (Lechan and Fekete, 2007). This location is of physiological relevance with 
regards to the third ventricle cerebrospinal fluid (CSF) being a source of T4 from which the 
thyroid hormone signal is transduced to the hypothalamus or pituitary. Following its 
activation by D2 in tanycytes, T3 enters neighbouring cells in a paracrine fashion to interact 
with its nuclear TR (Freitas et al., 2010). D3 expression in the CNS is primarily neuronal (Tu 
et al., 1999), thus intraneuronal thyroid hormone is readily inactivated upon upregulation of 
D3 (figure 1.5). 
The myriad effects of thyroid hormone on peripheral tissues require localised regulation by 
the deiodinases and this is also relevant to the CNS. Hypothalamic thyroid hormone has been 
identified as a critical regulator of various regulatory processes including; the HPT axis, 
torpor, the gonadal axis and appetite. 
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Figure 1.8: Mechanism of thyroid hormone action in the brain. T4 is transported into 
tanycytes by OATP1C1, where it is deiodinated to give the active T3 molecule. T3 is then 
exported from the glial cell by MCT8 into extracellular space before entering neighbouring 
neurones via MCT8. D3 enzyme present at the plasma membrane is able to inactivate T3, 
therefore upregulation of this deiodinase can block the neuronal effects of T3 (Freitas et al., 
2010). 
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1.7.1 HPT Feedback 
Plasma levels of thyroid hormone are maintained within a physiological range by negative 
feedback to the hypothalamus, whereby T3 represses the transcription of TRH to reduce 
thyroid gland activity. In the fasted state, D2 is upregulated in the hypothalamus 
approximately 2-fold to increase local T3 availability and downregulate TRH (Diano et al., 
1998), which ultimately reduces energy utilisation in the periphery. The precise 
hypophysiotropic pathway controlling T3 feedback to the PVN is unclear. TRβ2 is generally 
accepted as the dominant TR isoform in T3 stimulated TRH expression. However, wild-type 
and TRβ2 knock-outs show similarly reduced TRH expression during fasting, which suggests 
involvement of additional pathways (Abel et al., 2001). 
ARC neurones projecting to the PVN are thought to play a role in HPT axis regulation, 
whereby POMC/CART expressing neurones stimulate and NPY/AgRP populations inhibit 
TRH synthesis in the PVN (Mihaly et al., 2000). This is supported by studies that have 
localised melanocortin receptor-4 (MC4R) on almost all TRH-expressing neurones of the 
caudal-medial parvocellular PVN in addition to recent evidence also suggests that T3 directly 
regulates the expression of MC4R (Decherf et al., 2010). Further to these effects on the 
melanocortin pathway, T3 has also been found to modulate ARC NPY/AgRP neurones that 
project to the PVN. In this investigation, it was reported that T3 stimulates the expression of 
UCP2 in this ARC neuronal population, in turn elevating mitochondrial density and 
modulating the metabolic rate of these neuones (Coppola et al., 2007). 
1.7.1.1 The Role of the Deiodinases in HPT Feedback 
Deiodinase-mediated local control of thyroid hormone signalling is an important feature of 
the HPT negative feedback pathway. In the hypothalamus, D2 expression is highest in the 
MBH, where it is upregulated in the fasted state state (Diano et al., 1998, Tu et al., 1997). D2 
is not present in the PVN (Tu et al., 1997), which suggests that locally generated T3 arrives at 
the TRH-expressing neurones of the PVN from other hypothalamic nuclei or 3
rd
 ventricular 
CSF (Freitas et al., 2010). 
In the rat pituitary gland, D2 expression has been widely detected in TSH secreting cells 
(Christoffolete et al., 2006). In addition, D2 mRNA was also detected in anterior pituitary 
cells that were TSH-negative, suggesting that D2 is also expressed in non-TSH secreting cells 
(Christoffolete et al., 2006). The accepted pathway is that, through the coordinated expression 
of D2, the thyrotroph integrates circulating levels of T3 and T4 to direct TSH secretion. D2 
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expression in the thyrotroph is inversely correlated with serum TSH levels. This is because 
T4 binding to the D2 active site potentiates D2 ubiquitination (Sagar et al., 2007). 
Through these pathways, serum fT4 concentration regulates HPT feedback, where reduced 
fT4 promotes a two to three-fold increase in serum TSH (Larsen et al., 1982, Riesco et al., 
1977). This regulation has been shown to be dependent on D2 given that serum TSH levels 
are not suppressed by T4 administration in D2 knock-out mice (Schneider, 2001). However, 
PVN TRH levels were suppressed by T4 in this mouse model, despite the lack of effect on 
serum levels, indicating that resistance to T4 occurs primarily in the pituitary gland rather 
than the hypothalamus. 
During early postnatal life, alterations in the expression of D3 are critical for maturation of 
the HPT axis (Hernandez et al., 2006b, Hernandez et al., 2006a). This is highlighted by the 
phenotype of the D3KO mouse, which undergoes extensive changes in thyroid homeostasis 
during the neonatal period before developing central hypothyroidism (Hernandez et al., 2007, 
Hernandez et al., 2006a). At birth, the expression of D3 is localised to the bed nucleus of the 
stria terminalis and hypothalamic preoptic nuclei, but by postnatal day 10 its expression is 
diffuse. It has been suggested that this neonatal expression pattern is linked with the 
establishment of the set-point for TRH secretion, which is essential for proper development 
of the HPT axis (Hernandez et al., 2006a). 
1.7.2 Regulation of Sympathetic Outflow 
The interplay between T3 and catecholamines is an essential, ubiquitous feature of 
physiology. An effect of this nature has been identified in the hypothalamus, where T3 
appears to modulate hepatic gluconeogenesis via sympathetic outflow from the hypothalamic 
PVN. 
Thyrotoxicosis is associated with elevated endogenous glucose production with associated 
hepatic insulin resistance. Sympathetic and parasympathetic denervation of the liver 
attenuated the increased glucose output, which suggests that hepatic glucose output could be 
affected by thyroid hormone at the level of the hypothalamus (Klieverik et al., 2008). In 
euthyroid rats, T3 microdialysis in the PVN stimulated endogenous glucose production by 
11%, which highlights hypothalamic thyroid hormone as a potential activator of sympathetic 
outflow to the liver (Klieverik et al., 2009). 
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It remains to be ascertained whether this is a sole pathway of sympathetic activity under the 
control of thyroid hormone, although it is possible that additional organs may be regulated by 
thyroid hormone concentration in specific hypothalamic nuclei. 
A role for thyroid hormone in sympathetic signalling was also highlighted in mice expressing 
TRα mutations (Sjögren et al., 2007, Pelletier et al., 2008). Despite the disruption to thyroid 
hormone signalling in peripheral tissues, which would normally hinder catabolic processes, 
these mice presented with a lean phenotype at an ambient temperature of 21°C. When housed 
at 30°C, these mice had a suppressed response to a norepinephrine challenge, suggesting 
modulated sympathetic signalling. Given the effect on body weight, it was perceived that the 
phenotype was due, in part, to an increased sympathetic drive from the CNS. 
1.7.3 Photoperiodic Regulation 
In mammals, nocturnal melatonin secretion by the pineal gland conveys temporal information 
to the hypothalamus to modulate the activity of its neural circuits and conserve energy-
demanding processes. There is evidence from several species that the iodothyronine 
deiodinases are regulated by photoperiod to modulate energy homeostasis via hypothalamic 
energy circuits. In the Syrian hamster MBH, D2 is highly expressed in reproductively active 
hamsters during long day periods and downregulated during short days (Revel et al., 2006). 
Pinealectomy demonstrated that this regulation is melatonin dependent and injections of long 
day hamsters with melatonin for just one week were sufficient to reduce Dio2 expression to 
that of short day levels (Yasuo et al., 2007). In Siberian hamsters, D3 shows temporal 
regulation by photoperiod in the MBH during periods of hibernation. Upregulation of D3 in 
short-day periods was associated with a state of reduced metabolic activity, outlined by 
decreased body weight, and an inactive reproductive system, marked by significantly reduced 
testicular weight (Barrett et al., 2007). 
1.7.4 Appetite and Energy Homeostasis 
Hyperthyroidism is generally associated with increased energy expenditure and reduced body 
weight. The increased appetite is generally thought to compensate for the increase in 
metabolic rate, however roughly 5-10% of hyperthyroid individuals have a sufficiently 
increased appetite to gain weight despite the catabolic processes (Gurney, 1970). This 
suggests that thyroid hormone may directly affect hypothalamic energy circuits, with several 
regulators of appetite and energy expenditure implicated. 
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Intramuscular administration of T3 to rats has been shown to stimulate food intake, without 
affecting energy expenditure, and increase early growth response factor 1 (EGR-1) 
expression, a marker of neuronal activity, in VMN neurones (Kong et al., 2004). Dio2 mRNA 
upregulation in this region has been demonstrated within 12 and 24 hour of fasting, which 
suggests that an increased level of T3 production may function to promote refeeding. 
Furthermore, third ventricle α1 tanycytes are known to project to the VMN (Lechan and 
Fekete, 2007), which implicates this nucleus as a key hypothalamic target of thyroid 
hormone. Direct administration of T3 (50pmol) to the VMN caused a 4-fold increase in food 
intake without affecting systemic levels of thyroid hormone,  an effect that was not witnessed 
in the ARC (Kong et al., 2004). 
T3 has been linked to the genomic regulation of several mediators of hypothalamic 
neuropeptides, which present as potential players in its regulation of food intake. In addition 
to the direct regulation of MC4R (section 1.7.1), T3 is also associated with negative control 
over other anorectic factors, such as TRH, BDNF and POMC, and disinhibition of the 
hyperphagic neuropeptide AgRP via downregulation of LEPR (Byerly et al., 2009). The 
common end product of these mechanisms is that T3 stimulates hypothalamic pathways 
which promote feeding. 
It has been mentioned that nutritional status can be affected by thyroid hormone homeostasis, 
however there is also evidence to suggest that regulation also occurs in the opposite direction. 
Low levels of leptin stimulate feeding via hypothalamic appetite centres. During fasting, 
circulating levels of leptin decrease, permitting an increase in plasma corticosterone, which 
has been shown to increase hypothalamic D2 expression both in vitro and in vivo (Coppola et 
al., 2005, Germain, 1986). 
1.7.5 Controversy of Theories Regarding Hypothalamic T3 Action 
Recent investigations into the role of thyroid hormone in the hypothalamus have brought 
about various conclusions, some of which contradict others. The theories surround the 
mechanisms by which hypothalamic T3 affects appetite and BAT stimulation, with respect to 
AMPK activity. 
It has been proposed that an unliganded TR can induce hypermetabolism, as a result of 
elevated BMR, in mice lacking TRα1 (Sjögren et al., 2007, Pelletier et al., 2008). The 
investigators concluded that this phenotype was caused by increased sympathetic drive from 
the CNS due to increased incidence of apoTR, which was driving the process. This indicates 
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that holoTR, that is T3-bound TR, would drive the opposite phenotype in which T3 reduces 
systemic hypermetabolism as a consequence of reduced sympathetic activity. 
However, this is counterintuitive to the findings of Lopez et al, who concluded that T3 
stimulates peripheral metabolism by increasing sympathetic drive to BAT. In this study, rats 
were rendered hyperthyroid by chronic subcutaneous administration of T4, which induced an 
increase in food intake. Central administration of T3 to the 3
rd
 ventricle resulted in a rapid 
decrease in activated AMPK (pAMPK) levels. (López et al., 2010). The role of AMPK in T3 
signalling in the VMN was further explored in this investigation by employing an adenovirus 
encoding a constitutively active AMPKα, which was administered to the VMN of 
hyperthyroid Sprague-Dawley rats. The effect was body weight gain in hyperthyroid, but not 
in euthyroid rats. There were no reported effects on food intake in euthyroid rats despite an 
increase in markers of BAT activation (López et al., 2010). 
The finding that T3 does not affect food intake via the hypothalamus has also been 
demonstrated in another study which investigated the effect of T3 on glucose homeostasis 
(Klieverik et al., 2009). This provides further cause for controversy when considering that 
two publications have identified a role for T3 in the VMN where it was shown to stimulate 
food intake (Ishii et al., 2008, Kong et al., 2004). Furthermore, Ishi et al demonstrated that 
AMPK is activated in this process, which also contradicts recent findings (López et al., 
2010). 
In summary of these contrasting findings, we have reports that: T3 stimulates feeding in the 
VMN (Ishii et al., 2008, Kong et al., 2004), with contradicting reports from other sources 
(Klieverik et al., 2009, López et al., 2010); T3 stimulates the BMR via the CNS (Sjögren et 
al., 2007, Pelletier et al., 2008), with contradicting reports from other sources (López et al., 
2010); AMPK is activated by T3 in the VMN (Ishii et al., 2008), with contradicting reports 
from other sources (López et al., 2010). This illustrates the opacity of our current 
understanding of how T3 affects these hypothalamic energy circuits, with regards to appetite 
and energy expenditure. 
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1.8 Hypothesis and Purpose of Study 
T3 is known to have a widespread effect on energy homeostasis. Its role in the developed 
central nervous system is to regulate activity of the thyroid gland via the HPT axis, although 
increasing evidence suggests that it may regulate other metabolic pathways via the CNS. 
Administration of a thyrotoxic dose of T3 directly to the VMN induced hyperphagia in adult 
rats. This highlights a potential role for thyroid hormone in the VMN in the regulation of 
energy homeostasis. 
This research will examine the role of thyroid hormones in the VMN with respect to their 
regulation of energy homeostasis. Recombinant viral vectors have previously been used in 
the investigation of hypothalamic function with much success. In this investigation, 
recombinant viruses will be designed to overexpress the iodothyronine deiodinases for use in 
this investigation of the role of thyroid hormone in the VMN. 
Initially, plasmids will be constructed to overexpress the dominant rat CNS deiodinases D2 
and D3, with green fluorescent protein (GFP) packaged into the control plasmid. These 
plasmids will be tested for efficacy in vitro before being used for production of viral vectors, 
which will subsequently be administered to the VMN of male Wistar rats. The levels of food 
intake and body weight will be measured in these rat models, which will be analysed for body 
composition after termination of the experiment. Plasma will be analysed for various 
metabolic parameters, such as leptin, insulin and free thyroid hormones. Hypothalami will be 
assayed for the expression of various genes, in addition to deiodinase enzyme activity. 
Given the hyperphagic association of T3 with the VMN, it is expected that D2 
overexpression will increase food intake and body weight following rAAV-D2 treatment, 
whereas D3 overexpression by rAAV-D3 treatment will produce the opposite phenotype. 
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Chapter 2  
Materials & Methods 
All reagents were supplied by Invitrogen Life Technologies, Paisley, UK, unless otherwise 
stated. 
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2.1 Construction of rAAV Plasmids 
Plasmids vectors were prepared for the transfer of constitutively expressed Dio2 and Dio3 
transgenes. These plasmids (pTR-CGW-D2, pTR-CGW-D3) were then employed for the 
production of rAAV for overexpression of the relevant transgene. 
2.1.1 Reverse Transcription 
Materials 
Rat hypothalamic RNA (5mg/ml)  
10mM dNTPs (GE Healthcare , Little Chalfont, UK) 
5x reverse transcriptase buffer (Promega, Madison, WI) 
Avian myoblastoma virus reverse transcriptase (RT) 10U/µl (Promega, Madison, WI) 
Oligo dT (12-18) 200ng/µl (GE Healthcare, UK) 
Method 
The reaction was set up in a final volume of 20µl containing the following: 1mg/ml RNA, 1x 
RNA buffer, 1mM dNTPs (deoxynucleotide phosphates) and 10mg/ml oligo dT. The solution 
was heated to 65°C for five minutes and allowed to cool at room temperature for thirty 
minutes. Ten units of reverse transcriptase were then added and the reaction was incubated at 
42°C for one hour. The reaction was then used in PCR. 
2.1.2 Polymerase Chain Reaction 
Materials 
10x Taq buffer 
20µM oligonucleotide primers (Oswel DNA service, Southampton, UK) (appendix I) 
Taq DNA polymerase (5U/µl) 
10mM dNTPs (GE Healthcare, UK) 
Reverse-transcribed cDNA template 
Method 
Complementary DNA (cDNA) from the RT reaction was amplified using primers 
corresponding to sequences on the target gene. Half of the reverse transcription reaction was 
added to a tube containing 1x Taq ® buffer, 0.2mM dNTPs, 200nM oligonucleotide primers. 
The reaction was heated to 95°C for five minutes and then 5U Taq DNA polymerase added. 
The reaction was then cycled 30 times through the following temperatures: 95°C for 30 
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seconds, 60°C for 30 seconds and 72°C for 45 seconds. After completion of the reaction, 
10µl of the PCR products were visualised by gel electrophoresis on a 1% TAE/agarose gel. 
2.1.2.1 Visualisation of PCR Amplicon 
Materials 
Agarose, type II-A medium EEO 
50x TAE: (appendix I) 
Ethidium Bromide (10mg/ml) (VWR International Ltd, Poole, UK) 
DNA marker (BRL 1Kb plus ladder) 
Gel loading buffer (appendix I) 
Method 
A 1% (w/v) agarose gel was prepared by dissolving the agarose in 1x TAE using a 
microwave oven. The gel was cooled to 45°C and ethidium bromide added to a final 
concentration of 0.5µg/ml. Once set the gel was placed into an electrophoresis tank 
containing 0.5x TAE with 0.5µg/m ethidium bromide. Three microlitres of loading buffer 
were added to 10µl PCR product. In a separate tube, 1µl of DNA marker was added to 9µl 
GDW and treated in the same way. The samples were loaded onto the gel and 
electrophoresed at 10V/cm. The DNA was visualised by illumination with UV light (300nm). 
2.1.3 Insertion of Amplicon into pTR-CGW 
One of the most important advances in the field of molecular biology was the ability to cut 
DNA at specific sites and to ligate the cut ends. Restriction endonucleases (isolated from 
bacteria) recognise specific target sites within double stranded DNA and cleave it. Ligating 
cut fragments relies on the use of a virus-derived enzyme that catalyses the formation of 
phosphodiester bonds between a free 5‟ phosphate and a free 3‟ hydroxyl group. 
2.1.3.1 Restriction Endonuclease Digestion of PCR Products and AAV Plasmid 
Materials 
PCR amplicon 
pTR-CGW (rAAV plasmid)  (gift from Dr. Verhaggen, Amsterdam) 
Restriction endonucleases: BamHI, AgeI and BsrGI (New England Biolabs, Hitchin, 
Hertfordshire, UK) 
10x restriction buffer (New England Biolabs, Hitchin, Hertfordshire, UK) 
10x bovine serum albumin (BSA) (New England Biolabs, Hitchin, Hertfordshire, UK) 
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Phenol/Chloroform 
3M sodium acetate, pH 5.2 
Shrimp alkali phosphatase (SAP) 4U/µl (GE Healthcare) 
Method 
In separate reactions the amplicon and pTR-CGW were diluted in autoclaved glass distilled 
water (GDW). Restriction buffer, BSA and equal volumes of each restriction endonuclease 
(Dio3 – BamHI and BsrGI; Dio2 – BsrgI and AgeI; SECIS – BamHI and AgeI) were added 
to give a final concentration of 1x. The total volume of enzyme added was kept below 10% of 
the final volume. The reaction was incubated for at least one hour at 37°C. In the digestion of 
pTR-CGW, 8U SAP was added 30 minutes before the end of the incubation. SAP removes 5‟ 
phosphate groups preventing self-ligation of the plasmid. The reactions were extracted with 
an equal volume of phenol/chloroform and the phases separated by centrifugation for three 
minutes at 13,000g. The DNA was ethanol precipitated with 0.1 volumes 3M sodium acetate 
pH5.2 and 2.5 volumes absolute ethanol and was incubated at -20°C for at least one hour. 
The DNA was recovered by centrifugation for seven minutes at 13,000g. 
2.1.3.2 Electroelution of DNA Fragments 
Following restriction digestion it is advantageous to purify the DNA fragment of interest and 
remove any contaminating fragments. This is especially true for plasmids as restriction 
digests are not 100% efficient and a small amount of closed plasmid DNA can produce a high 
background during transformations. The DNA was therefore size fractionated by 
electrophoresis on an agarose gel and the bands of interest electroeluted. 
Materials 
50x TAE (appendix I) 
Dialysis tubing (New England Biolabs Ltd, Hitchin, Hertfordshire, UK) 
Gel loading buffer (appendix I) 
DNA marker 
Method 
A 1% agarose gel was prepared (as described in section 3.1.2.1). The precipitate DNA was 
dissolved in twenty microlitres of GDW and six microlitres of loading buffer added. One 
microlitre of DNA marker was added to 9µl GDW and 3µl loading buffer added. Samples 
were loaded onto the gel and electrophoresed at 10V/cm.  
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The DNA was visualised by illumination with 302nm ultraviolet light whilst the band of 
interest was cut out from the gel using a scalpel and placed into dialysis tubing sealed at one 
end with a clip. Four hundred microlitres of 0.5x TAE were added to the gel slice, air 
excluded from the end of the tubing and the other end sealed with a clip. The DNA was 
eluted from the gel by electrophoresis at 20V/cm for 20 minutes. The TAE was removed 
from the tubing, phenol/chloroform extracted and ethanol precipitated (as described in section 
3.1.2.5). The DNA was dissolved in GDW and quantified visually by running 1µl on a 1% 
agarose gel. 
2.1.3.3 Ligation of Amplicon into pTR-CGW 
Materials 
T4 DNA ligase, 6U/µl (New England Biolabs Ltd, Hitchin, Hertfordshire, UK) 
10x Ligase buffer (as supplied) 
Digested PCR product 
Digested pTR-CGW 
Method 
DNA ligation was used to insert the digested Dio3 cDNA into pTR-CGW plasmid. Twenty 
nanograms of plasmid were dissolved in GDW and a four-fold molar excess of PCR product 
added. Reaction buffer was added to a final concentration of 1x and 6U T4 DNA ligase added 
to give a final volume of 10µl. The reaction was incubated at 16°C overnight.  
2.1.4 Preparation and Purification of Plasmid Constructs 
2.1.4.1 Transformation of Competent Bacteria by Electroporation 
Competent bacteria can be induced to take up DNA via the process of electroporation. 
Passing a voltage across a bacteria/plasmid mixture opens transient pores in the bacteria 
plasma membrane allowing the plasmid to move into the cell. pTR-CGW contain an 
ampicillin resistance gene. Subsequent incubation allows the expression of the resistance 
genes before exposure to antibiotic. 
Materials 
Ligation reaction 
SOB (appendix I) 
LB(amp) plates (appendix I) 
JC8111 bacteria (ATCC, Middlesex, UK) 
Glyercol (VWR International Ltd, Poole, UK) 
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Method 
Prior to transformation, all salts must be removed from the reaction mixture to prevent arcing 
during electroporation. One microlitre of glycogen was added to the ligation reaction, to act 
as a carrier and the reaction ethanol precipitated for at least one hour. DNA was recovered by 
centrifugation for seven minutes at 13000g. The ligation reaction was then dissolved in 10 µl 
GDW.  
An aliquot of frozen bacteria (JC8111 cells) was thawed on ice, 10ng of plasmid (5µl ligation 
reaction) added and the mixture transferred to an electrocuvette with an intra-electrode 
distance of 1mm. A voltage of 1.2 kilovolts was then passed across the cuvette. Eight 
hundred microlitres of warmed SOB was then added and the reaction incubated at 37°C for 
an hour. Agar plates (supplemented with 100µg/ml ampicillin) were warmed and 150µl of the 
transformed bacteria added to the plate. The bacteria were spread over the surface of the agar, 
the plate inverted and incubated at 37°C overnight. 
2.1.4.2 Small Scale Plasmid Preparation (Sambrook and Russell, 2001) 
Plasmids are isolated from several bacterial colonies on an agar plate to allow several clones 
to be analysed simultaneously. To isolate the plasmids from bacteria it is necessary to disrupt 
the cell wall to release the plasmid and at the same time contaminants (proteins, genomic 
DNA and RNA) must be removed. Treatment with alkaline SDS (sodium dodecyl sulphate) 
disrupts the cell wall and bacterial debris is then precipitated using potassium acetate. This 
step also removes most of the genomic DNA; RNA is removed later by treatment with RNase 
A.  
Materials 
LB(amp) (appendix I) 
GTE (appendix I) 
0.2M NaOH 1% SDS (w/v) (appendix I) 
5M potassium acetate (appendix I) 
Phenol/Chloroform  
Propan-2-ol (VWR International Ltd, Poole, UK 
Method 
A single bacterial colony was placed in 2ml LB supplemented with 0.05mg/ml ampicillin. 
This was incubated overnight at 37°C with vigorous shaking.  From this, 1.5ml was removed 
and centrifuged at 13,000g for 3 minutes, the remainder was stored at 4°C for future use. 
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Supernatant was removed and the bacterial pellet dissolved in 100µl GTE. Two hundred 
microlitres of alkaline SDS were added to the bacteria and the mixture left on ice for 5 
minutes. One hundred and fifty microlitres of 5M KAc were then added and the mixture left 
on ice for a further 5 minutes. The mixture was centrifuged at 13,000g for 5 minutes and 
350µl supernatant was removed to a fresh tube. The supernatant was purified by the addition 
of 350µl of phenol-chloroform to each sample before their centrifugation for 4 minutes. The 
upper aqueous phase, containing the genetic material, was then carefully removed using a 
sterile Pasteur pipette. DNA was precipitated out of the solution by the addition of 0.6 
volume propan-2-ol and incubation at room temperature for 10 minutes. This was centrifuged 
at 13,000g for 7 minutes to pellet the DNA. Following removal of the supernatant, DNA was 
dissolved in 100µl GDW. An ethanol precipitation was carried out (as described in section 
2.1.3.1) to further purify the recovered DNA. Restriction endonuclease digestion was carried 
out (as described in section 2.1.3.1) to verify which clones contained the correct plasmid 
insert. Purified DNA was dissolved in 10µl GDW. XmaI was used to check for presence of 
inverted terminal repeats (ITRs) and visualised by gel electrophoresis. Clones containing the 
correct insert and ITRs were selected for large scale purification. 
2.1.4.3 Large Scale Plasmid Preparation(Sambrook and Russell, 2001) 
Materials 
LB(amp) (appendix I) 
GTE (appendix I) 
Lysozyme 
0.2M sodium hydroxide/1% (w/v) SDS (appendix I) 
5M potassium acetate (KAc) 
Propan-2-ol (VWR International Ltd, Poole, UK) 
100x TE (appendix I) 
DNase free RNase A 10mg/ml in GDW (GE Healthcare) 
Phenol/Chloroform 
Method 
A small quantity of bacteria containing pTR-CGW with the correct size insert was inoculated 
into 500ml LB(amp) and incubated at 37°C overnight with vigorous shaking. The bacteria were 
recovered by centrifugation for eight minutes at 3000g (4000rpm in HS-4 rotor in RC-5B 
superspeed centrifuge, Du Pont) at 4°C. The pellet was dissolved in 25ml GTE supplemented 
with 2mg/ml lysozyme and the sample incubated at room temperature for 5 minutes. Fifty 
62 
 
millilitres of NaOH/SDS were added, the sample mixed by inversion and incubated on ice for 
5 minutes. Then 38ml 5M KAc were added, the sample mixed by inversion and incubated on 
ice for 10 minutes. Bacterial debris was removed by centrifugation for 15 minutes at 9000g 
(7000rpm in HS-4 rotor in RC-5B superspeed centrifuge, Du Pont) at 4°C. The supernatant 
was transferred to a clean tube and 0.6 volumes propan-2-ol added. The sample was 
incubated on ice for 15 minutes and the DNA recovered by centrifugation for 15 minutes at 
9000g at 4°C. The pellet was dissolved in 10ml GDW to which 100µl 100x TE was added. 
RNase A was added at a concentration of 0.1mg/ml and the reaction incubated at 37°C for 30 
minutes. The reaction was extracted with an equal volume of phenol/chloroform and the 
phases separated by centrifugation for 20 minutes at 10000g and 4°C. The DNA was 
recovered by addition of 0.1 volumes 2M sodium acetate pH 5.2 and one volume propan-2-ol 
and incubation at -20°C for at least one hour. 
2.1.4.4 Caesium Chloride Gradient Purification 
Large scale plasmid purification was carried out using a caesium chloride gradient. This 
purification method depends on the decrease in density of nucleic acids when bound to 
ethidium bromide. Because ethidium bromide binds by intercalation into the DNA, it causes 
unwinding of the helix. In closed circular DNA this increases supercoiling of the plasmid so 
binding of ethidium bromide is limited and the plasmid has a higher buoyant density than 
linear or nicked plasmids. The difference in buoyant density allows separation of the plasmid 
on a caesium chloride density gradient. 
Materials 
TES (appendix I) 
Caesium chloride 
10mg/ml ethidium bromide (VWR International Ltd, Poole, UK) 
Propan-2-ol, caesium chloride saturated (appendix I)  
Polyallomer tubes (Ultracrimp, Du Pont) 
Method 
DNA obtained from large scale plasmid purification was recovered by centrifugation for 20 
minutes at 24,000g (12,000rpm in HBS rotor in RC5B superspeed centrifuge, Du Pont) and 
4°C. DNA was then dissolved in 8.25ml TES. Eight-point-four grams of caesium chloride 
were dissolved in the DNA solution and 150µl of ethidium bromide added and the solution 
mixed. The sample was divided between two polyallomer tubes, balanced, and overlaid with 
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mineral oil. The tubes were sealed and centrifuged for 16 hours at 20°C and 60,000rpm (in an 
A1256 rotor in a Sorvall 100SE centrifuge, Fisher Scientific, Loughborough, UK). 
After centrifugation, DNA bands were visualised by 302nm ultraviolet illumination and the 
band containing the closed pTR-CGW DNA removed using a 20-gauge needle and a 2ml 
syringe. Ethidium bromide was removed from the plasmid by repeated extraction with an 
equal volume of caesium chloride saturated propan-2-ol, until both phases were colourless. 
The DNA was precipitated by addition of two volumes of GDW and six volumes of room 
temperature absolute ethanol. DNA was removed by centrifugation for 15minutes and 
24,000g at 20°C. The DNA pellet was dissolved in 0.4ml GDW, ethanol precipitated and 
recovered by centrifugation for 7 minutes at 13,000g. The DNA was then dissolved in 1ml 
GDW. 
pTR-CGW was then quantified spectrophotometrically, 10µl of DNA solution was diluted 
1:100 and placed into a quartz cuvette. Absorbance was read at 260 and 280nm UV 1101 
spectrophotometer (WPA, Cambridgeshire, UK). The reading at 280nm gives an indication of 
the purity of the sample as phenol absorbs more strongly at 280nm than DNA. The 
concentration of the DNA was calculated using the following formula:  
Concentration (µg/ml) = (A260 x dilution factor) x 50 
Sample was digested using specific endonucleases BamHI and BsrGI to check insert size and 
XmaI to check for ITR integrity. 
2.1.4.5 Sequence Analysis of Large Scale Plasmid Preparation 
Insert sequences were determined by DNA sequencing (Advanced Biotechnology Centre, 
Imperial College London, UK). A dye-based chain termination method was utilised, which 
involves a PCR-based reaction in which dideoxynucleotides (ddNTPs) are included. These 
ddNTPs lack the ability to form phosphodiester bonds, which results in the production of 
multiple fragments of different lengths depending on where each of the dNTPs are located in 
the sequence. 
In dye-termination sequencing, each of the four dideoxynucleotide terminators is labelled 
with a different fluorescent dye that emits light at a certain wavelength. The resulting 
amplicons are then separated by size and analysed photometrically to determine the sequence 
of dNTPs based on where each dye is detected. 
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Method 
Sequencing reactions were performed using PCR-based dye termination, where dilutions of 
each primer and the DNA sample were prepared in advance. Primers were designed to 
sequence the constructs in both directions. One 20µl aliquot of DNA (100ng/µl) and 20µl 
aliquots of each primer (3.2pmol/µl) were prepared in 0.5ml eppendorf tubes. 
Sequencing reactions are processed using the following PCR programme: 96°C for 2 
minutes; followed by 35 cycles of 96°C for 10 seconds, 50°C for 10 seconds, 60°C for 4 
minutes. Reactions are then loaded onto an agarose gel to separate bands by size. The 
sequence of dyes is then determined photometrically by loading the gel onto a sequence 
analyser (Advanced Biotechnology Centre, Imperial College London, UK). 
2.1.5 In Vitro Preparation of rAAV in HEK293T Cells 
Adeno-associated virus was produced by using the two plasmid transfection system, which is 
illustrated in figure 2.1 (Grimm et al., 1998). Briefly, host cells (HEK293T) are co-
transfected with the rAAV plasmid (figure 2.1) and a helper plasmid pDG (figure 2.2) using 
calcium phosphate. There is no homology between the two plasmids so they cannot 
recombine and form wild-type virus. This results in the production of rAAV particles. To 
release the particles cells are lysed by freeze thawing and the rAAV produced is purified. 
2.1.5.1 Cell Maintenance 
Materials 
DMEM 
Trypsin 
Versene (appendix I) 
Method 
Cells were cultured in 75cm
2
 flasks with 15ml DMEM (Gibco, Paisley, UK) containing 
DMEM and supplemented with 10% fetal bovine serum (FBS) and 5% penicillin and 
streptomycin.  The cells were incubated at 37°C in a 5% CO2 atmosphere.  Medium was 
changed every 2 to 3 days. Cells were passaged 1:10 when confluent, approximately every 6 
days.  Briefly, cells were washed in 10ml versene. To detach cells from the flask, 0.25% 
trypsin in versene was added and cells left for several minutes until all appeared to have 
detached from the flask. The suspension was then added to 10ml DMEM to inactivate the 
trypsin and centrifuged for 5 minutes at 100g. The resulting pellet of cells was dissolved in 
10ml DMEM and 1ml was used to seed two 75cm
2
 flasks. 
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2.1.5.2 Calcium Phosphate Transfection 
Materials 
HEK293T cells 
pTRCGW (including transgene) 
pDG 
1x HEBS buffer (appendix 1) 
2M CaCl2 
Method 
Cells were plated into a 10 chamber cell factory (L x W x H (mm): 335 x 205 x 190, culture 
area: 6320cm
2
). Cells were incubated in 2000ml DMEM with 10% FBS. After 24 hours, 
when cells were 50% confluent, the culture medium was replaced (250ml culture medium 
was retained for transfection) and transfection performed 2 hours later.  
Transfection mix was prepared for the cell factory, consisting of 560µg pTRCGW, 1.68mg 
pDG, 7.2ml 2M CaCl2 and 52ml GDW. Immediately before transfection, 12ml of HEBS 
buffer in 48ml GDW was added and mixed gently. After standing at room temperature for 1 
minute the mixture was added slowly to 250ml DMEM with 10% FBS and added to the cell 
factory. 
 
Figure 2.1: Transfection systems for rAAV production (Grimm et al., 1998). Cells are 
transfected with the vector plasmid and an AAV/adenovirus hybrid helper plasmid. X, 
transgene; ITR, inverted terminal repeats; Ad5, adenovirus helper genes. 
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2.1.6 Recovery and Purification of rAAV Titre 
Materials 
0.01M PBS  
DNaseI  
Sepharose column (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
Iodixanol (Life Sciences Technology, Eggenstein, Germany) 
0.3x PBS/0.1M NaCl 
0.3x PBS/2mM EDTA 
2M MgCl2  
Benzonase (Novagen, Nottingham, UK) 
Lysis buffer (appendix I) 
Method 
Forty-eight hours after transfection, cell medium was removed and cells were washed using 
500ml PBS and then harvested using 500ml PBS/2mM EDTA. Cells were collected by 
centrifugation at 5000g for 10 minutes, resuspended in 150ml PBS and then re-centrifuged at 
5000g for 10 minutes. Cells were then resuspended in a total of 60ml lysis buffer in falcon 
tubes. Cells were exposed to 3 freeze thaw cycles, ten minutes in dry ice/ethanol followed by 
10 minutes in a 37°C waterbath. 7.3µl 2M MgCl2 and 1.2µl Benzonase were then added to 
each falcon tube and incubated at 37°C for 30 minutes. The solutions were then centrifuged 
at 2000g for 10 minutes to pellet cell debris. The supernatant was equally loaded into 4 
polyallomer tubes (Sorvall). A preformed iodixanol gradient composed of 15%, 25%, 40% 
and 60% iodixanol was layered underneath. The tubes were then topped up with lysis buffer, 
heat sealed and centrifuged at 69,000g for 1 hour at 18°C (Sorvall 100 SE). To remove the 
rAAV particles the top of each tube was punctured with an 18G needle and rAAV collected 
by puncturing the bottom of the tube and collecting 5ml of iodixanol gradient from the 
60/40% interface. The fractions from the 4 tubes were pooled, added to 20ml PBS and loaded 
onto a Sepharose column (pre-washed with 25ml 0.1M NaCl/0.3x PBS and 50ml 0.3x PBS). 
The column was washed with 50ml 0.3x PBS and the virus eluted with 15ml 350mM 
NaCl/0.3xPBS. The eluant was transferred to an Apollo Concentrator containing 10ml PBS 
and centrifuged at 4000g for 5 minutes. The flow through was discarded with a further 5ml 
PBS added below and 19.5ml PBS above the filter. The tube was again centrifuged at 4000g 
for 5 minutes with the remaining 0.5ml rAAV aliquoted into eppendorf tubes.  Viral titre was 
quantified by dot blot analysis (section 2.1.7). 
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Figure 2.2: Structure of pTR-CGW plasmid vector. 
 
 
 
 
Figure 2.3: The structure of helper/packaging plasmid pDG. Contains AAV and adenovirus 
genes required for amplification and packaging of rAAV. RTR – right terminal repeat, 
MMTV-Rep-Cap – promoter region encoding Rep and Cap proteins, expression is driven by 
mouse mammary tumour virus (MMTV) and long terminal repeat (LTR), VA, E2A and E4 – 
adenovirus helper genes required for replication. 
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2.1.7 Determination of Total Viral Titre by Dot Blot Analysis 
The level of trangene expression is affected by the rAAV titre so total viral particle number 
was determined by dot blot analysis. Dot blot analysis is based on similar principles to 
Southern and Northern blots; a specific probe can be used to quantify a specific DNA or 
RNA species in a sample. Rather than being separated by size and transferred to a membrane, 
the sample being analysed is placed directly onto a membrane. The DNA or RNA species 
present in the sample can be detected and quantified using radiolabelled probes.  
Materials 
rAAV viral preparation 
Solution A (appendix I)  
Solution B (appendix I) 
1mg/ml proteinase K 
Phenol/chloroform 
3M sodium acetate (appendix I) 
Ethanol (VWR International Ltd, Poole, UK) 
Glycogen 
Denaturing solution:1.5M NaCl 0.5M NaOH 
Neutralising solution:1M Tris/HCl pH7.4 1.5M NaCl 
pTRCGW  
Hybridisation buffer (appendix I) 
Amasino wash buffer (appendix I) 
Universal wash buffer (appendix I) 
Method 
Forty-five microlitres of solution A was added to 5µl rAAV virus stock and incubated for 30 
minutes at 37°C. Two hundred microlitres of solution B was added and the sample was 
incubated at 55°C for 1 hour. DNA was extracted by adding an equal volume of 
phenol/chloroform. Ethanol precipitation of the DNA was performed by adding 1/10 volume 
3M sodium acetate pH 5.2, 40µg glycogen and 2.5 volumes ice cold ethanol. After 1 hour at -
20°C the solution was centrifuged at 8000g at 4°C, the supernatant removed, the pellet 
washed in 75% cold ethanol and air-dried. The pellet was dissolved in 10µl GDW and 1µl 
applied to a nylon membrane (Hybond-N). A series of dilutions of pTRCGW (50 to 0.1ng) 
were also applied to the membrane to act as a standard curve. The membrane washed for 5 
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minutes in denaturing solution, then washed twice for 5 minutes in neutralising solution. The 
membrane was then baked at 80°C for 2 hours. 
A cDNA fragment of WPRE was used as a probe for rAAV transgenes. The probe was radio 
labelled with 
32
P dCTP as described in section 2.4.6.4. Half of the labelled probe was boiled 
and added to 10ml hybridisation buffer. Hybridisation was carried out overnight at 60°C. The 
following day the membrane was washed as described in section 2.4.6.5. The membrane was 
then placed on a phosphorimager screen overnight. Radiolabelled areas were visualised and 
quantified by image densitometry using ImageQuant software (Molecular Dynamics). 
Quantification was performed by comparing viral DNA to known amounts of pTR-CGW in 
the standard curve. 
2.2 In Vitro Investigations 
Deiodinase activity was measured in collaboration with the Department of Endocrinology 
and Metabolism of the Academic Medical Centre at the University of Amsterdam. Activity 
was measured in vitro following transfection of JEG3 cells with plasmid constructs. 
2.2.1 Cell Culture Maintenance 
Materials 
JEG3 Cells 
DMEM/F12 Media 
Foetal Bovine Serum 
Sodium Selenite (Sigma-Aldrich, Poole, UK) 
Trypsin 
Versene (appendix I) 
Method 
1 x 10
6
 cells were cultured in 75cm
2
 flasks with 10ml DMEM/F12 (Gibco, Paisley, UK) 
supplemented with 10% fetal bovine serum (FBS) and 100nM sodium selenite.  The cells 
were incubated at 37°C in a 5% CO2 atmosphere.  Medium was changed every 2 to 3 days. 
Cells were passaged 1:10 when confluent, approximately every 4 days.  The cells were 
washed in 10ml versene and detached from the flask using versene with 0.25% trypsin. The 
suspension was then added to 10ml DMEM/F12 to inactivate the trypsin and spun for 5 
minutes at 100g. The resulting pellet of cells was dissolved in 10ml DMEM/F12 and 1ml was 
used to seed two 75cm
2
 flasks. 
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2.2.2 Transient Plasmid Transfection Using Calcium Phosphate 
Materials 
JEG3 cells 
pTR-CGW 
1x HBS buffer (appendix I): 
2M CaCl2 
Method 
1 x 10
6
 cells were grown to 70% confluence in 60mm plates. Transfection mixes for each 
well were prepared in cryotubes with the following constituents: 5µl HBS, 1µg pTR-CGW 
and GDW (to give a final volume of 50µl). Three microlitres of CaCl2 were then slowly 
added to each tube to initiate precipitation of the plasmid DNA. After 5 minutes, the contents 
of the tube were spotted into its respective well, containing 6ml of DMEM/F12 media. 
2.2.3 Measuring Extracellular Thyroid Hormone Content 
The concentration of fT3 and fT4 in DMEM/F12 media was analysed by radioimmunassay 
(RIA). Owing to the presence of specific thyroid hormone transporters and the lipophillic 
structure of iodothyronines, thyroid hormones are able to cross the plasma membrane of 
JEG3 cells. Therefore, measuring the content of fT3 and fT4 in culture media gives some 
indication of the level of deiodination following transfection of the constructs. 
Materials 
Transfected JEG3 Cells 
DMEM/F12 Media 
Method 
Two hours prior to transfection (see 2.2.2), media was replaced. Cells were transfected with 
either pTR-CGW (n=4), pTR-CGW-D2 (n=4), or pTR-CGW-D3 (n=4). Fresh media was 
introduced to each well 48 hours after transfection. Twenty-four hours later, media was 
sampled for analysis of fT4 and fT3 content by radioimmunoassay (see 2.4.6.3). 
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2.2.4 Measurement of Deiodinase Activity in vitro 
Iodothyronine deiodinase type III activity was measured in cells transfected with either pTR-
CGW or pTR-CGW-D3. The JEG3 cell lines were harvested and delivered to collaborators at 
the Department of Endocrinology and Metabolism of the Academic Medical Centre at the 
University of Amsterdam. 
Materials 
1x PBS (appendix I) 
PE buffer (100 mM phosphate buffer containing 2 mM EDTA and 50mM DTT) 
Polytron homogeniser 
Method 
Cells were transfected with either pTR-CGW (n=5) or pTR-CGW-D3 (n=5) as described in 
section 2.2.2). After 72 hours, JEG3 cells were harvested in 1x PBS, using a cell-scraper, and
 
centrifuged at 10,000g for 3min. The pellet was dissolved in PE buffer before 
homogenisation on ice using a polytron homogeniser. Sample protein concentrations were 
limited to 0.1 mg/ml for D3 activity. Cell lysates were stored
 
at -80°C until assaying for D3 
activity. 
Deiodinase activity assays were performed as described previously (Boelen et al., 2005, 
Boelen et al., 2004a). Duplicate incubations of homogenates ( 100 µg protein) were 
incubated for 1 hour at 37 C with 1 nM [3'-125I]T3/T4 (200,000 cpm) in a final volume of 
0.1 ml PE buffer. Reactions were terminated by adding 0.1 ml ice-cold methanol. After 
centrifugation, 0.1 ml of the supernatant was added to an equal volume of 0.02 M ammonium 
acetate (pH 4). One hundred microlitres of this mixture were applied to a 4.6 x 250 mm 
Symmetry C18 column connected to an Alliance HPLC system. The column was eluted with 
acetonitrile (28–42% in 15 min) in 0.02M ammonium acetate (pH 4.0). Eluate radioactivity 
was measured using a Radiomatic Z-500 flow scintillation detector. 
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2.3 Analysis of Tissue Samples 
Several metabolic parameters were analysed in male Wistar rat carcasses following intra-
VMN administration of rAAV-D2, rAAV-D3, or rAAV-GFP. 
2.3.1 Calculation of Rat Body Composition 
Body composition was analysed to establish the ratio of fat mass to lean body mass. Rat 
carcasses were dissolved (saponified) in a strong organic solvent before glycerol and protein 
concentrations were measured using standard assay procedures. 
2.3.1.1 Saponification of Carcass 
Materials 
3M KOH 65% ethanol (v/v) (Appendix I) 
Ethanol (VWR International Ltd, Poole, UK) 
Method 
Animals were weighed and placed in separate 1L plastic containers. Carcasses were dissolved 
using 3M KOH in 65% ethanol in equal volume to carcass weight (1ml/g). Vessels were then 
incubated at 70°C for one hour to initiate liquefaction. Following this, the containers were 
placed in an oven at 70°C for 5 days. The resultant liquid was made up to 1.7L with absolute 
ethanol and stored at room temperature until required. 
2.3.1.2 Glycerol Assay 
In order to determine total fat content in rats, a glycerol assay was used. Whole carcass 
glycerol concentrations were determined using reagents and methods from Randox 
laboratories Ltd, Crumlin, Co. Antrim. 
Materials 
1M Glycerol (VWR International Ltd, Poole, UK) 
Glycerol Assay Kit (Randox Laboratories Ltd, Crumlin, Co. Antrim) 
Buffer R (appendix 1) 
Reagent R (appendix 1) 
Method 
In order to determine the total fat content per rat a glycerol assay was used. All buffers were 
supplied ready to use and one vial of reagent R was reconstituted with 15 ml of buffer R. One 
molar glycerol stock solution was diluted in GDW to provide standard glycerol 
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concentrations of 5mM, 2mM, 1mM, 0.5mM, 0.2mM, 0.1mM, and 0.05mM. Ten microlitres 
of dissolved carcass sample was diluted 1:100 with GDW in separate mictrotubes ready for 
use in the assay. To begin the assay 1 ml reagent R was added to a new set of tubes. To this 
30μl of sample, standard, or buffer R (for blank value) was added and left to incubate at room 
temperature for 10 minutes. Each tube was then read using a spectrophotometer at an 
absorbance of 520 nm. The carcass fat content was calculated from the glycerol reading by 
assuming a molecular weight of 885 per triglyceride molecule (Baginski et al., 1974). 
2.3.1.3 Lowry Protein Assay 
Carcass lean mass was determined by analysis of the protein content using a well established 
modified Lowry protein assay (Lowry et al., 1951). This method involves reaction of proteins 
with cupric sulphate and tartrate in an alkaline solution to form tetradentate copper-protein 
complexes. When a certain reagent is added (Folin- Ciocalteu) it is reduced in proportion to 
these copper complexes producing a product blue in colour that can be measured at 750 nm. 
The relative protein concentration can be calculated using the formula: A750 = ε750 x c x l 
Materials 
Biuret Reagent (Sigma-Aldrich, Poole, UK) 
Folin-Ciocalteu Reagent (Sigma-Aldrich, Poole, UK) 
Bovine Serum Albumin 
Method 
A bovine serum albumin (BSA) stock solution that was diluted in GDW to make up nine 
standard solutions of 1, 5, 25, 125, 250, 500, 750, 1,000, and 1,500 μg/ml. Ten microlitres of 
dissolved carcass was diluted in 1 ml GDW. 1X Folin-Ciocalteu reagent was prepared by 
diluting the supplied 2X reagent 1:1 with ultra pure water. All other reagents were supplied 
ready to use. 200 μl of standard and unknown sample were added in duplicate to microfuge 
tubes. 1ml modified Lowry reagent was then added to each tube at 15 second intervals, mixed 
well, and incubated for exactly 10 minutes. 100 μl of the prepared 1X Folin-Ciocalteu reagent 
was then added and vortexed. The tubes were covered and incubated at room temperature for 
30 minutes. The samples were then immediately measured in a spectrophotometer at a 
wavelength of 750 nm. Absorbance values of the blank readings were subtracted from the 
absorbance readings of all samples and a standard curve plotted. The protein concentration of 
each sample was extrapolated from the standard curve. 
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2.3.2 In Situ Hybridisation for WPRE mRNA 
In situ hybridisation is a method for the detection and quantification of mRNA whilst 
maintaining the structural integrity of the tissue. It relies on the hybridisation of a 
complimentary probe, usually radiolabelled, to the target mRNA in tissue mounted on poly-
lysine coated slides. Rats received either bilateral injections of rAAV-D2 or unilateral 
injections of iVMN rAAV-D3. Three weeks after surgery in situ hybridisation was performed 
to confirm transgene expression and verify localisation of the virus. 
An in situ hybridization reaction was performed to confirm expression of rAAV-plasmids in 
brain parenchyma. Coronal sections of 12μm were used for 35S-labeled antisense RNA 
probes complementary to the woodchuck posttranscriptional regulatory element (WPRE). 
The WPRE sequence is part of the expression cassette of all vectors used in this study to 
enhance expression. A 
35
S-labelled sense probe was also used as a control to validate that 
there was no non-specific binding of the antisense probe. 
2.3.2.1 Production of Radiolabelled RNA Probe for In Situ Hybridisation 
Materials 
Linearised template (for WPRE in situ pBluescript-WPRE (200ng/µl) linearised by digestion 
with Bam HI for antisense probe or EcoRI for sense) 
100M DTT (appendix I)   
RNase inhibitor, 30U/µl 
10x nucleotide mix: 10mM of each ATP, UTP, GTP 
T7 RNA polymerase, 20U/µl (Promega, Madison, WI, USA) 
T3 RNA polymerase (Promega, Madison, WI, USA) 
10x RNApolymerase buffer (Promega, Madison, WI, USA) 
DNase I, 7.5 U/µl (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
10x DNase buffer 
Ammonium acetate (appendix I)  
[
35S]CTPαS, 30TBq/mmol, 1.5GBq/ml (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK) 
Method 
Radioactively labelled RNA was produced using an in vitro transcription reaction. Two 
hundred nanograms of template were added to a reaction buffer containing 10mM DTT, 1x 
nucleotide mix, 1x polymerase buffer, 30U RNase inhibitor and 3.75MBq [
35S]CTPαS in a 
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total volume of 9µl. To this 20U of RNA polymerase was added (T3 to the anti-sense 
reaction and T7 to the sense reaction) and the reaction incubated for at least 2 hours at 37°C. 
After incubation, 6µl GDW, 1µl DNase I and 3µl DNase buffer was added. This was 
followed by a 15 minute incubation at 37°C. Ammonium acetate was added to a final 
concentration of 2M and 2.5volumes ice cold absolute ethanol was added and the mixture left 
at -20°C for at least an hour for the RNA to precipitate. RNA was recovered by centrifugation 
at 8,000g for 7 minutes and the pellet was dissolved in 100µl GDW. To measure the activity 
or the radiolabelled probe, 1µl was counted on a microbeta counter (Wallac, Waltham, MA). 
2.3.2.2 Preparation of Slides 
Materials 
4% formaldehyde (VWR International Ltd, Poole, UK) in 0.01M PBS (Appendix I) 
0.01M PBS (Appendix I) 
100% acetic anhydride (VWR International Ltd, Poole, UK) 
0.1M Triethanolamine pH 8.0 (TEA) 
20x SSC (Appendix I) 
3M sodium chloride 
70% ethanol in distilled water 
100% ethanol (VWR International Ltd, Poole, UK) 
Chloroform (VWR International Ltd, Poole, UK) 
Method 
Twelve micrometre sections of rat brain were cut on a cryostat at -25˚C (Bright Instrument 
Company, Huntingdon, Cambridge, UK).  The sections were mounted onto poly-lysine 
coated slides (VWR) and stored at -70˚C until hybridisation.  In situ hybridisation was 
performed on every 3
rd
 slide. 
The selected slides were placed in a rack and fixed in 4% formaldehyde in 0.01M PBS on ice 
for 20 minutes.  Slides were then washed twice in 0.01M PBS for 5 minutes.  Slides were 
subsequently washed in 0.1M TEA for 2 minutes and acetylated in 0.25% (v/v) acetic 
anhydride in 0.1M TEA for 10 minutes, they were then rinsed twice in 0.01M PBS for 2 
minutes each time. Slides were dehydrated by sequential immersion in 70%, 95% and 100% 
ethanol solutions before washing in distilled water for 3 minutes. Finally slides were 
delipidated in chloroform for 5 minutes before rehydration in 95% and then 70% ethanol and 
finally being left to air dry. 
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2.3.2.3 Hybridisation of Radiolabelled Probe to Slides  
Materials 
1x RNAse Buffer (appendix I) 
Hybridisation Buffer (appendix I) 
2% Dextran sulphate (Appendix I) 
 
Biomax film (Kodak, Hemel Hempstead, Hearts, UK) 
Developer (Jet X-Ray, London, UK)  
Fixer (Jet X-Ray, London, UK) 
Method 
Enough 
35
S labelled probe for 1 million counts per slide was added to the hybridisation buffer 
and 70μl was applied to each slide.  A coverslip was placed on each slide, the slides were 
hybridised overnight at 60˚C. 
The slides were soaked in 4x SSC with gentle agitation to remove coverslips and then washed 
four times in 4x SSC for 5 minutes.  Slides were RNase treated by incubation for 30 minutes 
at 37˚C in 1x RNase buffer containing 100μg/ml RNase, followed by two 5 minute washes in 
10mM DTT/2x SSC, followed by a 10 minute wash in 10mM DTT/1x SSC and a 10 minute 
wash in 10mM DTT/0.5x SSC, all at room temperature.  Finally, slides were washed in 
10mM DTT/0.1x SSC at 60˚C for 30 minutes, rinsed briefly in 10mM DTT/0.1x SSC at 
room temperature and then washed for 3 minutes in 70% ethanol and 3 minutes in 100% 
ethanol and air dried.  After washing and dehydration the slides were exposed to Bio-Max 
film at room temperature.  After 3 days‟ exposure the film was developed and WPRE 
distribution determined by observation of specific hybridisation. 
2.3.3 Northern Blot Analysis of mRNA 
Northern blotting was used to analyse the size and quantity of UCP-1 RNA in BAT.  The 
RNA is size fractioned on a denaturing agarose gel by electrophoresis, transferred by 
capillary action to a nylon filter and covalently linked to it by baking. The RNA is denatured 
to remove secondary structure ensuring the rate of migration of the RNA is proportional to its 
total length. 
2.3.3.1 Total RNA Extraction 
Materials 
Tri-reagent (Helena Biosciences, Sunderland, Tyne and Wear, UK) 
Bromo-Chloro-Propane (Sigma-Aldrich, Poole, UK) 
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Isopropanol (VWR International Ltd, Poole, UK) 
Ethanol (VWR International Ltd, Poole, UK) 
GDW 
Method 
Total RNA was extracted using the Tri-reagent method according to the manufacturer‟s 
protocol. Brown adipose tissue was ground under liquid nitrogen with a pestle and mortar 
before its homogenisation in 1ml Tri-reagent and subsequent transfer to 1.5ml eppendorfs to 
incubate at room temperature for five minutes.  One hundred microlitres of bromo-chloro-
propane were then added, mixed vigorously for 15 seconds, and then incubated for a further 
five minutes at room temperature. The emulsion was then centrifuged at 4˚C, for 15 minutes, 
at 12000g, with the brake off.  The upper aqueous phase was transferred to a clean eppendorf, 
precipitated with a half volume (300μl) room temperature isopropanol for five minutes at 
room temperature, and then centrifuged at 12000g for ten minutes at 4˚C. This resulted in a 
pellet which was washed with 1 volume (1ml) 75% ethanol in GDW, centrifuged at 12000g 
for a further 10 minutes at 4˚C, the pellet was then air dried, and dissolved in 400μl 
autoclaved GDW. 
RNA concentration was determined spectrophotometrically.  The RNA was diluted 1:100 in 
GDW and 1ml placed in a quartz cuvette. The absorbance was read at 260 and 280nm (UV-
160 spectrophotometer, Shimadzu, Kyoto, Japan).  The 280nm reading gives an indication of 
the purity of the sample.  The concentration of RNA was calculated using the following 
formula: 
RNA (µg) = dilution factor x 40 x OD260 
Following quantification on the spectrophotometer the RNA samples were ethanol 
precipitated with 0.1 volumes sodium acetate pH 5.2 and 2.5 volumes ice cold absolute 
ethanol. The samples were precipitated at -20°C for a minimum of one hour and centrifuged 
at 12000g for 20 minutes, the supernatant was discarded and the pellet vacuum dried for five 
minutes. The pellets were re-suspended in the appropriate volume of GDW to give a 5mg/ml 
solution. 
2.3.3.2 Integrity Analysis of the Total RNA 
Materials 
Agarose, type II-A medium EEO 
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Formaldehyde (VWR International Ltd, Poole, UK) 
20x MOPS pH 7.0 (appendix 1) 
Ethidium bromide (VWR International Ltd, Poole, UK) 
DENAT (appendix I) 
Gel loading buffer (appendix I) 
100x TE pH 7.5 (appendix 1) 
2M Sodium acetate pH 5.2  
GDW 
Method 
The RNA secondary structure was denatured before confirming the integrity of the samples 
using a formaldehyde gel. One microlitre of this solution was added to 12μl DENAT. The 
samples were denatured at 65°C for five minutes and 3μl gel loading buffer added. The 
samples were loaded onto the gel and run in 1x MOPS buffer with 7.5 % formaldehyde (v/v) 
at 10 V/cm. The gel was stained in 1x TE with 0.1 mg/ml ethidium bromide on a shaking 
platform for thirty minutes and de-stained overnight in 1x TE to allow visualisation of the 
18S and 28S ribosomal bands under UV light. The presence of intact ribosomal bands 
indicated the RNA was not degraded. 
2.3.3.3 Transfer of RNA to Nylon Filters (Lehrach et al., 1977) 
Materials 
Formaldehyde (VWR International Ltd, Poole, UK) 
20x MOPS pH 7.0 (appendix 1) 
Hybond-N (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
Method 
An agarose gel was made by dissolving 1g agarose in GDW, 20x MOPS was added to a final 
concentration of 1x and formaldehyde added to 3% (v/v). Once set, the gel was transferred to 
an electrophoresis tank containing 1x MOPS, and 3% formaldehyde (v/v). Before loading, 
50µg of total RNA was denatured by addition of 10μl denaturing buffer and incubation at 
60˚C for 5 minutes. After denaturation, 3μl loading buffer was added and the samples loaded 
onto the gel. The gel was electrophoresed at a constant voltage of 10V/cm. After 
electrophoresis, the RNA in the gel was transferred to Hybond-N by capillary action (Figure 
2.4). After transfer, the filter was baked at 80°C for 1-2 hours. 
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Figure 2.4:  Diagrammatic representation of the apparatus used for capillary transfer of 
RNA from a gel onto the Hybond nylon membrane prior to Northern blot analysis. 
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2.3.3.4 Random Primer Labelling of DNA Fragments  
Materials 
DNA fragment 
5x ABC Buffer (appendix I) 
12.5mM magnesium chloride 
125mM Tris-HCl, pH8.0 
23μM 2-mercaptoethanol 
50μM dATP (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
20x SSC (appendix I) 
Filter paper 
Saran wrap 
Inverted gel 
Hybond-N (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
Paper towels 
Glass plate  
Weight (approx 200g) 
50μM dGTP (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
50μM dTTP (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
1M N-2-hydroxyethylpiperazine-N‟-2-ethanesulphonic acid (HEPES) (Sigma Aldrich, Poole, 
UK) 
34μg/ml random deoxynucleotide hexamers (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) 
10mg/ml BSA, fraction V (Sigma Aldrich, Poole, UK) 
[α-32P]-dCTP: 10Ci/ml, 3000Ci/mmol (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK) 
DNA polymerase I, Klenow fragment 9U/μl (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) 
Sephadex G50 (appendix I) 
1x TE (appendix I) 
Method 
20ng DNA in a total volume of 15μl GDW was boiled for five minutes. After boiling, the 
solution was made up to a total volume of 25μl containing 1x ABC buffer, 5mg/ml BSA, 
10μCi dCTP and 1U Klenow. The reaction was incubated at 37˚C for one hour and 
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incorporation calculated. Incorporation of radionucleotide into the oligonucleotide was 
measured using a mini Sephadex G50 column. The column was prepared by plugging a glass 
Pasteur pipette with glass wool and adding Sephadex G50. The labelling reaction volume was 
made up to 200μl with 1x TE and this was loaded onto the column. The column was eluted 
with 1x TE and 200μl fractions collected. The fractions were counted and the percentage 
incorporation calculated. The hottest two fractions were pooled and half added to the 
hybridisation mix. 
2.3.3.5 Hybridisation of Northern Filters 
Materials 
Hybridisation/pre-hybridisation buffer (appendix I) 
Amasino wash (appendix I) 
Universal wash buffer (appendix I) 
Methods 
The baked nylon filter was pre-hybridised in a clean plastic bag with 20ml of pre-
hybridisation buffer at a 60°C for at least two hours. Before hybridisation of the nylon filter, 
the radio-labelled probe was denatured for five minutes in a boiling water bath. The pre-
hybridisation mix was then removed and replaced with 20ml fresh hybridisation buffer and 
200μl probe was added to this and sealed. The sealed filter was then left to hybridise with the 
radio-labelled probe overnight at 60˚C. The following day, the filter was washed to remove 
any non-specifically bound probe. The filter was washed three times in 50ml Amasino wash 
buffer for 20 minutes each time at 60˚C.  The filter was washed a further three times in 
Universal wash; each wash lasted for 20 minutes at 60˚C.  Finally the filter was exposed to a 
phosphor screen for two days and quantified using the imagequant computer package (GE 
Healthcare , Little Chalfont, UK). 
2.3.3.6 Filter Stripping 
Following hybridisation with a radiolabelled probe, northern filters can be stripped of 
radioactivity and re-used with minimal loss of RNA. Most northern filters can be stripped and 
re-probed five or six times depending on the abundance of the transcript of interest. 
Materials 
100 x TE (appendix I) 
20% SDS  
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Method 
The filter was stripped in 100-200 ml of 1xTE/0.5% SDS for 30 minutes in an 80°C water 
bath. The filter was then exposed overnight to a phosphoimager plate to ensure that all 
radioactive probe had been removed. 
2.3.3.7 Oligo dT Correction (Sambrook and Russell, 2001) 
To correct for variation in gel loading and RNA transfer when performing northern analysis, 
total mRNA on filters was quantified by oligo dT probing. The radiolabelled oligo dT probe 
hybridises with the poly A tail of mRNA species. 
Materials 
20ng Oligo dT template 
5x Reaction buffer: 
500mM cacodylate, pH6.8 
5mM cobalt (II) chloride 
0.5mM dithiothreitol (DTT) 
0.5mg/ml Bovine serum albumin (BSA) 
Terminal deoxytransferase, 20U/μl (Promega, Madison, WI, USA) 
[α-32P]-dATP: 10ci/ml (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
20x SSPE: (appendix 1) 
3.6M sodium chloride 
120mM di-sodium hydrogen orthophosphate 
20mM EDTA 
Sephadex G50 (appendix 1) 
1x TE (appendix 1) 
Method 
Twenty nanograms of oligonucleotide was added to 1x reaction buffer that contained 70µCi 
of dATP and 20U of terminal transferase, in a final volume of 20μl. The reaction was 
incubated for one hour at 37˚C. Incorporation of nucleotide into the oligonucleotide was 
measured using a mini Sephadex G50 column. The column was prepared by plugging a glass 
Pasteur pipette, with glass wool, and adding Sephadex G50. The labelling reaction volume 
was made up to 200μl with TE and this was loaded onto the column. The column was eluted 
with 1x TE and 200μl fractions collected. The fractions were counted and the percentage 
incorporation calculated.  The hottest two fractions were pooled and one tenth added to the 
hybridisation mix.  Filters were prehybridised in 20ml of prehybridisation buffer (5x SSPE, 
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0.2% (w/w) milk powder, 0.2% (v/v) nonidet) for a minimum of two hours at room 
temperature in a polythene bag on a shaking platform. Hybridisation solution was made by 
adding one tenth of the labelled probe to 10ml of the prehybridisation buffer.  The 
prehybridisation solution was removed and replaced with the hybridisation solution. 
Hybridisation was carried out overnight at room temperature. Nonspecifically bound probe 
was removed by increasingly stringent washes. All wash steps were performed at room 
temperature. The first washes were carried out in; 5x SSPE; 0.2% SDS. The hybridisation 
solution was removed and replaced with 20ml of washing buffer and washed for five minutes 
at room temperature. This was repeated and then followed by two washes for thirty minutes 
each in 2x SSPE/0.2% SDS. Following this, the filter was exposed to a phosphoimager screen 
and radiolabelled bands quantified by image densitometry using ImageQuant software 
(Molecular Dynamics, Sunnyvale, CA, U.S.A.). 
2.3.4 Quantification of mRNA by qPCR 
Quantitative PCR (qPCR) was used to analyse the expression of a range of mRNA sequences 
in dissected hypothalami using TaqMan® gene expression assays. Total RNA was extracted 
from tissue samples. From this RNA, mRNA was amplified by reverse transcription and used 
for qPCR analysis. All materials for qPCR were supplied by Applied Biosystems, 
Warrington, UK, unless otherwise stated. 
2.3.4.1 RNA Extraction 
Materials 
Tri-reagent (Helena Biosciences, Sunderland, Tyne and Wear, UK) 
Method 
RNA was extracted from hypothalami using the Tri-reagent method according to the 
manufacturer‟s protocol. Hypothalamic tissue was homogenised in 1ml Tri-reagent before 
subsequent transfer to 1.5ml eppendorfs and incubation at room temperature for five minutes. 
2.3.4.2 RNA Purification 
Sample RNA needed to be devoid of any genomic DNA contamination in order to accurately 
analyse mRNA levels by TaqMan
®
 probe assay. This was achieved by treating the RNA 
samples with DNase solution. 
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Materials 
Purelink RNA Mini kit 
Chloroform (VWR International Ltd, Poole, UK) 
Purelink DNase 
Method 
Following nucleoprotein dissolution with Tri-reagent, nucleic acids were extracted by adding 
200µl of chloroform per 1ml of Tri-reagent used. RNA samples were processed for DNA 
removal using the Purelink RNA mini kit according to the manufaturer‟s protocol (figure 2.5) 
(Gardiner et al., 2010). 
The RNA was then dissolved and stored in RNase-free water before its yield was determined 
spectrophotometrically according to the following equation: 
RNA (µg) = dilution factor x 40 x OD260 x sample volume (ml) 
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Figure 2.5: Extraction of total RNA using Invitrogen RNA minikit. Following incubation in 
Tri-reagent, samples were extracted in chloroform before „on-column‟ digestion with 
Purelink DNAse to leave „pure‟ RNA. 
Dissociation of nucleoprotein complexes in 
Tri-reagent 
Isolation of nucleic acids by chloroform 
extraction 
Add sample to spin cartridge and centrifuge 
to allow RNA to bind membrane 
Removal of DNA contaminants by 15 
minute incubation at room temperature with 
80µl of Purelink DNAse solution. 
Elution of sample in sterile GDW 
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2.3.4.3 Reverse Transcription of Hypothalamic mRNA 
Messenger RNA was converted into its complementary cDNA sequence by reverse 
transcription in order to allow its amplification by PCR. The High Capacity cDNA Reverse 
Transcription Kit uses the random primer scheme for initiating cDNA synthesis. 
Materials 
High Capacity cDNA Reverse Transcription Kit 
96 Well Assay Plate  
Method 
500ng of each RNA sample was added in triplicate to reaction wells containing 1X RT 
buffer, 4mM dNTP mix, 1X RT random primers, and Multiscribe reverse transcriptase. The 
plate was then foil-sealed before its incubation in a thermal cycler programmed to the 
following conditions: 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes. 
Following cycle completion, cDNA templates were stored at -20°C. 
Endogenous control cDNA templates were prepared by adding 50ng of each RNA sample 
before following the above procedure. 
2.3.4.4 qPCR Assays from Hypothalamic cDNA 
Each qPCR TaqMan® assay allows accurate quantification of gene expression by 
incorporating a reporter-tagged probe, which is complementary to part of the targeted cDNA 
sequence, into the amplification process. Probes were designed to cross exon-exon junctions 
to ensure amplification was limited to mRNA only. During PCR, the minor-groove binding 
probe anneals specifically to a complementary sequence between the forward and reverse 
primer sites. When the probe is intact, the proximity of the reporter dye to the quencher dye 
results in suppression of the reporter fluorescence, primarily by Förster-type energy transfer. 
The DNA polymerase cleaves only probes that are hybridized to the target. Cleavage 
separates the reporter dye from the quencher dye to allow fluorescence of the reporter. 
Materials 
Sample cDNA template (25µg/ml) 
Endogenous control cDNA template (2.5µg/ml) 
TaqMan
®
 Gene Expression Assay  
TaqMan
®
 Gene Expression Master Mix  
384 Well Assay Plate  
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Method 
The following constituents were mixed in each well for each qPCR reaction: 1µl of cDNA 
template (25ng), 10µl master mix, and GDW to give a 20µl reaction volume. For total RNA 
quantification, a gene expression assay targeting the 18S ribosomal subunit and 2µl of cDNA 
template (5ng) were used. Each reaction was mixed before the plate was sealed. 
The sealed plate was loaded onto a „7900HT Fast Real-Time PCR System‟ (Applied 
Biosystems, Warrington, UK) thermal cycler, on the ΔΔCt programme, under the following 
conditions: Held at 50°C for 2 minutes before 95°C for 10 minutes. Thermal cycling then 
proceeded where 15 seconds incubation at 95°C followed by 1 minute incubation at 60°C 
was repeated for 40 cycles. The amplification data for the target gene was normalised to the 
expression of the 18S endogenous control and expressed relative to an internal calibrator 
(control group sample), using the formula:       . 
2.3.4.5 Validation of qPCR Assays 
Each qPCR assay was validated for use in a particular tissue prior to analysis, to assess 
suitability of 18S as an endogenous control target. This involved generating standard curves 
from hypothalamic RNA (at concentrations covering 3 logs) using both the 18S assay and 
target assay. 
Materials 
High Capacity cDNA Reverse Transcription Kit  
96 Well Assay Plate  
TaqMan
®
 Gene Expression Assay  
TaqMan
®
 Gene Expression Master Mix 
384 Well Assay Plate 
Method 
Standard curves of RNA mass were prepared, in triplicate, for reverse transcription (see 
2.4.3.3) in the following manner: 
Assay Standards (ng/µl) 
18S 50 25 10 5 1 0.5 0.1 
Target 100 75 50 25 10 - - 
Figure 2.6: Standards for validation of qPCR assays. 
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qPCR was then performed on each replicate (see 2.4.3.4) using the absolute quantification 
programme. The mean Ct values were plotted versus RNA mass to give standard curves. The 
assay efficiency was determined by the slope, where a value of 3.32 indicated 100% 
efficiency. 
2.3.5 Measurement of Deiodinase Activity in Vivo 
Deiodinase activity was measured in MBH punches in collaboration with Dr Anita Boelen of 
Department of Endocrinology and Metabolism of the Academic Medical Centre at the 
University of Amsterdam. 
Materials 
1.0mm Micron Biopsy Punch (Harvard Appuratus, Kent, UK) 
PE Buffer (appendix 1) 
4.6 x 250 mm Symmetry C18 column (Waters UK, Hertfordshire, UK) 
Alliance HPLC system (Waters, Etten-Leur, The Netherlands) 
Radiomatic Z-500 flow scintillation detector (Packard, Meriden, CT) 
Method 
Dissected brains were sliced in the coronal plane to the anterior commissure using a sled 
microtome. Three 800µm slices were then sequentially taken and placed onto separate poly-
lysine slides on dry ice. Punch biopsies of the MBH were sampled under a light microscope, 
using a 1mm micron punch, and stored in an eppendorf vial at -80°C. These vials were 
packaged on dry ice and posted to the University of Amsterdam where the following 
methodology was used. 
Samples were homogenised in 10x PE buffer to give approximately 500µl suspensions. Fifty 
microlitres of each sample was used in a reaction in duplicate to allow measurement of D2 
and D3 activity in the same hypothalamic block. Deiodinase activity assays were performed 
as described previously (Boelen et al., 2005, Boelen et al., 2004a). Duplicate incubations of 
homogenates ( 100 µg protein) were incubated for 1 hour at 37 C with 1 nM [3'-
125I]T3/T4 (200,000 cpm) in a final volume of 0.1 ml PE buffer. Reactions were terminated 
by adding 0.1 ml ice-cold methanol. After centrifugation, 0.1 ml of the supernatant was added 
to an equal volume of 0.02 M ammonium acetate (pH 4). One hundred microlitres of this 
mixture were applied to a 4.6 x 250 mm Symmetry C18 column connected to an Alliance 
HPLC system. The column was eluted with acetonitrile (28–42% in 15 min) in 
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0.02M ammonium acetate (pH 4.0). Eluate radioactivity was measured using a Radiomatic Z-
500 flow scintillation detector. 
2.3.6 Radioimmunoassays 
Radioimmunassay (RIA) was used to determine the concentrations of plasma hormones. The 
principle of RIA is based on the competitive nature of the binding of radiolabelled ligand and 
cold ligand for limited antibody binding sites. 
Plasma insulin, TSH and luteinising hormone (LH) were measured by „in-house‟ RIA 
methods. Natural porcine insulin, TSH and LH were iodinated using the iodogen method by 
Professor Mohammed Ghatei (Wood et al., 1981) and purified by HPLC. 
2.3.6.1 Insulin Radioimmunoassay 
Materials 
Phosphate Buffer (appendix I) 
125
I labelled insulin 
Rabbit anti-insulin (MP Biomedicals LLC, Orangeburg, NY) 
Polyethyleneglycol (PEG) 
Method 
Plasma samples were vortexed and analyzed in duplicate using a specific rabbit antiserum 
(primary antibody) and synthetic hormone derivatives labelled with 
125
I as a tracer. Labelled 
insulin was reconstituted in phosphate buffer. Reaction tubes were incubated for 2 hours (22-
25°C), with 200μl of 125I tracer prior to 200μl antiserum. The fractions of insulin were 
separated using charcoal precipitation where the pellet contained antibody-bound substrate 
and the supernatant contained free substrate. These free and bound fractions were counted for 
100 seconds in a gamma scintillation counter and sample concentrations were calculated 
using a data reduction program (NE1600, NE Technology, UK). 
2.3.6.2 Thyroid Stimulating Hormone Radioimmunassay 
Plasma samples were vortexed and analyzed in duplicate using a specific rabbit antiserum 
(MP Biomedicals LLC, Orangeburg, NY) and synthetic hormone derivatives labelled with 
125
I as a tracer. 
Materials 
Kemteck Buffer (appendix I) 
125
I labelled TSH 
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Rabbit anti-TSH (MP Biomedicals LLC, Orangeburg, NY) 
Goat anti-rabbit γ-globulins 
Method 
Plasma samples were vortexed and analyzed in duplicate using a specific rabbit antiserum 
and synthetic hormone derivatives labelled with 
125
I as a tracer. Labelled TSH was suspended 
in kemteck buffer. Samples were incubated for 2 hours (22-25°C), with 200μl of 125I tracer 
prior to 200μl antiserum. Free and bound molecules of TSH were separated using a 
secondary antibody; 500μl of PEG and Goat anti-rabbit γ-globulin in TRIS solution were 
added to each tube prior to centrifugation at 2500rpm for 15 minutes. The pellet and the 
supernatant were counted separately for 100 seconds in a gamma scintillation counter. 
Sample concentrations were calculated using a data reduction program (NE1600, NE 
Technology, UK). 
2.3.6.3 Luteinising Hormone Radioimmunoassay 
Plasma samples were vortexed and analyzed in duplicate using a specific rabbit antiserum 
(MP Biomedicals LLC, Orangeburg, NY) and synthetic hormone derivatives labelled with 
125
I as a tracer. 
Materials 
Kemteck Buffer (appendix I) 
125
I labelled LH 
Rabbit anti-LH (MP Biomedicals LLC, Orangeburg, NY) 
Goat anti-rabbit γ-globulins 
Method 
Plasma samples were vortexed and analyzed in duplicate using rabbit anti-LH. Labelled LH 
was suspended in kemteck buffer. Free and bound molecules of LH were separated using 
secondary antibody. Samples were incubated for 2 hours (22-25°C), with 200μl of 125I tracer 
prior to 200μl antiserum. Secondly, 500μl of PEG and goat anti-rabbit γ-globulin in TRIS 
solution were added to each tube prior to centrifugation at 2500rpm for 15 minutes. Bound 
and free fractions were then separated and counted for 100 seconds in a gamma scintillation 
counter and sample concentrations were calculated using a data reduction program (NE1600, 
NE Technology, UK). 
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2.3.6.2 Leptin Radioimmunoassay 
Materials 
Rat Leptin RIA Kit (Millipore, Watford, UK) 
Method 
Plasma samples were vortexed and were then analyzed in duplicate using a specific rabbit 
antiserum and a synthetic leptin derivative labelled with 
125
I as a tracer. Free and bound 
molecules were separated using secondary antibody. For this, 100µl sample was incubated 
for 24 hours (20-25°C), with 100μl antiserum prior to 100µl of 125I tracer. Secondly, 1ml of 
precipitating reagent was added to each tube and incubated for 20mins prior to centrifugation 
at 2500rpm for 20 minutes. Bound and free fractions were then separated and both the pellet 
and the supernatant counted for 1min in a gamma scintillation counter and sample 
concentrations were calculated using a data reduction program (NE1600, NE Technology, 
UK). 
2.3.6.3 fT3 and fT4 RIA 
Materials 
fT4 RIA Kit (Siemens Medical Solutions, Surrey, UK) 
fT3 RIA Kit (Siemens Medical Solutions, Surrey, UK) 
Method 
Solid phase RIA relies on a specific antibody immobilised to the wall of a polypropylene 
tube.  The antibody is then incubated with 
125
I labelled antigen and unlabelled antigen, from 
standards included in the kit, or sample, for a short fixed time.  The bound and free fractions 
are separated by decanting and the bound fraction counted on a γ-counter.  The non-linear 
calibration curve is determined and the amount of fT3 and fT4 calculated in terms of standard 
preparations.  
The calibrators and 
125
I-labelled antigen were supplied in ready to use liquid form.  Both 
calibrator and sample were added in the appropriate volume (fT3: 100µl, fT4 50µl) before 
addition of 1ml labelled antigen.  The tubes were vortexed before being incubated at 37˚C for 
three hours.  Free and bound fractions were separated by decanting and the remaining activity 
in the tubes counted for sixty seconds.  The mean counts per minute were calculated for 
standard and samples and then plotted against the standards to construct a standard curve.  
The standard curve was used to interpolate the fT3 and fT4 concentrations for the unknown 
samples. 
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2.4 In Vivo Techniques 
2.4.1 Animals 
Male Wistar rats (Charles River, Bicester, UK) were maintained in individual cages under a 
controlled temperature of 21-23˚C with 12 hour light cycles and ad libitum access to food and 
water. All animal procedures were conducted under the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project License 70/6377). 
2.4.2 Intranuclear rAAV Administration Technique 
Materials 
Isoflurane system (Vet-Tech Solutions Ltd., UK) 
Betadine (Seton Healthcare, Oldham,UK) 
Stereotaxic Frame (Clark electromedical instruments, Pangbourne, UK) 
23.5 Gauge Steel Cannula (Plastics One Inc., Roanoke, VA, USA) 
33 gauge steel injector (Plastics One Inc., Roanoke, VA, USA) 
0.9% sodium chloride (Schering-Plough Ltd., UK) 
Buprenorphine (Reckitt-Benckiser Healthcare, Hull, UK) 
Method 
Male Wistar rats, of body weights ranging from 230 to 260g, were anaesthetised with an 
isoflurane system and immobilised on a stereotaxic frame. The incisor bar was set at 3.0mm 
below the interaural plane.  The surgical area was shaved with an electronic razor and cleaned 
with 10% w/v povidine-iodine solution (Betadine).  A small (<2cm) rostro-caudal incision 
was made in the scalp, which was cleared of subcutaneous tissue.  Animals were injected 
bilaterally into the VMN using coordinates -2.8mm caudal, +/-0.7mm lateral to the bregma 
and 9.6mm below the skull, determined from the rat brain atlas of Paxinos and Watson (126). 
A stereotaxically mounted drill was used to make a 0.65mm burr hole in the skull.  A 23.5 
gauge steel cannula was placed, using a cannula arm, bilaterally into the VMN.  Each animal 
was injected via a 33 gauge steel injector, which projected 1mm below the tip of the guide 
cannula.  Either 1µl rAAV-D3 (titre: 5.56x10
12
) genome particles/ml, 1µl rAAV-D2 (titre: 
1.12 x 10
14
), or rAAV-GFP (titre: 5.04x10
12
) genome particles/ml was administered 
bilaterally into the VMN of each rat.  The pressure was removed from the injector and the 
cannula/injector unit was maintained in situ for 5 minutes before being slowly extracted with 
the aid of the stereotaxic frame to minimise backflow. The incision was sutured with two 
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mattress sutures with 6.0 proline thread. All animals received peri-operative care including: 
antibiotics (floxicillin:amoxicillin equal volumes, 37.5 mg/kg, i.p. 1 ml/rat), analgesia 
(buprenorphine, 45 mg/kg s.c. 0.05 ml/rat) and rehydration therapy (0.9% sodium chloride, 
i.p. 2.5 ml/rat). All surgical procedures were performed under aseptic conditions. 
Injection coordinates were initially established and tested by following above procedure on 
eusthanised Wistar rats, where Indian ink was administered to the injection site. Rat brains 
were then dissected (see 2.4.5) and mounted on corkboard, from which sections were taken 
and analysed for injection accuracy. 
2.4.3 Cumulative Food Intake and Body Mass Change  
Male Wistar rats were injected intra-VMN bilaterally with either rAAV-GFP, rAAV-D3 or 
rAAV-D2. After a 7 day recovery period, food intake and body mass were measured three 
times per week (between 09.00-11.00hours). Animals were maintained on either a normal 
chow diet (NCD) (Research Diets) or a high fat diet (HFD) (Research Diets). 
2.4.5 Dark Phase Refeeding Profile 
Food was removed from animal cages either 12hours or 24hours prior to replacement of 
measured food quantity. Food was reweighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured prior to fasting, post-fasting and post-refeeding. 
2.4.5 Collection of Tissue Samples 
Rats were killed by carbon dioxide asphyxiation or decapitation in the early light phase. 
Brains were rapidly removed and lateral sections cut away using a razorblade to isolate 
hypothalami, which were frozen in liquid nitrogen before storage at -80°C. 
Blood was taken by cardiac puncture and collected in heparinised or EDTA-chelated tubes 
containing 100μl aprotinin, and was immediately placed on ice before centrifugation at 4°C 
to obtain plasma. Plasma samples were stored at -80°C until performance of RIA. 
Interscapular BAT was dissected, weighed, frozen in liquid nitrogen and stored at -80°C until 
RNA extraction. 
The contents of rat gastrointestinal tracts were removed before storing carcasses at -20°C in 
preparation for saponification. 
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2.5 Statistical Analysis 
Data are presented as arithmetic means ± standard error of mean (SEM). Differences in body 
mass and cumulative food intake were assessed using a Generalised Estimation Equation 
(GEE) for repeated measures, using Stata 9 software (Stata, StataCorp LP, USA). The GEE is 
used to analyse longitudinal data and highlight correlation between data sets where random 
fluctuations could occur. 
Group differences in body composition, RIA results, and tissue expression were analysed 
using unpaired t-tests, and were considered statistically significant at the 95% confidence 
level (p<0.05). Time-controlled feeding studies and qPCR data were analysed by one-way 
analysis of variance (ANOVA) and corrected for multiple testing using a Bonferroni post-hoc 
test. Data analysis was performed using Graphpad Prism 5 software. 
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Chapter 3  
Production and Analysis of rAAV-D2 and rAAV-D3 
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3.1 Introduction 
The investigations in this research involve the manipulation of D2 and D3 mRNA levels to 
modulate the local levels of T3. D1 enzyme was not utilised as it lacks specificity in its locus 
of deiodination, thus could either activate or inactivate thyroid hormones. The exploitation of 
local enzymatic regulation of hormone activity is advantageous over administration of 
exogenous hormones which would be rapidly degraded in vivo. 
Investigations have previously been carried out to look at the roles of D1 and D2 using 
genetic knock-out (KO) models. D2 KO models exhibit disrupted feedback regulation of 
pituitary TSH secretion (Schneider, 2001), CNS T3 content (Galton et al., 2007), and 
adaptive thermogenesis (De Jesus et al., 2001). Interestingly, combined D1/D2 KO models 
demonstrate only mild phenotypes and are not unlike euthyroid wild-types (Galton et al., 
2009). This indicates that additional mechanisms could exist to compensate for the absence of 
systemic T4 to T3 conversion. D3 KO models are characterised by neonatal thyrotoxicosis 
followed by central hypothyroidism from postnatal day15 to adulthood with decreased levels 
of hypothalamic T3 and elevated TRH (Hernandez et al., 2006a). This phenotype is 
counterintuitive to what would be expected and suggests that D3 is important in defining the 
set-point of HPT feedback regulation by T3 during early postnatal life. 
The complex phenotypes of deiodinase KO models make the extrapolation of the role of 
thyroid hormones an arduous process, given the potential for compensatory changes in the 
expression of other isoforms and the critical role of these hormones in CNS development. 
DNA transfer allows localised expression of genetic material via infection of somatic cells. 
Stereotaxic injection of viral vectors is highly advantageous in the investigation of brain 
function as it allows specific nuclei to be directed in developed animals. 
In this work, recombinant adeno-associated virus (rAAV) has been designed to overexpress 
either the Dio2 gene (rAAV-D2) or Dio3 gene (rAAV-D3) as a means of manipulating 
thyroid hormone activity. 
3.1.1 Non-Viral Gene Transfer Methods 
Gene transfer allows the transduction of genetic material to a cell population. There are a 
number of methods that can be employed for this, with calcium phosphate being one of the 
earliest methods described. A number of techniques have since been developed, including 
liposomes, cationic polymers and electroporation (Davis, 2002). It has also been reported that 
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naked DNA can be injected directly into tissues to overexpress a gene (Zhang et al., 2004, 
Zhang et al., 1997). 
3.1.1.1 Calcium Phosphate Transfection 
Transfection with calcium phosphate relies on precipitates of DNA forming through 
interaction of DNA phosphate groups with calcium ions (Chen and Okayama, 1987). DNA 
and calcium chloride are mixed before the addition of phosphate-buffered saline (PBS). The 
resulting DNA precipitates are thought to enter the cell be endocytosis. The principal benefits 
of this process are its low cost and technical simplicity. Despite its advantages, this method is 
hindered by difficulties in its in vivo application and variation in sizes of DNA precipitates, 
which reduces experimental consistency (Luo and Saltzman, 2000). 
3.1.1.2 Polyethylenimine 
Polyethylenimine (PEI) is a cationic polymer, which can be used as a delivery vector both in 
vitro and in vivo (Chemin et al., 1998). The molecule can exist in two different 
conformations, being either branched or linear. Branched PEI is a more efficient transducer 
and is more commonly used for gene delivery, as it efficiently complexes with DNA. Its 
amine-rich structure neutralises the net negative charge of DNA phosphate groups, which 
facilitates its transport across the plasma membrane. The transduction efficiency depends on 
the molar ratio of PEI nitrogens to DNA phosphate groups, which is an aspect that must be 
optimised to minimise the level of protein binding to the PEI/DNA complex. The optimal 
molar ratio varies across different cell types and DNA constructs (Boussif et al., 1995). 
3.1.2 Recombinant Viruses for Gene Transfer 
There is a wide choice of vector for gene transfer, with each exhibiting different properties 
that make them more or less advantageous for the intended effect. The advantages and 
disadvantages of each vector depend on its method of production, period of expression, 
immune response, tissue tropism, packaging capacity, chromosomal integration and ability to 
infect quiescent cells. These characteristics have been reviewed in a number of publications 
(Thomas et al., 2003, Walther and Stein, 2000, Kay et al., 2001). 
3.1.2.1 Adenovirus 
The principal advantages of adenovirus vectors are their broad range of tissue tropism and 
large packaging capacity (36kb). They are able to infect both quiescent and non-quiescent 
cells, in which the transduced genetic material exists episomally within the nucleus. A 
principal disadvantage is the short duration of overexpression, which is generally limited to 2 
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weeks due to their strong induction of a host immune response. This makes them suitable for 
obtaining acute, transient expression of the genetic material, although chronic investigations 
would be difficult to sustain (Yang et al., 1994). 
3.1.2.2 Herpesvirus 
Herpesviruses are linear, double-stranded DNA (dsDNA) viruses that have a large genomic 
packaging capacity and provide long-term infection. Their natural tropism for neuronal cells 
makes them a useful tool for CNS research. Following infection, the herpesvirus enters a 
latent infection cycle whereby its genetic material does not integrate with the chromosome, 
but rather exists episomally. Herpes Simplex Virus (HSV) has more than 70 gene products, 
some of which encode toxic proteins (McGeoch et al., 1988). Removing these products from 
HSV vectors enables their use in gene transfer (Samaniego et al., 1998), however, retaining 
its efficiency in the face of these deletions complicates its use as a recombinant virus 
(Marconi et al., 1996). 
3.1.2.3 Retrovirus 
Retroviruses are small, single-stranded RNA (ssRNA) viruses. They have 3 essential genes 
flanked by long terminal repeats that are required for integration into the host genome. 
Following infection, transduced RNA is reverse transcribed into dsDNA, which then 
randomly integrates into the host genome. Retroviruses have a modest packaging capacity (7-
8kb), which can be a limiting factor. A major limitation of retroviral vectors is their inability 
to transduce quiescent cells due to the requirement for chromosomal exposure during cell 
division (Miller et al., 1990). 
A member of the retrovirus family is the lentivirus, which is termed so on account of its long 
incubation period. The lentiviruses, often derived from Human Immunodeficiency Viruses 
(HIV), differ from other retroviruses as they are able to gain access to the nucleus 
independently. This enables their transduction of non-dividing cells, such as neurones 
(Carlotti et al., 2004). Stringent measures must be taken in order to prevent recombinant 
lentiviruses from forming a potentially pathogenic strain (Buchschacher Jr and Wong-Staal, 
2000). 
3.1.2.4 Adeno-Associated Virus 
Adeno-associated viruses are small, ssDNA dependoviruses. They are termed 
„dependoviruses‟ as propagation is dependent upon coinfection with an unrelated virus, such 
as adenovirus. More than 11 serotypes of AAV have been characterised of which the most 
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common are types 2, 3 and 5.  Despite more than 80% of adults possessing neutralising 
antibodies against AAV (Russell and Kay, 1999), its residence within the host is generally 
commensal. AAV type 2 (AAV2) was the first characterised serotype and has natural 
neurotropism which allows specific transduction of brain parenchyma with minimal 
expression in neighbouring astroglial cells (Bartlett JS, 1998). 
An AAV particle is approximately 20nm in diameter and is generally stable to changes in 
temperature and pH. The wild-type viral genome consists of two open reading frames; a rep 
(replication) gene, controlled by the promoters P5 and P9, and the cap (capsid) gene, 
controlled by the promoter P40. The ssAAV genome is flanked by inverted terminal repeats 
(ITR), which are 140-170 nucleotides in length and vary across different serotypes. The ITRs 
are essential cis elements of the rAAV genome, important for packaging, self-priming and 
integration of the vector. 
Following successful infection of a cell, the ssAAV genome must be converted into dsDNA. 
This is achieved using the 3‟ ITR, which forms a hairpin loop to prime second strand DNA 
synthesis of the remaining AAV genome. The 3‟ ITR from the „parental‟ strand is transferred 
to the „daughter‟ strand where it used as a template for the original parent strand. The dsAAV 
genome then either integrates into the host genome or exists as a circular episomal element. 
Wild-type AAV (wtAAV) integrates into host chromosome 19q13.42 in the absence of a 
helper virus in its latent state (Kotin et al., 1990). In the presence of a helper virus, wtAAV 
proceeds by replicating and generating new infectious particles. The targeted region of 
chromosomal integration is termed AAVS1 and is located within the MBS85 gene, which is a 
constitutive mediator of actin remodelling (Tan et al., 2001). The estimated efficiency of 
AAVS1-targeted integration by wtAAV  is approximately 40–70% (Daya and Berns, 2008). 
Rep 68 and Rep 78, wtAAV proteins produced from transcripts under the control of the p5 
promoter, are trans-acting elements which appear to be required for AAVS1 targeting 
(Weitzman et al., 1994). 
3.1.2.5 Recombinant AAV 
Recombinant AAV (rAAV) is employed as a viral vector system for the delivery of genetic 
material to host cells. The recombinant virus is devoid of its Rep and Cap genes with only 
ITRs remaining, which act as primers for auto-regulation of its transcription. When 
administered directly to brain parenchyma, rAAV does not prime an immune response and 
allows sustained overexpression of a gene after a single surgical session. 
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Genetic material transduced by the recombinant virus may either incorporate into the host 
genome or exist extrachromosomally as an episomal genome in vivo. Research to date 
suggests that AAV integration is largely dependent on the presence of the integration 
efficiency element (IEE) of the p5 promoter and certain regions of the Rep gene in addition 
the ITRs (Philpott et al., 2002, Weitzman et al., 1994). Therefore, chromosomal integration of 
the rAAV genome is relatively inefficient, with an estimated 85 - 95% of rAAV genetic 
material existing episomally (Schnepp et al., 2005, Afione et al., 1996). One investigation 
highlighted that, following rAAV transduction of hepatic tissue, partial hepatectomy (to 
induce cell division) resulted in approximately 85% reduction in vector genome between 12 
weeks and 12 months post-infection (Nakai et al., 2001). In studies of rAAV transduction of 
mouse muscle tissue, it was demonstrated that the majority of vector DNA existed as double-
stranded circular DNA, the conformation that is adopted by extrachromasomal episomes 
(Schnepp et al., 2003). This does not confound the efficiency of rAAV vectors given that, 
unlike other vectors, they do not require chromosomal integration for efficient replication 
(Flotte et al., 1994). However, it is estimated that rAAV infection of quiescent cells would be 
stable for long term investigations, although its persistence in mitotic cells could be relatively 
short-lived (McCown et al., 1996). 
The efficiency of rAAV vectors can be improved by a variety of transcriptional elements. 
The cytomegalovirus (CMV) promoter has been frequently used to drive strong expression in 
the CNS, where high expression is witnessed 3 weeks after rAAV injection, but reduced by 4 
months post-injection (Kaplitt et al., 1994). This silencing of the CMV promoter has been 
linked to its susceptibility to transcriptional activation by methylation of cysteine on CpG 
(cytosine per guanine) dinucleotides (Prösch et al., 1996). However, additional modifications 
to the rAAV construct can be made to optimise the persistence of vectors under the control of 
the CMV promoter. The woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE) can be inserted, downstream of transgene sequence, to improve 3‟ RNA processing, 
increase vector titre, and ultimately stabilise mRNA accumulation within infected cells 
(Schambach et al., 2005). 
There are a number of disadvantages of using AAV for gene transfer. Being derived from one 
of the smallest DNA viruses, AAV constructs larger than 4.7kb are difficult to integrate into 
the viral genome. The AAV viral genome consists of ssDNA which must be converted to 
dsDNA before transgene expression reaches an optimal level (Ferrari et al., 1996). This 
process may reduce rAAV efficiency during the first few weeks after infection (Afione et al., 
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2000). This limitation may be overcome by the use of self-complementary AAV vectors 
(scAAV), which are designed to bypass this phase of ssAAV to dsAAV conversion, by virtue 
of its palindromic dsDNA structure (McCarty et al., 2001). However, this reduces the rAAV 
vector capacity to approximately 2.4kb, which limits its use in research (Wu et al., 2007). 
3.2 Aims of Study 
To produce and evaluate the efficacy of plasmid constructs and rAAV titres that overexpress 
Dio2 and Dio3. 
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3.3 Experimental Results 
Plasmid vectors were designed to overexpress the iodothyroinine deiodinase genes Dio2 and 
Dio3 (figure 3.1). Both enzymes require the SECIS element for optimal efficacy in 
deiodination. In the case of the Dio2 gene, the SECIS coding region lies 7.4kb downstream of 
the D2 coding sequence, in the 3‟ UTR (Buettner et al., 1998). Incorporation of this full 7.4kb 
fragment into rAAV would be extremely difficult, given this vector‟s packaging limitations 
(Le Bec and Douar, 2006). When designing the rAAV-D2 plasmid construct, the SECIS was 
manually inserted downstream of the Dio2 in much closer proximity. It has been reported that 
closer association of the D2 and SECIS coding sequences by deletion of a 3.7kb UTR 
sequence can in fact increase D2 activity (Gereben et al., 2002). 
The Dio2 coding sequence was subcloned into pTR-CGW, before subsequent downstream 
ligation of the SECIS element. This was not required for the rAAV-D3 construct, as the 
SECIS locus is within suitable proximity of the Dio3 gene. 
JEG3 cells selected for transfection as they exhibit very little endogenous deiodinase 
expression (Friesema et al., 2006). The prepared plasmid constructs were used to generate in 
vitro models of D2 and D3 overexpression for the analysis of deiodinase activity and cellular 
secretion of thyroid hormone molecules. Following these tests of efficacy, the plasmids were 
packaged into AAV virions with titre stored for the subsequent in vivo experiments. 
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Figure 3.1 Plasmid maps of pTR-CGW constructs. A, rAAV-D2 expression cassette; B, rAAV-
D3 expression cassette. Restriction sites are indicated with arrows and number of nucleotides 
from the first base of the ITR is indicated in parentheses. 
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3.3.1 Amplification of Dio3, Dio2, and SECIS cDNA by RT-PCR 
The PCR products from each reaction were analysed on a 1% TAE/Agarose gel. Each band 
corresponded to the expected size of the amplicon when compared to a 1kb DNA ladder, 
where Dio2 was 959bp, SECIS 600bp and Dio3 1495bp (figure 3.2). 
 
Figure 3.2: Agarose gel to show relative sizes of PCR amplicons. Lane 1; 1KB ladder 
(Invitrogen, UK) with bands marked for 500bp, 1000bp, 1500bp and 2000bp. Lane2; Dio2 
amplicon of 959bp. Lane 3; SECIS amplicon of 600bp. Lane 4; Dio3 amplicon of 1495bp. 
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3.3.2 Small-Scale Preparation of Transformed Bacteria 
Each ligated product was used to transform competent JC8111 bacteria, which were selected 
for the antibiotic resistance marker present in the pTR backbone by plating the bacteria on 
ampicillin-positive plates. Ten individual colonies were subsequently cultured and analysed 
for the presence of the correct insert by restriction digest. Example given shows pTR-CGW-
D2-SECIS transformed colonies in lanes 3, 4, 6, 7, 8, 9, 10, and 11 possessing the correct 
1559bp Dio2-SECIS ligated product (figure 3.3A). 
The integrity of AAV ITRs was checked by XmaI restriction digest on each sample, as the 
ITR sequence contains the XmaI restriction site. The intensity of the 2 smaller sized 
fragments (2905bp, 3323bp), representing plasmid with ITRs successfully digested by XmaI, 
was compared to the intensity of the largest, undigested fragment (6228bp), representing 
plasmid deficient of ITRs. Figure 3.3B shows recovered DNA from pTR-CGW-D2-SECIS 
transformed colonies following XmaI restriction digest. The band profile visualised in lanes 
3, 4, 7 and 9 indicates a good ITR ratio). 
From this array of transformants, the colony represented by lane 4 was selected for large 
scale preparation and processing for rAAV production, as it was deemed to show the best 
overall profile. 
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Figure 3.3: Agarose gels demonstrating restriction digests of small-scale preparations of 
transformed bacteria. A: BamHI and BsrgI double-digest to reveal presence of Dio2-SECIS. 
B: XmaI digest to reveal presence of AAV ITRs in transformed Ptr plasmid. Lane1, 1KB+ 
DNA ladder (Invitrogen, UK); Lanes 2 -11, DNA samples from small-scale preparations of 
transformants.  
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3.3.3 Sequencing of pTR-CGW Plasmids 
Sequencing of pTR-CGW plasmids was performed in both directions using a dye-termination 
protocol in collaboration with the Advanced Biotechnology Centre at Hammersmith Hospital, 
London. Sequence data obtained from the resulting chromatogram was uploaded onto NCBI 
nucleotide blast to compare the plasmid sequence homology with the NCBI gene database. 
TGACTGGGGAAGCAGAGTGCCCAGGAGACTGACCGAGGAGGCAGAGAAGATGGGACTCCT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGACTGGGGAAGCAGAGTGCCCAGGAGACTGACCGAGGAGGCAGAGAAGATGGGACTCCT 
 
CAGCGTAGACTTGCTGATCACCCTGCAGATCCTGCCAGTCTTTTTCTCCAACTGCCTCTT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGCGTAGACTTGCTGATCACCCTGCAGATCCTGCCAGTCTTTTTCTCCAACTGCCTCTT 
 
CCTGGCGCTCTATGACTCGGTCATTCTGCTCAAGCACGTGGCGTTGCTTCTGAGCCGCTC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCTGGCGCTCTATGACTCGGTCATTCTGCTCAAGCACGTGGCGTTGCTTCTGAGCCGCTC 
 
CAAGTCCACTCGCGGAGAGTGGAGGCGCATGCTGACCTCAGAAGGGCTGCGCTGTGTCTG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAAGTCCACTCGCGGAGAGTGGAGGCGCATGCTGACCTCAGAAGGGCTGCGCTGTGTCTG 
 
GAACAGCTTCCTCCTAGATGCCTACAAACAGGTTAAACTGGGTGAAGATGCTCCCAATTC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GAACAGCTTCCTCCTAGATGCCTACAAACAGGTTAAACTGGGTGAAGATGCTCCCAATTC 
 
CAGTGTGGTGCACGTCTCCAATCCTGAATCAGGTAACAATTATGCCTCGGAGAAGACCGC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGTGTGGTGCACGTCTCCAATCCTGAATCAGGTAACAATTATGCCTCGGAGAAGACCGC 
 
TGATGGGGCCGAATGCCACCTTCTTGACTTTGCCAGTGCAGAGCGCCCACTGGTGGTCAA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGATGGGGCCGAATGCCACCTTCTTGACTTTGCCAGTGCAGAGCGCCCACTGGTGGTCAA 
 
CTTTGGTTCAGCCACCTGACCACCTTTCACTAGGCAACTGCCAGCCTTCCGCCAGCTGGT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTTTGGTTCAGCCACCTGACCACCTTTCACTAGGCAACTGCCAGCCTTCCGCCAGCTGGT 
 
GGAAGAGTTCTCCTCGGTGGCTGACTTCCTGTTGGTATACATTGATGAGGCTCACCCTTC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGAAGAGTTCTCCTCGGTGGCTGACTTCCTGTTGGTATACATTGATGAGGCTCACCCTTC 
 
GGATGGCTGGGCAGTGCCTGGGGACTCCTCTCTGTCTTTTGAGGTTAAGAAGCACCGGAA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGATGGCTGGGCAGTGCCTGGGGACTCCTCTCTGTCTTTTGAGGTTAAGAAGCACCGGAA 
 
CCAAGAGGACCGATGTGCAGCAGCTCACCAGCTCCTGGAGCGTTTCTCCTTGCCGCCCCA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCAAGAGGACCGATGTGCAGCAGCTCACCAGCTCCTGGAGCGTTTCTCCTTGCCGCCCCA 
 
GTGTCAAGTTGTGGCTGACCGCATGGACAATAATGCCAACGTAGCTTACGGGGTAGCCTT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GTGTCAAGTTGTGGCTGACCGCATGGACAATAATGCCAACGTAGCTTACGGGGTAGCCTT 
 
TGAACGTGTGTGCATCGTGCAGAGACGGAAAATTGCTTACTTAGGAGGGAAGGGCCCCTT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGAACGTGTGTGCATCGTGCAGAGACGGAAAATTGCTTACTTAGGAGGGAAGGGCCCCTT 
 
CAGCTATAACCTACAAGAAGTCCGAAGTTGGCTGGAGAAGAATTTCAGCAAGAGATGAAT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGCTATAACCTACAAGAAGTCCGAAGTTGGCTGGAGAAGAATTTCAGCAAGAGATGAAT 
 
TCTAGATTAGCTGGATACAAGTGTGATTGTAATAGAGTTTATTATTTTAAAGAAATATGT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCTAGATTAGCTGGATACAAGTGTGATTGTAATAGAGTTTATTATTTTAAAGAAATATGT 
 
AAAAGAAGTTGAGAACTGAACTGAATCTATTATTTCAACTGAATCCCATTGCCTCACCG 
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAAAGAAGTTGAGAACTGAACTGAATCTATTATTTCAACTGAATCCCATTGCCTCACCG 
   
A 
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TGGTGGTCGGAGAAGGTGAAGGGCCCCCGGGGGCTTCGGGGCCCGCGGCCACCATGCTGC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGGTGGTCGGAGAAGGTGAAGGGCCCCCGGGGGCTTCGGGGCCCGCGGCCACCATGCTGC 
 
GCTCCCTGCTGCTTCACTCTCTGAGGCTCTGCGCCCAGACCGCCTCGTGCCTCGTGCTGT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCTCCCTGCTGCTTCACTCTCTGAGGCTCTGCGCCCAGACCGCCTCGTGCCTCGTGCTGT 
 
TCCCGCGCTTCCTAGGCACGGCCTTCATGCTCTGGCTTTTAGATTTCTTGTGCATCCGCA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCCCGCGCTTCCTAGGCACGGCCTTCATGCTCTGGCTTTTAGATTTCTTGTGCATCCGCA 
 
AGCATTTCCTGCGCCGTCGTCATCCTGACCACCCCGAGCCCGAAGTAGAGCTCAACAGTG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGCATTTCCTGCGCCGTCGTCATCCTGACCACCCCGAGCCCGAAGTAGAGCTCAACAGTG 
 
AAGGTGAGGAGATGCCCCCTGACGACCCACCCATCTGCGTATCCGACGACAACCGGCTGT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AAGGTGAGGAGATGCCCCCTGACGACCCACCCATCTGCGTATCCGACGACAACCGGCTGT 
 
GCACCCTGGCCTCTCTCAAGGCCGTGTGGCATGGCCAGAAGTTGGATTTCTTCAAGCAGG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCACCCTGGCCTCTCTCAAGGCCGTGTGGCATGGCCAGAAGTTGGATTTCTTCAAGCAGG 
 
CCCATGAGGGTGGCCCAGCACCTAACTCGGAGGTCGTCCGGCCTGATGGCTTCCAGAGCC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCCATGAGGGTGGCCCAGCACCTAACTCGGAGGTCGTCCGGCCTGATGGCTTCCAGAGCC 
 
AGCGCATCCTCGACTACGCACAAGGGACCCGCCCGTTGGTGCTCAATTTTGGCAGCTGTA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGCGCATCCTCGACTACGCACAAGGGACCCGCCCGTTGGTGCTCAATTTTGGCAGCTGTA 
 
CCTGACCACCGTTCATGGCGCGGATGAGCGCCTTCCAGCGCCTGGTCACCAAGTACCAGC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCTGACCACCGTTCATGGCGCGGATGAGCGCCTTCCAGCGCCTGGTCACCAAGTACCAGC 
 
GCGACGTTGACTTCCTTATCATCTACATCGAGGAAGCCCACCCATCCGATGGCTGGGTCA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GCGACGTTGACTTCCTTATCATCTACATCGAGGAAGCCCACCCATCCGATGGCTGGGTCA 
 
CCACAGATTCACCCTACGTCATCCCACAGCACCGCAGCTTGGAGGACCGTGTCAGCGCAG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCACAGATTCACCCTACGTCATCCCACAGCACCGCAGCTTGGAGGACCGTGTCAGCGCAG 
 
CAAGAGTACTTCAGCAAGGCGCACCTGGCTGTGCTCTGGTTCTGGACACGATGGCCAACT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAAGAGTACTTCAGCAAGGCGCACCTGGCTGTGCTCTGGTTCTGGACACGATGGCCAACT 
 
CCAGCAGTTCCGCATATGGTGCCTATTTTGAGCGCCTCTACGTCATCCAGAGCGGCACCA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCAGCAGTTCCGCATATGGTGCCTATTTTGAGCGCCTCTACGTCATCCAGAGCGGCACCA 
 
TCATGTACCAGGGAGGCCGTGGCCCCGACGGTTACCAGGTGTCTGAGTTGCGCACTTGGT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCATGTACCAGGGAGGCCGTGGCCCCGACGGTTACCAGGTGTCTGAGTTGCGCACTTGGT 
 
TGGAGCGCTATGACGAGCAGTTGCATGGTACTAGGCCACGTCGACTCTAAAAAACCAAGG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGGAGCGCTATGACGAGCAGTTGCATGGTACTAGGCCACGTCGACTCTAAAAAACCAAGG 
 
GACAAGTGACTGAATTGGTGGGCTGGGTCTTCTGGGCCTTCGAAGCTCATGTGCGAATGC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GACAAGTGACTGAATTGGTGGGCTGGGTCTTCTGGGCCTTCGAAGCTCATGTGCGAATGC 
 
TCCAAAAGAAGTCAAGGTTTTCAGGGGTCCCGTGACACAGATGAGCACAGCCACAGAACT 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TCCAAAAGAAGTCAAGGTTTTCAGGGGTCCCGTGACACAGATGAGCACAGCCACAGAACT 
 
CAGGCTGAGTCTGGCTAACTTGAGACTCTGCTATAGTGACTCCCTTTTGGTACTTTTTGG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGGCTGAGTCTGGCTAACTTGAGACTCTGCTATAGTGACTCCCTTTTGGTACTTTTTGG 
 
CTTGCTTTCTGGAGCATTGCTGTGGCTCGAACTGGCAACTTTGTCCCTGCTGAAGTTTAC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTTGCTTTCTGGAGCATTGCTGTGGCTCGAACTGGCAACTTTGTCCCTGCTGAAGTTTAC 
B
 
 A 
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CTGCTGGACTTTCTGACACCTGCTCCCCAGCGCTATTTCAGCAAAGCGCAATAAGTCGCC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGCTGGACTTTCTGACACCTGCTCCCCAGCGCTATTTCAGCAAAGCGCAATAAGTCGCC 
 
AGCATCTCACAGCTCGGGACTTGTTGGCCACGCCCGCGCGCCCTGAGCGCAGCTGGGTTC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
AGCATCTCACAGCTCGGGACTTGTTGGCCACGCCCGCGCGCCCTGAGCGCAGCTGGGTTC 
 
CAGCAGCGCCTCCGGCTCTAGCTAGTTGCCTGGCACCCACCTGTCGAGAGCAGGGAGTCC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CAGCAGCGCCTCCGGCTCTAGCTAGTTGCCTGGCACCCACCTGTCGAGAGCAGGGAGTCC 
 
TGCTGCTTTTGTGTTTATTTCTTATCCCTGGGTTGGGGGAGGGGCTCAAGATAAAGGGTG 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGCTGCTTTTGTGTTTATTTCTTATCCCTGGGTTGGGGGAGGGGCTCAAGATAAAGGGTG 
 
GGCAGGGTAATTTCCCCGCCTAGCTTTAGGTGCGCTGGAACCCTGGCTGCTGATGACGAA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GGCAGGGTAATTTCCCCGCCTAGCTTTAGGTGCGCTGGAACCCTGGCTGCTGATGACGAA 
 
CCGCCTCTAACTGGGCTTGACCACGGGTCGGCTCTGAATTGCAGAGGGGCTCGAAACAGC 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCGCCTCTAACTGGGCTTGACCACGGGTCGGCTCTGAATTGCAGAGGGGCTCGAAACAGC 
 
  GCCTAAAGTA 
  |||||||||| 
  GCCTAAAGTA 
Figure 3.4: Sequencing data for pTR-CGW-D2-SECIS and pTR-CGW-D3. The submitted 
queries were 100% homologous to the Dio2 (A) and Dio3 (B) cDNA gene sequences (NCBI 
Refs: NM_172119.2, NM_017210.3 respectively). Areas highlighted blue indicate location of 
oligos used for sequencing reactions; areas highlighted yellow indicate coding sequences; 
areas highlighted black with yellow text indicate location of Sec codon; area highlighted 
black with red text indicates region containing conserved SECIS elements. 
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3.3.4 Effect of Plasmid Transfection on Deiodination in vitro 
The efficacies of pTR-CGW-D2 and pTR-CGW-D3 were assessed by transfection of these 
plasmids into JEG3 cells, where pTR-CGW was used as a control plasmid. The fT3 and fT4 
concentrations of DMEM/F12 (10% FBS) media were used as markers of deiodination by the 
transgenes. RIA was used to measure the concentrations of fT3 and fT4 in the culture 
medium twenty-four hours after replenishment with fresh media, which was added 
approximately 48 hours after transfection (see section 2.2.3). Data are expressed as 
percentage of pTR-CGW values for each hormone. 
The RIA results (figure 3.5) demonstrated that, following pTR-CGW transfection, both fT3 
and fT4 levels were at 8.1 +/- 0.03pmol/L and 7.5 +/- 0.43pmol/L, respectively. In the case of 
fT4, this was not significantly affected by pTR-CGW-D2-SECIS (96.1 +/- 9.2% of pTR-
CGW value) or pTR-CGW-D3 transfection (112.1 +/- 5.1% of pTR-CGW value). 
However, fT3 concentrations were affected, whereby pTR-CGW-D2-SECIS treated cells 
showed significantly (P=0.01) higher levels of fT3 (110.6 +/- 2.3% of pTR-CGW value) and 
pTR-CGW-D3 transfected cells showed significantly (P=0.002) lower levels of fT3 (94.3 +/- 
0.8% of pTR-CGW value). 
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Figure 3.5: Free T3 and free T4 concentrations 24 hours after replacement of DMEM/F12, 
10% FBS. Media content of fT3 and fT4 was measured by RIA 48 hours after calcium 
phosphate transfection of either pTR-CGW (green bars) (n=4), pTR-CGW-D2-SECIS (blue 
bars) (n=4), or pTR-CGW-D3 (black bars) (n=4). Data are expressed as percentage of pTR-
CGW values for each hormone. * P<0.05, ** P<0.01 
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3.3.5 Effect of Plasmid Transfection on Deiodinase Activity in vitro 
The level of deiodinase activity was analysed and compared in JEG3 cells transfected with 
either pTR-CGW or pTR-CGW-D3. The effect of pTR-CGW-D2 was not investigated as D2 
enzyme activity must be measured in fresh cell homogenate, which would be unlikely to 
maintain viability through transport to Amsterdam (Department of Endocrinology and 
Metabolism of the Academic Medical Centre at the University of Amsterdam). 
Activity measurements demonstrated that pTR-CGW-D3 produced a higher level of D3 
activity (51.28 +/- 8.54 fmol/min/mg) than pTR-CGW (5.23 +/- 0.86 fmol/min/mg), which 
was a statistically significant difference (P < 0.001) (figure 3.6). 
 
Figure 3.6: Iodothyronine deiodinase III activity in transfected JEG3 cells. D3 activity was 
measured in thawed JEG3 cell homogenate, which had been harvested 72 hours post calcium 
phosphate transfection of either pTR-CGW (green bar) (n=5) or pTR-CGW-D3 (black bar) 
(n=5). Data are expressed in fmol/min/mg. ***P<0.001 
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3.3.6 Dot Blot Analysis of Purified rAAV Titres 
Dot blot analysis was performed to determine the yield of the purified rAAV titres. A 
standard curve was prepared covering three logs of pTR-CGW quantity (figures 3.7A and 
3.7B). The phosphorescence of the rAAV preparation (rAAV-D3 shown here as an example) 
was interpolated into this standard curve, in neat and 1:10 dilutions (figure 3.7C), with the 
quantity of plasmid then extrapolated. The rAAV-GFP titre yielded 1.5 x 10
14 
vg/ml, the 
rAAV-D2  titre was 1.7 x 10
14 
vg/ml and the rAAV-D3 titre was 1.8 x 10
14 
vg/ml. 
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Figure 3.7: Dot Blot Analysis of rAAV Titres. Phosphorescence obtained from standard curve 
serial dilutions of rAAV-GFP (A). Quantity of pTR-CGW plotted versus phosphorenscence 
(B). Neat and 1:10 dilutions of rAAV-D3 (n=3) (C). 
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3.4 Discussion 
Gene transfer was chosen as a method for manipulating thyroid hormone levels within the 
hypothalamus. KO models are confounded by developmental compensation; therefore it was 
important to choose a strategy that allows physiological manipulation of a developed animal 
model. Previously, direct administration of T3 to the hypothalamus has been used to 
investigate its role within this brain region. However, this technique is limited by the duration 
of T3 persistence. An alternative strategy to combat this limitation would be the use of 
osmotic minipumps, which have been used to prolong administration of T3 to the PVN in 
more long-term investigations. However, this method is limited by the safety of having these 
minipumps secured to the rat in vivo for an extended period of time, whereas rAAV can be 
administered and expressed indefinitely after a single neurosurgical session. Therefore, gene 
transfer of the iodothyronine deiodinases was deemed the optimal research strategy for the 
investigations. 
Recombinant AAV was the vector of choice for these investigations amid the availability of a 
range of other viral vectors. For the long-term transduction of the CNS, lentiviral vectors and 
AAV are most frequently used given their ability to transduce quiescent cells and their lack 
of immunogenicity. AAV has been identified as the optimal vector for the transduction of the 
hypothalamus and amygdala, when it was demonstrated that more cells can be efficiently 
transduced using rAAV in comparison to lentiviral vectors (de Backer Marijke et al., 2010). 
The basic design of the pTR-CGW packaging constructs was to overexpress the appropriate 
gene through the combined action of the CMV promoter and the WPRE, which is known to 
achieve a sustained, high-level of transgene expression. In the case of rAAV-D2, the process 
was slightly more complex due to the necessity for a manual insertion of the SECIS. The 
SECIS was placed in closer proximity to the Dio2 coding region, which has been shown to 
have a positive impact on D2 activity (Ferrari et al., 1996). However, the effect of situating 
the SECIS element in such close proximity to the WPRE is not known and could influence 
the efficacy of either element. Thus, given that the manual insertion of SECIS was not 
optimised and evaluated, it is not certain that this vector system was of maximal efficiency. 
Each pTR-CGW construct was transfected into JEG3 cells in order to assess its respective 
efficacy on thyroid hormone metabolism prior to its use in rAAV production. This was 
achieved by the measurement of fT3 and fT4 concentrations in cell media samples after 24 
hours incubation. The results indicated that pTR-CGW-D2-SECIS increased the level of 
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cellular T3 secretion and pTR-CGW-D3 decreased T3 secretion. This was expected given the 
repective roles of D2 and D3. However, T4 levels were not of a detectable difference 
between each group. 
A more comprehensive profile would be gathered if a time-course experiment were 
undertaken. This would involve sampling culture medium at various time points over a 
twenty-four hour period following the introduction of cell media with a known starting 
concentration of hormones, rather than simply relying on FBS for the fT3 and fT4 pool. This 
would provide greater detail of the kinetics of each construct in addition to a more 
quantitative set of data, rather than proportional differences. 
The efficacies of the constructs were tested further by measuring iodothyronine deiodinase 
enzyme activity in transfected JEG3 cells. This was carried out in collaboration with Dr Anita 
Boelen at the University of Amsterdam who was able to measure D3 enzyme activity in 
frozen homogenates. D2 enzyme activity was not measured in JEG3 cells as the enzyme is 
must be measured in fresh cell homogenate, which would be unlikely to survive transport to 
Amsterdam. The D3 activity measurements demonstrated that the pTR-CGW-D3 construct 
produced an almost ten-fold higher level of JEG3 cell D3 activity than pTR-CGW. This 
indicated that the pTR-CGW-D3 construct was effective in vitro and was suitable for use in 
production of rAAV. 
The production method for the rAAV titres used in these investigations involved a two 
plasmid transfection system, whereby the adenoviral helper genes were present on a single 
vector (pDG) and transfected simultaneously with the packaging vector (pTR-CGW) (Grimm 
et al., 1998). This improved method is identified as a safer and more efficient alternative to 
the adenovirus-dependent transduction method for the production of high quality AAV 
serotype 2 vectors that efficiently infect rat brain cells (Grimm et al., 2003). 
The vector stocks of rAAV-GFP, rAAV-D2 and rAAV-D3 were all quantified and 
demonstrated high viral particle numbers. The infectious titres were not measured subsequent 
to this, although it has been reported that purification of rAAV using a NHS-activated 
HiTrap-Sepharose column yields infectious titres of more than 65% of the total particle 
number (Grimm et al., 1998). Therefore, the infectious titres would be expected to be in the 
region of 7 x 10
13
 vg/ml, which would be sufficient for use in the intended 1µl injection 
volumes in vivo. 
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Chapter 4  
The Effect of rAAV-D2 to the VMN of Rats 
Maintained on a Normal Chow Diet 
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4.1 Introduction 
Thyroid hormones are important for the hypothalamic regulation of several homeostatic 
pathways, such as; the HPT axis, torpor, the gonadal axis and appetite. Their activity within 
the CNS is controlled through the coordinated regulation of the iodothyronine deiodinases. 
Acute administration of T3 to the VMN of male Wistar rats induced a rapid hyperphagic 
response. D2 is the principal thyroid hormone activator, which produces active T3 hormone 
from the T4 precursor. 
In this chapter, the physiological role of T3 in the VMN has been investigated in chronic 
investigations whereby rAAV-D2 has administered to achieve a long-term increase in Dio2 
mRNA levels. D2 has a very short half-life and is extremely labile in vivo, therefore the 
mechanism of its rapid clearance by ubiquitination has been reviewed. 
4.1.1 Iodothyronine deiodinase II in the Hypothalamus 
As previously mentioned, D2 expression in the hypothalamus is limited to astrocytes and a 
subset of glial cells known as tanycytes (Lechan and Fekete, 2007), where Dio2 mRNA is 
expressed at a high concentration relative to other CNS regions (Fekete et al., 2000, 
Guadaño-Ferraz et al., 1997, Tu et al., 1999). The tanycytes can be classified as either α-
tanycytes or β-tanycytes, which are then further organised into α-1, α-2, β-1 and β-2 
subtypes. α-1 and α2 tanycytes line the walls of the third ventricle and can be distinguished 
by their endpoints. α1 tanycytes project to the VMN and appear to terminate on neurones, 
whereas α2 tanycytes project to the ARC ending either on a single capillary vessel or a single 
neurone, or extend to join the basal processes of β-1 tanycytes (Rodriguez et al., 1979, 
Akmayev et al., 1973). 
T4 is transported into a third ventricle tanycyte, both passively and by OATP1C1, before 
undergoing deiodination. The product T3 is then transported out of the tanycyte, facilitated 
by the transporter MCT8, which effluxes the molecule into the extracellular space. From 
here, T3 can enter neighbouring neuronal cells to mediate its effects on neuronal metabolism 
(Freitas et al., 2010). In neurones, T3 has been shown to mediate its effects via both genomic 
and extragenomic interactions, generally via the TR, of which both the TRα and TRβ 
isoforms are expressed throughout the hypothalamus in rats and humans (Alkemade et al., 
2005, Bradley et al., 1989). 
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D2 mRNA in the brain is transcriptionally regulated by numerous effects, such as stress, 
trauma, light, infection and hypothyroidism (Fekete and Lechan, 2007, Fliers et al., 2006, 
Lechan and Fekete, 2005). It has been reported that D2-expressing tanycytes are in direct 
opposition to NPY/AgRP neurones in the MBH (Coppola et al., 2007). In some rodent 
species, hypothalamic D2 activity exhibits a 12hour light/dark cycle which coincides with 
their metabolic activity. Furthermore, hypothalamic D2 activity increased in the fasted state 
(Diano et al., 1998). This increase in D2 activity has been linked to the relationship between 
circulating leptin levels and corticosterone (Coppola et al., 2005). It was reported that D2 
activity is not affected by leptin in the fed state, but interestingly leptin administration 
attenuated the fasting-induced increase in D2. Furthermore, adrenalectomized rats did not 
show fasting-induced induction of D2 activity until they were treated with exogenous 
corticosterone. Leptin administration to these animals attenuated the rise in D2 activity. This 
presents an interesting pathway in which fasting-associated reductions in plasma leptin plays 
a role in D2 regulation via modulation of corticosterone. 
4.1.1.1 Triiodothyronine in Hypothalamic Regulation of Food Intake 
T3 serves essential roles in hypothalamic pathways of appetite regulation. It has already been 
mentioned that peripheral administration of T3 increases Egr1 immnuoreactivity in the VMN 
and direct administration of T3 to the VMN potently increases food intake in male Wistar 
rats, (Kong et al., 2004). These findings were not associated with any changes in locomotion 
or hypothalamic neuropeptide levels, therefore the effect was perceived to be solely on 
appetite. 
The downstream mediators of T3 signalling within the CNS have been the focus of 
investigation, where several hypothalamic neuropeptides and adenosine monophosphate 
kinase (AMPK) have been presented as potential contributors to T3-associated hyperphagia. 
It has been reported that Sprague-Dawley rats with T3-induced thyrotoxicosis display 
hyperphagia with suppressed circulating leptin levels, increased hypothalamic NPY mRNA 
levels and decreased hypothalamic POMC mRNA levels (Ishii et al., 2000). Furthermore, it 
was reported that subcutaneous administration of 4.5nmol/kg T3 induced a 70% increase in 
hypothalamic AMPK activity complete with a 90% increase in phosphorylated ACC, the 
inhibited form of this enzyme (Ishii et al., 2008). Inhibition of ACC reduces the local 
concentration of malonyl CoA, which is known to promote food intake. Therefore, given that 
AMPK is known to inhibit ACC by phosphorylation, it was suggested that T3 stimulates 
feeding via activation of AMPK and modulation of hypothalamic fatty acid metabolism. 
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4.1.3 Post-Translational Regulation of Iodothyronine Deiodinase II 
It is essential that D2 protein activity is regulated tightly given the potency of its product T3. 
In addition to its transcriptional regulation, important post-translational modifications of D2 
exist to ensure that its activity is maintained at a safe level (Burmeister et al., 1997). This is 
reflected by its half-life of approximately 40 minutes. In comparison, the half-life of D1 is 12 
hours (Gereben et al., 2000). One post-translational modification to D2 enzyme is its 
ubiquitination, which results in its degradation. This complicates efforts to locally 
overexpress this enzyme. The ubiquitination of D2 can be instigated by substrate inhibition 
from physiological concentrations of T4, rT3 and high concentrations of T3 (Sagar et al., 
2007, Obregon et al., 1986). This potent and rapid feedback loop ensures that T3 levels are 
maintained within an appropriate physiological range and protects the cell from a potentially 
damaging hyperthyroid state. 
Proteins with short half-lives, such as D2, are conjugated to ubiquitin prior to their 
proteasomal degradation. There are three essential components of this mechanism: E1, which 
activate the ubiquitin enzyme; E2, which conjugate the target; and E3, the ubiquitin ligases 
that facilitate assembly of the ubiquitination complex (Varshavsky, 1997). The E2 enzymes 
that have been identified as regulators of D2 ubiquitination include UBC6 and UBC7, where 
yeast strains lacking these enzymes exhibit stabilised D2 activity and impaired sensitivity to 
substrate-induced degradation (Botero et al., 2002). An E3 enzyme, WSB1 (WD repeat and 
SOCS box-containing protein 1), has been identified as a D2-specific ubiquitin ligase 
(Callebaut et al., 1997, Dentice et al., 2005). TEB4 is another E3 ligase that has been co-
localised with WSB1 in D2-expressing cells, suggesting that D2-specific ubiquitination 
involves the interaction of a number of proteins. 
It has been demonstrated that the WSB1 gene locus of chromosome 11 undergoes a 
chromosomal interaction with an imprinted Igf2/H19 locus on chromosome 7, which is 
required for appropriate WSB1 expression (Krueger and Osborne, 2006, Ling et al., 2006, 
Spilianakis and Flavell, 2006). This Igf2/H19 locus is part of a large network that also 
regulates Dio3 expression, thus it is possible that the regulation of both D2 and D3 are linked 
genomically (Da Rocha and Ferguson-Smith, 2004, Hernandez et al., 2002). 
The ubiquitination pathway can be reversed in a process known as deubiquitination. The 
ubiquitination complex merely disrupts D2 homodimerisation without causing terminal 
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disassembley and is reversible (Sagar et al., 2007). Deubiquitination is mediated by ubiquitin-
specific peptidases (USPs), of which USP20 and USP33 have been linked to D2 
modifications, prolonging both the half-life and activity of D2 (Curcio-Morelli et al., 2003). 
Expression of both WSB1 and USP33 has been demonstrated in the hypothalamus and BAT, 
which highlights the importance of D2 ubiquitination to the role of T3 in homeostatic 
regulation. 
4.1.3.1 Previous Attempts to Overexpress Deiodinase II 
The D2 enzyme is subject to tight post-translational regulation, which limits its 
overexpression in vivo. However, D2 overexpression has been attempted in previous 
investigations. The most promising attempt to date was achieved by a transgenic method 
where D2 was overexpressed in the heart under the control of a αMHC receptor (Pachucki et 
al., 2001). This model presented with a minimal increase in myocardial T3 concentration, 
despite high myocardial D2 activity, which was increased approximately 100 fold.  It was 
hypothesised that the lack of an increase in T3 concentration was owing to diffusion of T3 
from myocardium into the blood stream, although this was not supported by the finding that 
similar levels of plasma thyroid hormones were detected in the control group. Despite 
absence of a significant effect on thyroid-responsive genes in the heart, an increased heart 
rate was detected in animals overexpressing D2. This suggests that the increased level of 
ectopic D2 activity was affecting heart rate, although no clear transcriptional pathway was 
determined. 
4.2 Aims of Study 
Until now, no investigation has been undertaken to examine the effect of increasing the local 
pool of T3 in hypothalamic networks. Work in this chapter was designed to increase T3 
availability in the VMN by overexpresing D2 enzyme following iVMN administration of 
rAAV-D2. 
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4.3 Experimental Results 
Male Wistar rats were bilaterally injected with either 1μl rAAV-D2 or 1μl rAAV-GFP into 
the VMN as described in chapter 2.3.2. Their phenotypes were analysed using the molecular 
biological techniques described in chapter 2. 
4.3.1 Confirmation of Vector Expression in vivo 
An initial investigation was undertaken, whereby 5 male Wistar rats received bilateral 
injections of rAAV-D2 to localise the transcript. Successful expression of rAAV in the VMN 
was verified by radioactive
 
WPRE in situ hybridization. An in situ hybridisation picture is 
shown in figure 4.1. 
121 
 
 
 
Figure 4.1A:  In situ hybridisation with Wpre-anti-sense probe. Demonstrates Wpre mRNA 
expression in rats with bilateral injection of rAAV –D2 in the VMN (white arrows) 
Figure 4.1B: In situ hybridisation with Wpre-sense probe, to show non-specific binding in 
rats with bilateral intra-VMN injection of rAAV-D2. 
Figure 4.1C: Schematic representation of coronal sections through the rat hypothalamus 
depicting the injection site. -2.76mm indicates caudal distance from bregma. Reprinted from 
“The Rat Brain in Stereotaxic Coordinates”(Paxinos and Watson, 2007)  
B 
A 
C 
122 
 
4.3.2 Effect of iVMN rAAV-D2 Administration on Food Intake and Body 
Weight 
Male Wistar rats received bilateral iVMN injections of either 1µl rAAV-GFP or 1µl AAV-
D2. All animals were allowed to recover for 7 days after surgery. After this recovery period, 
consumption of normal chow and body weight gain were measured regularly. 
4.3.2.1 Cumulative Body Weight Gain  
Prior to rAAV injection there was no difference in body weight between the rAAV-GFP 
(260.8 +/- 1.9g) and rAAV-D2 (262.7 +/- 2.5g) groups. At day 64, when the experiment was 
terminated, there was still no difference in body weight between the rAAV-GFP controls 
(547.4 +/- 10.9g) and rAAV-D3 treated animals (555.1 +/- 17.7g) (Figure 4.2). 
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Figure 4.2: Body weight profile following iVMN administration of either rAAV-GFP (green 
line) (n=12) or rAAV-D2 (black line) (n=13). Data are expressed as mean +/- SEM for both 
groups. 
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4.3.2.2 Cumulative Food Intake 
At day 64, there was no difference in the mass of food consumed by the rAAV-GFP group 
(1859.7 +/- 42.2g) compared to the rAAV-D2 group (1888.9 +/- 65.9g) (figure 4.3). 
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Figure 4.3: Cumulative food intake following bilateral iVMN injection of either rAAV-GFP 
(green line) (n=12) or rAAV-D2 (black line) (n=13). Data are expressed as mean +/- SEM 
for both groups. 
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4.3.2.3 Refeeding and Body Weight Profiles Following 24 Hour Fast 
On day 64, the collection of longitudinal data was terminated. At this point, the level of food 
intake in rAAV-treated rats was examined following a 24 hour fast.  There were no 
significant differences in food intake over any time period starting from the point of refeeding 
(figure 4.4A). 
When analysing feeding over incremental time periods, it was noted that a significantly 
higher level of food intake was detected in the rAAV-D2 treated group (3.64 +/- 0.4g) 
compared to the rAAV-GFP controls (2.0 +/- 0.4g) during the period from 1 to 2 hours after 
refeeding (P = 0.01). There were no other differences detected at any other time increment. 
(figure 4.4B). There were no differences in body weight detected at any point over the 
investigation. 
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Figure 4.4: The effect of rAAV-D2 (black bars) (n=13) treatment on refeeding following a 24 
hour fast compared to rAAV-GFP controls (green bars) (n=12). Refeeding data were 
measured at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours after replacement of 
food (A). Refeeding data were analysed during the increments between each time point (B). 
Data are expressed as mean +/- SEM. * P<0.05 
A 
B 
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4.3.2.4 Refeeding and Body Weight Profiles Following 12 Hour Fast 
One week after analysing the effects of a 24 hour fast onn acute food intake, the effect of a 12 
hour fast was investigated in rAAV-treated rats was examined following a 12 hour fast.  
There was a significantly greater level of food intake in the rAAV-D2 treatment group (11.1 
+/- 0.6g) compared to the rAAV-GFP controls (8.8 +/- 0.7g) during the first 2 hours of 
refeeding (p=0.02).  There were no other statistical differences when data were analysed in 
this way (figure 4.5A). 
When feeding over the incremental time points was analysed, the mean level of food 
consumed by the rAAV-D2 group during the 0-1 and 1-2 hours of reefeding was not 
significantly greater. However, a significantly lower level of food intake was detected in the 
rAAV-D2 treated group compared to the rAAV-GFP controls during the time point 
increments 2-4 hours (2.4 +/- 0.6g vs 0.7 +/- 0.5g) and 4-8 hours (4.1 +/- 0.5g vs 2.2 +/- 0.5g) 
after refeeding (P = 0.03 and 0.02, respectively). These periods of reduced food intake were 
followed by an increased level of food intake in the rAAV-D2 treated group (4.8 +/- 0.6g) 
compared to the rAAV-GFP controls (3.0 +/- 0.4g) between 8 and 12 hours post-refeeding (P 
= 0.03) (figure 4.5B). 
There were no differences in body weight detected at any point over the investigation (data 
not presented). 
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Figure 4.5: The effect of rAAV-D2 (black bars) (n=13) treatment on refeeding following a 12 
hour fast, compared to that of rAAV-GFP (green bars) (n=12). Refeeding data were 
measured at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours after replacement of 
food (A). Refeeding data were analysed during the increments between each time point (B). 
Data are expressed as mean +/- SEM. * P<0.05 
A 
B 
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4.3.3 Hypothalamic Expression Profile Following rAAV-D2 Treatment 
Dissected hypothalami were analysed for specific mRNA levels by qPCR. There was a 3.5 
fold upregulation of Dio2 mRNA in the rAAV-D2 treated group compared to rAAV-GFP 
controls (P < 0.001). A 1.6 fold increase in Dio3 mRNA was also detected in the rAAV-D2 
treated group, although this failed to reach statistical significance (P = 0.08). There was no 
apparent difference in the level of hypothalamic WSB1 mRNA between the experimental 
groups (figure 4.6). 
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Figure 4.6: Hypothalamic mRNA profile was analysed by qPCR. mRNA was quantified for 
Dio2, Dio3 and Wsb1. qPCR assays were performed 78 days after bilateral administration of 
rAAV-D2 (black bars) (n=13) or rAAV-GFP (green bars) (n=12). Data are expressed as fold 
change relative to the mean ΔΔCt value for the rAAV-GFP controls +/- SEM. *** P<0.001 
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4.3.4 MBH Deiodinase Activity Following rAAV-D2 Treatment 
A group of male Wistar rats were injected with either rAAV-D2 (n=8) or rAAV-GFP (n=9) 
and housed for 38 days before being decapitated with their brains collected. MBH punch 
biopsies were collected and assayed for D2 and D3 activity in collaboration with Dr Anita 
Boelen (Department of Endocrinology and Metabolism of the Academic Medical Centre at 
the University of Amsterdam). 
The mean level of D2 enzyme activity was significantly higher (P = 0.03) in the rAAV-D2 
group (0.12 +/- 0.05 fmol/min/mg) compared to controls (0.01 +/- 0.001 fmol/min/mg) 
(figure 4.7). However, a large increase in D2 activity was detected in only four of eight 
rAAV-D2 treated animals, which is reflected by the large standard error value for the rAAV-
D2 treated group. 
The mean level of D3 enzyme activity was several orders of magnitude higher than that of D2 
activity, in both treatment groups. This was calculated as being approximately double the 
normal level of MBH D3 enzyme activity (9.55 +/- 0.2 fmol/min/mg). However, there was no 
statistical difference between D3 activity in rAAV-D2 treated animals (18.96 +/- 3.2 
fmol/min/mg) compared with rAAV-GFP treated controls (23.33 +/- 3.4 fmol/min/mg). 
 
Figure 4.7: Hypothalamic D2 activity following rAAV-D2 treatment. Dissected hypothalami 
were assayed for D2 activity 38 days after bilateral iVMN injection of either rAAV-GFP 
(n=9) (green bars) or rAAV-D2 (n=8) (black bars). Non-injected MBH samples are included 
as controls (n=2) (white bars). Data are expressed as fmol/min/mg +/- SEM. * P<0.05 
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4.3.5 Energy Homeostasis in Animals with Increased D2 Activity 
Given that an increase in D2 activity was only detected in four of the eight rAAV-D2 treated 
rats, energy homeostasis parameters were re-analysed to include only those with increased 
activity. The mean enzyme activity in this group of animals was calculated to be 2.4 +/- 1.2 
fmol/min/mg, which was approximately 25 fold higher than that of rAAV-GFP treated 
animals (0.009 +/- 0.001 fmol/min/mg) (P<0.001). However, this profound increase in D2 
activity did not bring any noticeable differences in cumulative food intake or body weight 
gain upon reanalysis of these data sets (figure 4.8). 
 
Figure 4.8: The effect of increased D2 activity on food intake and body weight. Left axis: 
cumulative body weight gain and food intake were calculated from the date of either rAAV-
GFP (green bars) (n=9) or rAAV-D2 (black bars) (n=4) until the final time point 
(decapitation at day 38). Data are expressed as kg +/- SEM. Right axis: D2 enzyme activity 
was analysed in MBH punches 38 days after administration of either rAAV-GFP (green bars) 
or rAAV-D2 (black bars). Data are expressed as fmol/min/mg +/- SEM. *** P<0.001 
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4.4 Discussion 
Previous studies examining the effect of thyroid hormones in the hypothalamus have 
involved either their chronic administration via a peripheral route (Klieverik et al., 2008, 
Klieverik et al., 2009, Ishii et al., 2008, Ishii et al., 2000) or acute administration of T3 
centrally (Klieverik et al., 2009, Kong et al., 2004). rAAV-mediated overexpression of D2 is 
exploited here to modulate the local metabolism of T4 to T3, which enables chronic 
manipulation of the local T3 pool without the need for chronic administration. Work in this 
investigation looks specifically at the role of T3 within the VMN with respect to its 
regulation of energy homeostasis. 
An initial experiment was conducted to analyse whether the rAAV cassette was successfully 
expressed in a region limited to the VMN, given that migration of the AAV into surrounding 
areas would complicate the separation of the VMN-specific effects from surrounding nuclei 
and hinder the reproducibility of the investigations. WPRE was the probe-target for in-situ 
hybridisation to coronal slices through the region encompassing the MBH. The results 
demonstrated a strong signal localised to the area containing the VMN at approximately 
2.7mm caudal to bregma. The relative brain region was determined by its similarity to the 
surrounding architecture observed in the coronal slices published in “The Rat Brain in 
Stereotaxic Coordinates” (Paxinos and Watson, 2007). 
One limitation when analysing the data is the lack of information regarding the specific site 
of virus injection. In this work, initial experiments were undertaken whereby euthanised 
animals were used for stereotaxic injection of Indian ink using the specified coordinates. Rat 
brains were then dissected and coronal sections were examined to determine the site of 
injection with respect to the rat brain atlas. However, the injection accuracy was not 
determined in the animals whose phenotypes were extensively analysed. This could be 
overcome by including a fluorescent marker, such as GFP, in the transgene construct, which 
could then be used to assess injection accuracy before processing tissues. Specifically, this 
could be carried out using laser dissection, where coronal slices of hypothalami are visualised 
under a blue 488nm argon laser to obtain green fluorescence, from which the transduced 
tissue can be identified anatomically and dissected for further analysis. 
In a separate experiment, rats once again received either rAAV-D2. It has previously been 
reported that acute administration of T3 to the VMN of male Wistar rats induces a 
hyperphagic response (Kong et al., 2004). Again, rAAV-D2 administration to the VMN of 
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male Wistar rats gave a weak phenotype without notable differences in cumulative body 
weight gain or cumulative food intake. D2 enzyme is subject to tight post-translational 
regulation in order to prevent the development of a potentially damaging hyperthyroid 
environment (Gereben et al., 2000, Zavacki et al., 2009). However, both hypothalamic D2 
expression and activity are increased in response to a fast (Diano et al., 1998). In light of this, 
it was hypothesised that fasting could reverse any hindrance in the efficacy of rAAV-D2-
generated D2 enzyme. 
The level of Dio2 mRNA detected by qPCR was significantly greater in the rAAV-D2 
experimental group, in line with results from the cohort that demonstrated an increase in D2 
activity. WSB1 mRNA was analysed as a marker of whether the D2 ubiquitination pathway 
had been activated by increased D2 expression, however, there was no significant change 
detected. A small change was witnessed in the level of Dio3 mRNA in the hypothalamus, 
whereby it was higher in the rAAV-D2 group, yet this was not statistically significant. This 
suggests that post-translational modification of D2 had not been greatly affected, although 
this would need clarification by quantifying the expression of other markers of the D2 
ubiquitination pathway, such as TEB4, UBC6 and UBC7. 
In an attempt to potentiate the increase in D2 expression, rats were fasted before having food 
intake measured at various time-points over a 24 hour period after reintroduction of food. The 
effect of a 24 hour fast was minimal with the only significant effect being an increase in food 
intake during the second hour after refeeding. A slight increase in food intake was also 
detected in rAAV-D2 treated animals during the first two hours of refeeding after a 12 hour 
fast. This was followed by a brief period of reduced food intake, which was presumably a 
compensatory response to the hyperphagia witnessed over the initial 2 hours of refeeding. 
This goes some way to supporting the findings made by Kong et al., whereby an increased 
local T3 pool in the VMN has an effect on food intake, albeit a modest one. This could be 
due to a lower level of T3 being produced by rAAV-D2 than the 1 to 5 nmol/kg dose range 
administered by Kong et al. In order to evaluate this, T3 could be measured by 
radioimmunassay in rAAV-D2 treated hypothalamic samples following acid extraction of 
hormones. Analysis could then be made to determine whether the rAAV-D2 model provides 
a comparatively low level of T3 production, in line with the phenotype. 
The most significant finding in this chapter is arguably the promising ability for rAAV-D2 to 
successfully increase D2 activity in a localised region by viral gene transfer. D2 plays 
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important roles in many physiological systems; therefore, the rAAV-D2 virus could be 
exploited as a useful tool for examining the effects of D2 in other species, additional CNS 
regions, or even in additional tissues. The D2 enzyme is subject to tight post-translational 
regulation (reviewed in section 4.1.2), which limits its overexpression in vivo. Until now, this 
had only been achieved by transgenic methods in the heart, where D2 was overexpressed by 
almost 1000 fold (Pachucki et al., 2001). However, this was without significant physiological 
effects, as thyroid-responsive genes were only modestly upregulated and the overall 
presentation was reminiscent of a relatively mildly thyrotoxic patient. It was hypothesised in 
this publication that the weak effect was owing to some diffusion of T3 from the heart into 
circulation, although was not supported by plasma assays. With this considered, it is possible 
that the lack of physiological effects in the rAAV-D2 model, despite an increase in D2 
activity, could be due to similar reasons to those experienced by Pachucki et al. 
Deiodinase enzyme activity was assayed, in collaboration with the University of Amsterdam, 
in MBH punch biopsies sampled from rats treated with either rAAV-D2 or rAAV-GFP. 
Despite a ten-fold increase in mean D2 enzyme activity by rAAV-D2 treatment compared to 
rAAV-GFP, the effect was only statistically significant to the 97
th
 percentile. This was due to 
a disparity between the rAAV-D2 samples, in which only half of the subjects demonstrated a 
large increase in D2 activity, with the rest showing a level similar to controls. Given that D2 
enzyme is extremely labile, prolonged tissue dissection and subsequent punch biopsy may 
have allowed the D2 activity of some samples to have been diminished. In order to examine 
whether an increase in D2 actvity exerts any effect on energy homeostasis parameters, the 
cumulative body weight and food intake profiles of rAAV-D2 treated animals were 
reanalysed to include only those exhibiting an increase in D2 enzyme activity. However, 
there remained a lack of effect on either parameter, suggesting that the long-term effects of 
elevated T3 in the VMN are modest in comparison to the effect of acute administration. 
It is possible, however, that the local T3 pool was only modestly changed, despite a 
significantly increased level of D2 enzyme activity. This was also suggested by authors who 
achieved increased D2 activity in the heart (Pachucki et al., 2001). The influence of the 
manual insertion of SECIS into the rAAV-D2 cassette was not investigated either in vivo or 
in vitro. Without functional SECIS, D2 activity would be reduced; therefore it may have been 
possible to drive higher D2 activity than witnessed. This could be investigated initially in 
vitro by transfecting pTR-CGW-D2 without SECIS and comparing its effects on cultured 
cells to pTR-CGW-D2 constructs containing the SECIS at various insertion points. Evidence 
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form D1 polymorphisms suggests that mutations in the region of the SECIS can have both 
positive and negative effects on deiodinase activity (Dumitrescu et al., 2005), which suggests 
that its location could be rate limiting. Even assuming that the manual insertion of SECIS was 
effective, the availability of selenium in vivo could have been an influential factor for both 
investigations, as the activity of all selenoenzymes is selenium-dependent. This could be 
overcome by supplementing in vivo models with selenium in the diet, which was achieved in 
vitro with the addition of sodium selenite. 
An alternative theory for the lack of physiological effect in D2-overexpressing animals lies in 
the finding that D3 enzyme activity was increased in the MBH punches of both treatment 
groups. This increase in D3 activity could have suppressed any increase in local T3 
availability and hindered the physiological response. These non-injected samples 
demonstrated approximately half of the level of D3 activity that was recorded in the rAAV-
D2 and rAAV-GFP treated animals. These data were compared to results from a separate 
batch of non-injected MBH punches, which were analysed on a different day. A number of 
conclusions can be drawn from this. 
Firstly, it is possible that D3 activity has been induced as a direct result of D2 overexpression 
in the MBH. D3 is upregulated by holo-TR, therefore an increase in the local availability of 
T3 would be expected to produce this increase in D3 activity (Esfandiari et al., 1992). qPCR 
analysis of hypothalamic samples from a previous cohort did not detect a statistically 
significant change in the level of Dio3 transcript. However, these measurements were taken 
from whole hypothalami, which raises the possibility that Dio3 mRNA from other 
hypothalamic nuclei was reducing the impact of any detectable changes in the expression of 
this gene. In order to investigate this fully, Dio3 and WSB1 mRNA levels would need to be 
measured by qPCR in MBH punches of rAAV-D2 injected animals and compared to controls. 
However, this would not explain why D3 activity was raised in the rAAV-GFP treated 
control group. This suggests that rAAV administration by stereotaxic surgery somehow 
increases the local D3 enzyme activity. This could be explained by reports that D3 activity 
can be stimulated by inflammation and tissue injury (Li et al., 2001, Boelen et al., 2005). 
Therefore, D3 expression could have been induced by the inflammatory response to 
stereotaxic administration of a virus to the CNS. This activation of D3 by inflammatory 
signals has been well characterised in leukocytes, granulocytes and muscle tissue (Boelen et 
al., 2005, Boelen et al., 2008), however this pathway has not been extensively characterised 
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in brain parenchymal cells. In fact, reports demonstrate that bacterial LPS can decrease D3 
activity and increase D2 activity in the MBH. Furthermore, the CNS lacks classical 
lymphatics and elicits only a transient inflammatory reponse to infectious particles 
(Lowenstein, 2002). In addition to this, rAAV has been shown to lack profound 
immunogenicity (Nayak and Herzog, 2009). Therefore, inflammation due to tissue damage 
remains becomes the likely candidate for the induction of D3 activity, given that such a 
response has been reported in neurones (Li et al., 2001). 
The potential induction of inflammation in the MBH requires investigation. The activation of 
MAPK-associated factors could be analysed by ELISA as markers of tissue inflammation. In 
addition to new measurements of D3 enzyme activity, MAPK levels could be compared 
among: rAAV-GFP injected, rAAV-D3 injected, sham-injected and non-injected MBH 
samples. This would help ascertain whether rAAV or stereotaxic injection affects D3 
expression and the MAPK signalling pathway. 
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Chapter 5  
The Effect of rAAV-D3 Administration to the VMN 
of Rats Maintained on a Normal Chow Diet 
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5.1 Introduction 
D3 plays an essential role in the regulation of T3 signalling within the CNS. Following its 
production by D2 in tanycytes, T3 normally enters neuronal cells in a paracrine fashion to 
interact with the TR (Freitas et al., 2010). D3 expression in the CNS is primarily neuronal 
and localises at the plasma membrane (Baqui et al., 2003, Tu et al., 1999). Therefore, 
intraneuronal T3 is readily inactivated by D3, which gives rise to the hypothesis that the 
intracellular concentration of T3 lowers when D3 is upregulated. 
5.1.1 Iodothyronine Deiodinase III in the Hypothalamus 
In Siberian hamsters, D3 has shown to be temporally regulated by photoperiod in the MBH. 
It is thought this is a mechanism for energy conservation in hibernation (Barrett et al., 2007). 
Deiodinase expression is essential for the responses to disease and infection whereby 
hypothalamic D3 is up-regulated in the hyperthyroid state and in response to the 
administration of bacterial lipopolysaccharide (Boelen et al., 2004b, Tu et al., 1999). 
Acute administration of T3 to the VMN of male Wistar rats induced a rapid hyperphagic 
response without affecting locomotion (Kong et al., 2004), however, it has been suggested 
that a reduction in T3 signalling in hypothalamic networks could influence energy 
expenditure (Pelletier et al., 2008, Sjögren et al., 2007, López et al., 2010). In this respect, the 
affinity of TR for T3 has been targeted for investigation. Mice expressing a TRα variant with 
reduced affinity for T3 were reported as hypermetabolic with increased BAT sympathetic 
tone (Sjögren et al., 2007), an effect not explained by changes in systemic thyroid hormone 
status. These findings suggested that T3 could influence sympathetic innervation of BAT 
within the hypothalamus. 
5.1.2 Sympathetic Nervous Pathways Descend from the Hypothalmus 
Neurones of the SNS exist within both the CNS and the peripheral nervous system (PNS), 
which communicate via the sympathetic ganglia. Noradrenaline (NA) is released from post-
ganglionic nerve terminals at the site of tissue innervation. The effect of NA is mediated by 
adrenergic receptors, of which there are three types: β, α1, and α2. β-adrenoreceptors are 
classified into three subtypes; β1, β2, and β3. NA binds all three β-adrenergic receptor 
subtypes on adipocytes. 
β3-adrenoreceptors are the most significant subtype in mature rodent energy homeostasis. 
Stimulation with a selective β3 agonist, stimulates BAT thermogenesis (Arch et al., 1984). 
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Although, the majority of thermogenic regulation is thought to be mediated via β3 
adrenoreceptors, deletion of these receptors in rodents does not abolish thermogenic capacity, 
with β1 receptors thought to be compensatory (Susulic et al., 1995). 
NA interacts with β3-adrenergic receptors in mature brown adipocytes to activate adenylyl 
cyclase with subsequent intracellular elevation of cAMP production (Zhao et al., 1997). 
cAMP stimulates protein kinase A activity, which conveys the signal via phosphorylation of 
target proteins. Phosphorylation of nuclear targets, such as the transcription factor CREB, 
stimulates UCP-1 expression through interaction with the cAMP response element (CRE) in 
its promoter region (Thonberg et al., 2002). 
An area within the preoptic chiasma/anterior hypothalamic nuclei (POAH) in front of the 
third ventricle is important in the control of body temperature (Boulant, 2000). Its destruction 
renders animals unable to thermoregulate (Satinoff et al., 1976). This region receives inputs 
from other thermosensitive areas and integrates this information to convey a message to 
downstream brain centres. The finding that lesioning of POAH efferent connections elicits 
BAT activation suggests that this pathway is an inhibitory one (Chen et al., 1998). However, 
a putative model consisting of a long inhibitory pathway from POAH to sympathetic 
neurones has often proved an inadequate explanation (Rothwell et al., 1983, Rathner and 
Morrison, 2006). Several areas of the hypothalamus; including the VMN, PVN, and DMN 
have been implicated in the central regulation of thermogenesis, which implicates these 
nuclei act as intermediary centres of thermogenic regulation. 
Electrical and chemical stimulation of the VMN increases BAT activity (Halvorson et al., 
1990). A critical role for the VMN in POAH innervation of BAT was suggested following the 
discovery that stimulation of BAT thermogenesis is abolished by VMN destruction (Niijima 
et al., 1984). However, some doubt remains over the specific involvement of the VMN given 
that retrograde labelling of BAT efferent SNS neurones does not markedly identify this 
nucleus as a principal origin of the signal (Bamshad et al., 1999). Furthermore, the specificity 
of VMN lesions to VMN function has been questioned with respect to the potential damage 
to surrounding neurones of the ventral noradrenergic bundle (Gold, 1973), which could in 
fact be the true source of SNS transmission. 
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5.1.3 Triiodothyronine and the Sympathetic Nervous System: Brown 
Adipocyte Thermogenesis 
T3 is essential to the stimulation of BAT thermogenesis through its stimulation of 
mitochondrial UCP1 expression (figure 5.1). The synergistic relationship between the SNS 
and T3 in BAT is demonstrated in hypothyroid rats which completely fail to elevate 
thermogenesis in response to NA infusion (Ribeiro et al., 2000). The NA-induced signal 
cascade is also directly initiated by T3, which stimulates cAMP generation due to 
modifications at the adrenergic receptor, its Gi protein and adenylyl cyclase (Carvalho et al., 
1996, Rubio et al., 1995b, Rubio et al., 1995a). In addition, a TRE promoter has been 
identified in the UCP1 gene, suggesting both direct and indirect effects of T3 on its 
transcription and thermogenesis (Ribeiro et al., 2001). 
The effect of T3 on thermogenic tissues is modulated via regulation of the deiodinases where 
D2 is up-regulated in BAT within a few hours of cold-exposure (Bianco and Silva, 1987). 
BAT adaptive thermogenesis is also stimulated by food intake and the subsequent increased 
production of bile acids. It has been demonstrated that binding of bile acids to their receptor, 
TGR5, triggers an increase in BAT intracellular cAMP which drives Dio2 expression 
(Watanabe et al., 2006). Furthermore, mice fed a high-fat diet supplemented with bile acids 
were resistant to diet-induced obesity, an effect lost in Dio2 null mice (Watanabe et al., 
2006). 
Sympathetic innervation of BAT descending from the hypothalamus has been directly linked 
with T3 signalling in the VMN. Administration of T3 to the third ventricle increased c-Fos 
immunoreactivity in the raphe pallidus, the inferior olive nuclei and the dorsal motor nucleus 
of the vagus, all of which reportedly receive neuronal projections from the VMN (López et 
al., 2010). This effect was associated with a dose-dependent increase in BAT sympathetic 
activity. Administration of an adenovirus expressing a dominant-negative TR to the 
hypothalamus of rats resulted in reduced expression of UCP1, UCP3 and D2 in BAT along 
with several enzymes of fatty acid metabolism (López et al., 2010). As already mentioned, 
mice expressing a TRα variant with reduced affinity for T3 were reported as being 
hypermetabolic with increased BAT sympathetic tone (Sjögren et al., 2007). The disparity 
between the findings of these two studies suggests that the exact role of T3 signalling in 
hypothalamic regulation of BAT activity remains to be elucidated. 
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In addition to BAT thermogenesis, T3 also interacts with the SNS to regulate the function of 
other metabolically active tissues. Thyrotoxicosis has been linked with increased hepatic 
gluconeogenesis and hepatic insulin resistance (Klieverik et al., 2008). Sympathetic and 
parasympathetic denervation of the liver attenuated the increased glucose production, 
suggesting that these nervous inputs are required for the T3-mediated pathophysiology. 
Investigations have suggested that the interactions between T3 signalling and the SNS may 
occur at the level of the hypothalamus. In euthyroid rats, T3 microdialysis in the PVN 
stimulated endogenous glucose production by 11%, which highlights hypothalamic thyroid 
hormone as a potential activator of sympathetic outflow to the liver (Klieverik et al., 2009). 
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 Figure 5.1: Thermogenesis is stimulated by T3 in the Brown Adipocyte. T3 and the 
adrenergic nervous system act synergistically to stimulate UCP1 expression. UCP1 is 
inserted into the mitochondrial inner membrane to dissociate the electron transport chain 
from ATP synthesis, thereby promoting the dissipation of energy as heat (Celi, 2009). 
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5.2 Aims of Study 
Until now, no investigation has been undertaken to examine the effect of reducing the local 
activity of T3 in hypothalamic networks. Work in this chapter was designed to chronically 
inactivate T3 in the VMN through overexpression of rAAV-D3 in order to investigate the 
physiological role of T3 in this nucleus. 
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5.3 Experimental Results 
Male Wistar rats were bilaterally injected with either 1μl rAAV-D3 (rAAV-D3 treatment) or 
1μl rAAV-GFP (controls) into the hypothalamic VMN (iVMN), as described in chapter 2.3.2. 
Their phenotypes were analysed using the molecular biological techniques described in 
chapter 2. 
5.3.1 Confirmation of Vector Expression in vivo 
An initial investigation was undertaken, whereby five male Wistar rats received unilateral 
injections of rAAV-D3 to localise the transcript. Successful expression of rAAV in the VMN 
was verified by radioactive
 
WPRE in situ hybridization. The in situ hybridisation profile is 
shown in figure 5.2, where 5.2A represents a coronal section probed with an antisense WPRE 
sequence and 5.2B shows the control section probed with the sense WPRE sequence. 
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Figure 5.2A:  In situ hybridisation with Wpre-anti-sense probe. Demonstrates Wpre mRNA 
expression in rats with unilateral iVMN injection of rAAV -D3 (white arrow). 
Figure 5.2B: In situ hybridisation with WPRE-sense probe, to show non-specific binding in 
rats with unilateral iVMN injection of rAAV-D3. 
Figure 5.2C: Schematic representation of coronal sections through the rat hypothalamus 
depicting the injection site. -2.76mm indicates caudal distance from bregma. Reprinted from 
“The Rat Brain in Stereotaxic Coordinates” (126). 
B A 
C 
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5.3.2 Effect of iVMN rAAV-D3 Treatment on Food Intake and Body 
Weight 
After bilateral iVMN injection of either 1µl rAAV-GFP (n=13) or rAAV-D3 (n=11), all 
animals were left to recover for 7 days. After this recovery period, consumption of normal 
chow and body weight gain were measured regularly. 
5.3.2.1 Cumulative Body Weight Gain 
Prior to surgery, there was no difference in body weight between rAAV-GFP controls (252.2 
+/- 3.2g) and rAAV-D3 treated (255.7 +/- 3.0g) groups. At day 78, when the experiment was 
terminated, the mean body weight of the rAAV-D3 group (489.2 +/- 7.6g) was not 
significantly lower than the controls (511.6 +/- 13.2g) (P=0.140) (Figure 5.3A). 
The difference in body weight between the two groups appears to take effect approximately 3 
weeks after rAAV injection, the estimated time required for ssDNA of rAAV vectors to be 
converted to its dsDNA form for maximal expression. 
The body weight gained by the animals from this 3 week time-point until the terminal point 
of the experiment was calculated. The rAAV-D3 group (129.7 +/- 4.4) gained significantly 
less weight than the rAAV-GFP controls (149.8 +/- 7) over this 57 day period (P=0.008) 
(Figure 5.3B). 
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Figure 5.3:  Body weight following bilateral intra-VMN injection of AAV-GFP (green line) 
N=11, or rAAV-D3 (black line) n=13 (A) and from 21 days post-surgery (B). There was a 
significant reduction in body weight from day 21 in the rAAV-D3 group compared to the 
GFP group.  Data are expressed as mean +/- SEM for both groups. * P<0.05 
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5.3.2.2 Cumulative Food Intake 
After 78 days there was no difference when comparing the mass of food consumed by the 
rAAV-GFP controls (2146.2 +/- 50.0g) to the rAAV-D3 group (2112.8 +/- 47.6g) (figure 
5.4A). These data were also matched over the 57 day period of maximal rAAV expression 
(figure 5.4B). 
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Figure 5.4: Cumulative food intake on normal chow diet following bilateral intra-VMN 
injection of 1µl rAAV-GFP (green line) n=11, or 1µl rAAV-D3 (black line) n=13. Data are 
cumulative starting from the time of rAAV injection (A) or from the 21
st
 day after injection 
(B). Data are expressed as mean +/- SEM for both groups. 
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5.3.3 Hypothalamic Expression following rAAV-D3 Treatment 
The expression of Dio3 mRNA was increased 10 fold in the rAAV-D3 group (10.2 +/- 2.1 
AU) relative to the controls (1.0 +/- 0.1 AU), a difference that was statistically significant 
(P<0.001) by 1-way ANOVA. No significant changes were witnessed in the levels of Dio2, 
Mct8, Oatp1c1, Trh, Npy, Agrp, Pomc, Cart, Bdnf, Acca, Fasn, Ampk or Ucp2  mRNA 
(Figure 5.5). 
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Figure 5.5: Hypothalamic expression profile was analysed by qPCR. mRNA was quantified 
for Dio3, Dio2, Mct8, Oatp1c1, Trh, Npy, Agrp, Pomc, Cart, Bdnf, Acca, Fasn, Ampk, Ucp2. 
qPCR was performed 78 days after bilateral iVMN injection of either rAAV-GFP (green 
bars) n=11 or rAAV-D3 (black bars) n=13. Data are expressed as fold change relative to the 
mean ΔΔCt value for the rAAV-GFP controls +/- SEM. ***= P<0.001 
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5.3.4 Hypothalamic Deiodinase Activity following rAAV-D3 Treatment 
5.3.4.1 Deiodinase Activity in Whole Hypothalamic Blocks 
A batch of male Wistar rats were injected with either rAAV-D3 (n=5) or rAAV-GFP (n=4) 
and housed for 38 days before being decapitated when their hypothalami were dissected. 
Hypothalamic samples were assayed for D2 and D3 activity in collaboration with Dr Anita 
Boelen (Department of Endocrinology and Metabolism of the Academic Medical Centre at 
the University of Amsterdam). 
Deiodinase activity data were expressed by correcting the level of deiodination to the protein 
content of the tissue sample. There was no difference in the activity of D2 in these samples. 
Although D3 activity was marginally higher in the rAAV-D3 treated group (12.1 +/- 1.7 
fmol/min/mg) than controls (9.75 +/- 0.6 fmol/min/mg), this did not achieve statistical 
significance (P=0.2) (Figure 5.6). 
 
Figure 5.6: Dissected hypothalami were assayed for D2 and D3 activity 38 days after 
bilateral iVMN injection of either rAAV-GFP (green bars) (n=4) or rAAV-D3 (black bars) 
(n=5). Data are expressed as fmol/min/mg +/- SEM. 
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5.3.4.2 Deiodinase Activity in MBH Punch Biopsies 
A group of male Wistar rats were injected with either rAAV-D2 (n=8) or rAAV-GFP (n=9) 
and housed for 38 days before being decapitated with their brains collected. MBH punch 
biopsies were collected and assayed for D2 and D3 activity in collaboration with Dr Anita 
Boelen (Department of Endocrinology and Metabolism of the Academic Medical Centre at 
the University of Amsterdam). 
Consistent with the results gathered from whole hypothalamic blocks, the level of D2 activity 
in MBH punch biopsies from rAAV-GFP treated animals (0.0092 +/- 0.001 fmol/min/mg) 
was not different to the level of D2 activity in rAAV-D3 treated animals (0.0076 +/- 0.002 
fmol/min/mg). 
However, the level of D3 activity was different in this study. The levels of D3 activity in the 
MBH of rAAV-GFP treated rats (23.3 +/- 3.4 fmol/min/mg) and rAAV-D3 treated rats (19.0 
+/- 3.2 fmol/min/mg) were approximately double the value of D3 activity in non-injected 
controls (9.6 +/- 2.1 fmol/min/mg) (figure 5.7). 
 
Figure 5.7: MBH punch biopsies were assayed for D2 and D3 activity 38 days after bilateral 
iVMN injection of either rAAV-GFP (green bars) (n=9) or rAAV-D3 (black bars) (n=9). 
Non-injected MBH samples are included as a control reference value (n=2) (white bars). 
Data are expressed as fmol/min/mg +/- SEM. 
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5.3.5 Body Composition Analysis 
Body composition analysis indicated a 1.2% reduction in rAAV-D3 group carcass fat mass 
(17.0 +/- 0.8%) compared to the rAAV-GFP group (18.21 +/- 1.0%) which was not 
significant (Figure 5.8) (P=0.37). 
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Figure 5.8: Whole body composition was analysed following carcass dissolution. Fat mass 
was analysed 78 days after bilateral intra-VMN injection of rAAV-GFP n=11 or rAAV-D3 
n=10. Body composition data are represented by percent fat mass (black shading) and 
percent lean mass (grey shading). Data are expressed as mean +/- SEM. 
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5.3.6 Effect on Plasma HPT Axis Parameters 
Radioimmunassay for plasma TSH was without a statistically significant trend between 
circulating TSH levels in the rAAV-D3 group (1.64 +/- 0.14mU/L) compared to controls 
(1.88 +/- 0.11mU/L) (Figure 5.9). 
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Figure 5.9: Plasma levels of TSH were measured by RIA 78 days after bilateral intra-VMN 
injection of rAAV-GFP (green bar) n=11 or rAAV-D3 (black bar) n=13. TSH values are 
shown as mU/L +/- SEM. 
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No change was seen in plasma fT4 levels between rAAV-D3 (20.42 +/- 1.1 pmol/L) and 
rAAV-GFP (20.82 +/- 1.0pmol/L). There was no change in plasma fT3 levels between 
rAAV-D3 (1.24 +/- 0.1 pmol/L) and rAAV-GFP (1.26 +/- 0.1 pmol/L) (Figure 5.10). 
 
Figure 5.10: Plasma levels of fT4 and fT3 were measured by RIA 78 days after injection of 
rAAV-GFP (green bars) n=11 or rAAV-D3 (black  bars) n=13. fT4 and fT3 values are shown 
as pmol/L +/- SEM. 
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5.3.7 Effect on Plasma Leptin and Insulin 
Plasma insulin levels were measured by RIA. These data do not show a statistically 
significant trend between basal insulin levels in the rAAV-D3 group (22.07 +/- 2.13pM) 
compared to the rAAV-GFP group (24.17 +/- 2.28pM) (Figure 5.11). 
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Figure 5.11: Plasma insulin levels were measured by RIA 78 days after bilateral intra-VMN 
injection of rAAV-GFP (green bars) n=10 or rAAV-D3 (black bars) n=12. Values are shown 
as pmol/L +/- SEM. 
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Plasma leptin levels were also measured by RIA. Despite the differences in body weight, the 
mean leptin level of the rAAV-D3 group (7.3 +/- 0.6ng/ml) was not significantly different to 
the rAAV-GFP group (8.64 +/- 0.9ng/ml) (Figure 5.12). 
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Figure 5.12: Plasma leptin levels were measured by RIA 78 days after bilateral intra-VMN 
injection of rAAV-GFP (green bars) n=10 or rAAV-D3 (black bars) n=12. Values are shown 
as ng/ml +/- SEM 
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5.3.8 Effect on Reproductive Axis 
Plasma LH was measured by in-house RIA. There was no difference detected in the level of 
this hormone (5.13). 
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5.13: Plasma LH levels were measured 78 days after injection of either rAAV-GFP (green 
bars) n=11 or rAAV-D3 (black bars) n=13. Data are expressed as mean +/- SEM for both 
groups. 
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5.3.9 Effect on Interscapular BAT 
BAT tissue mass (mg) from the interscapular pad was analysed and corrected to total rat body 
mass (g). The mass of this BAT pad in the rAAV-D3 group (1.03 +/- 0.07 mg/g) was greater 
than that of the rAAV-GFP group (0.08 +/- 0.005 mg/g), which was a statistically significant 
difference (P=0.036) (Figure 5.14). 
rA
A
V
-G
FP
rA
A
V
-D
3
0.0
0.5
1.0
1.5
*
B
A
T
 M
a
s
s
 (
m
g
/g
)
 
Figure 5.14: Interscapular BAT pad was dissected and weighed 78 days after injection of 
either rAAV-GFP (green bar) N=11, or 1µl rAAV-D3 (black bar) n=13. Data are expressed 
as mean +/- SEM for both groups. * P<0.05 
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BAT UCP-1 mRNA was up-regulated by 56% in the rAAV-D3 group (5.2 +/- 0.97) when 
compared to the rAAV-GFP group (2.94 +/- 0.63) (P=0.031) (Figure 5.15). However, BAT 
Dio2 mRNA was unchanged by rAAV-D3 treatment. 
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Figure 5.15: BAT Ucp1 and Dio2 mRNA levels. Ucp1 and Dio2 mRNA were quantified in 
100mg dissected interscapular BAT, 72 days after injection of either rAAV-GFP (green bars) 
n=10 or rAAV-D3 (black bars) n=11. Data are expressed as mean +/- SEM. * P<0.05 
160 
 
5.4 Discussion 
In this chapter, rAAV-D3 has been administered to the VMN of male Wistar rats with the 
intention of inducing a state of „local hypothyroidism‟ owing to constitutive inactivation of 
T3. rAAV-D3 administration suppressed body weight gain without affecting systemic thyroid 
tone or food intake. Tissue analysis indicated a state of BAT stimulation, marked by 
upregulation of Ucp1 mRNA. 
Differences in body mass and cumulative food intake were assessed using GEE for repeated 
measures. The GEE is used to analyse longitudinal data with multiple automata in order to 
highlight correlation amongst random fluctuations. The reduced level of body weight gained 
by the rAAV-D3 treated animals appeared to take effect approximately 2 to 3 weeks after 
vector administration. A limitation of rAAV is latency in its expression during the initial few 
weeks post-injection. Maximal expression may not be witnessed during this period as the 
conversion of ssDNA into dsDNA is rate-limiting (Ferrari et al., 1996). This conversion of 
rAAV dsDNA is a prerequisite for transcription and could delay the onset of expression in 
brain parenchyma. Additional contributors to this latency may include delays in transduction 
of the genetic material to the nucleus and intracellular trafficking of the necessary cofactors. 
Therefore, the initial absence of effect from rAAV-D3 treatment could have been due to a 
period of inefficient rAAV expression (Meyers et al., 1997). 
When body weight data were analysed from the 21
st
 day post-injection, the suppressed body 
weight gain over the remaining 57 days was statistically significant. This suggests that AAV 
latency could have been responsible for the delay in phenotype presentation. During the 57 
days of maximal rAAV expression, the rAAV-D3 treated group gained 23.7g less weight 
than the controls. 
Body composition analysis was carried out to assess which constituents were accounting for 
this difference in body mass. Glycerol assay results indicated that rAAV-D3 treatment 
resulted in a 1.2% lower mean body fat percentage than rAAV-GFP control treatment. 
Plasma levels of leptin and insulin circulate in correlation with the level of adiposity. Both 
hormones demonstrated a mildly lower value in the rAAV-D3 treated group, which was 
consistent with the mildly reduced level body fat in this treatment group, relative to controls. 
The effect on body weight was independent of food intake, given that it was consistently 
matched between the two groups throughout the experiment. Previous investigations of acute 
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T3 application to the VMN have reported an effect on food intake without alterations in 
locomotion (Kong et al., 2004). These differences in the mode of energy homeostasis 
modulation by T3 could have been due to the mode of administration. While this thesis 
utilises gene transfer and transient modulation of physiological T3 levels, previous 
investigations have involved the acute administration of supraphysiological T3 doses. Given 
that the increase in food intake reported by Kong et al. occurred over a 1 hour period, it is 
possible that the responsible mechanism was an extra-genomic effect of T3. An alternative, 
genomic mechanism would be that increased levels of apoTR (from D3 overexpression) or 
increased holoTR (from acute T3 administration) may have induced different downstream 
effects in VMN neurones due to their differential recruitment of transcriptional co-activators 
or co-repressors (Brent et al., 1989, Brent, 1994). 
The expression of the deiodinases has been strongly linked to photoperiodic regulation in 
small mammals through interactions with melatonin signalling and effects on the 
reproductive axis (Barrett et al., 2007, Revel et al., 2006, Yasuo et al., 2007). Plasma 
luteinising hormone was measured as markers of reproductive function. However, no effect 
was detected in this marker, suggesting that reproductive function was unaffected. 
qPCR analysis of the dissected hypothalami indicated that Dio3 mRNA was 10 fold higher in 
the hypothalamus of rAAV-D3 treated animals than controls. This would be expected given 
that the Dio3 transgene is under the control of an exogenous constitutive CMV promoter and 
enhanced by the downstream WPRE. There were no significant changes detected in any of 
the other mRNA sequences quantified, including that of Trh, which suggests that the HPT 
axis was unaffected. However, the increases in Mct8 and Acca mRNA were approaching 
statistical significance by 1-way ANOVA. MCT8 is the dominant transporter for T3 across 
the plasma membrane, thus its upregulation could be suggestive of a reduced intraneuronal 
T3 concentration. ACCA is the predominant ACC isoform targeted by T3 in the 
hypothalamus and its upregulation could indicate that neuronal fatty acid metabolism has 
been affected in response to increased D3 expression. The expression of PACAP, LEPR and 
MC4R was not investigated, despite their interactions with T3, therefore it would be 
interesting to look at these peptides in future investigations. 
The activities of D2 and D3 in the hypothalamus were analysed by a deiodinase activity assay 
in collaboration with the University of Amsterdam. In these samples, both D2 and D3 
enzyme activity were measured. D2 enzyme activity was not affected by rAAV-D3 treatment. 
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The activity of D3 in whole hypothalamic blocks from rAAV-D3 treated animals was not 
higher than the rAAV-GFP controls. It was perceived that any clear increase in D3 enzyme 
activity was attenuated by the detection of D3 activity in additional hypothalamic nuclei, such 
as the PVN. Therefore, in order to answer this hypothesis, the experiment was repeated by 
measuring deiodinase activity in MBH punch biopsies which would limit the detection of D3 
activity in non-VMN sites. 
D2 measurements in the MBH punch biopsies were ten-fold lower than those detected in 
whole hypothalamic blocks. This could have been due to the increased period of time that the 
tissue samples were exposed to ambient room temperature, during biopsy, which would have 
allowed D2 ubiquitination and activation to proceed. Indeed, the levels of D2 enzyme activity 
in whole hypothalmi and MBH punches were profoundly lower than those of D3, which was 
consistent with data gathered in chapter 4. Given that D3 is normally expressed at a basal low 
level in the adult CNS, its higher level of activity than D2 in these samples suggests that D2 
had been degraded to some degree. 
An interesting observation was made in chapter 4 with regards to the level of D3 enzyme 
activity being similar in rAAV-D2 injected and rAAV-GFP injected MBH samples. This 
observation was again made when comparing rAAV-D3 with rAAV-GFP injected MBH 
samples. This reaffirms the assumption that rAAV administration to the hypothalamic 
parenchyma could induce D3 activity via stimulation of an inflammatory pathway. However, 
it is worth noting that these MBH measurements were made during the same assay batch as 
those presented in chapter 4. In both graphs, the non-injected control values are included, 
although these were processed on a separate day, potentially with different buffers and 
reagents. 
When comparing the D3 activity results obtained from whole hypothalami to those obtained 
from MBH punches, it can be seen that the D3 activity in whole hypothalami is at a similar 
level to that of the non-injected MBH controls. Perhaps this could be explained by the fact 
that MBH punches demonstrate a very restricted locus of inflammation, in the site of 
infection and tissue damage, which is undetectable in the case of whole hypothaalmi. 
Alternatively, it could be argued that the D3 assay batch reading MBH punches was reading 
false positive results due to buffer instability or contamination, or even contamination of the 
biopsies. In any case, this experiment would need repeating with new samples alongside the 
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experiment outlined in chapter 4.4 to examine the effects of rAAV and stereotaxic surgery on 
MBH D3 activity. 
A reduction of body mass despite unaltered energy consumption indicated an effect on 
energy expenditure. A reduced level of T3 in the hypothalamus is normally associated with 
stimulation of the HPT axis and BMR (Fekete and Lechan, 2007). Stimulation of the HPT 
axis could have accounted for the lean phenotype of rAAV-D3 treated animals had plasma 
fT3 and fT4 levels been affected. Plasma fT4, fT3 and TSH were not affected. These data 
suggest that the phenotype of rAAV-D3 treated rats was likely to be independent of HPT 
activity. 
A prominent site of energy expenditure in rodents is BAT, with the interscapular region being 
the largest of the BAT pads. The mass of interscapular BAT dissected from the rAAV-D3 
treated group was significantly greater than the control group. It is unknown whether this was 
due to hyperplasia or hypertrophy as histology was not examined in these samples. The level 
of UCP1 mRNA was significantly greater in the rAAV-D3 treated group by northern blot. 
UCP1 is often used as a marker of elevated thermogenesis and energy expenditure in rodents, 
thus it is possible that rAAV-D3 treatment to the VMN stimulates energy expenditure. This is 
supported by the cumulative body weight data which highlight that rAAV-D3 treatment 
causes a reduction in body weight gain without any apparent effect on food intake. The 
process of BAT UCP1 expression being stimulated by sympathetic activity is well established 
(Rubio et al., 1995a, Rubio et al., 1995b, Meyers et al., 1997, Zhao et al., 1997, Thonberg et 
al., 2002). The effect of NA in the brown adipocyte is markedly potentiated by the presence 
of T3, which is brought about by upregulation of BAT D2. No changes in the level of BAT 
Dio2 mRNA were picked up by northern blot. However, this enzyme is expressed at much 
lower levels than UCP1 in BAT, thus any changes may require a more sensitive method of 
mRNA quantification, such as qPCR. 
These findings could be considered counterintuitive to the classical understanding of thyroid 
hormone physiology, in which a reduction in circulating T3 levels (hypothyroidism) is 
associated with increased weight gain. It is well established that D2 is upregulated during a 
fast, which has been highlighted as a response to plasma leptin (Diano et al., 1998, Fekete et 
al., 2006). However, literature exists that both disagrees (López et al., 2010) and agrees 
(Sjögren et al., 2007, Pelletier et al., 2008) with the idea of decreased T3 signalling in the 
hypothalamus increasing energy expenditure. It is noteworthy that these studies have been 
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primarily focused on the role of TR, but no other studies to date have investigated the effect 
of deiodinase overexpression in the VMN. 
With T3 and adrenergic signalling co-operating at the site of BAT innervation, it is 
conceivable that their interaction is also relevant to sympathetic outflow descending to BAT 
from the VMN. Hypothalamic catecholamines have been suggested to increase the set point 
for TRH inhibition by T3 to promote higher T3 levels and greater thermogenesis (Fekete and 
Lechan, 2007). The data presented in this chapter regarding an increased BAT mass and 
UCP1 expression may outline an additional example of the thyroid axis and the adrenal axis 
interacting to regulate whole-body energy homeostasis. The potential stimulation of 
sympathetic drive to interscapular BAT could be investigated by pharmacological blockade 
of β3-adrenergic receptors following iVMN treatment with rAAV-D3. This could be 
performed in combination with CLAMS (Comprehensive Laboratory Animal Monitoring 
System) cages, which are able to detect changes in animal energy expenditure and body 
temperature. 
The mechanism for the observed phenotype remains to be elucidated at this point. The 
potential products of D3 inactivation of T4 and T3 are rT3 and T2, respectively. The chronic 
effects of these thyroid hormone metabolites have not been fully investigated, thus it is 
possible that they have played a role in the observed phenotype. rT3 has been implicated in 
the regulation of neuronal function through extragenomic interactions (Bassett et al., 2003), 
therefore the role of this thyroid hormone may be significant. In order to deduce which 
thyroid hormones are significantly affected by rAAV-D3 treatment, assays for T3, rT3 and 
T2 could be performed on dissected hypothalami post-methanol extraction. The specific 
effects of any predominant thyroid hormone metabolites could then be investigated by their 
direct administration to the VMN in a similar method to that of Kong et al. 
T3 modulates a number of cellular processes either by genomic interactions or extragenomic 
effects. The qPCR investigations failed to highlight any notable changes in targets of T3, 
which would suggest that the mechanism was an extragenomic one. T3 is known to affect the 
activity of Na
+
/K
+
 ATPases, which are present on neuronal axons and are essential to the 
generation of action potentials. D3 has been colocalised with Na
+
/K
+
 ATPases at the plasma 
membrane (Baqui et al., 2003), which implies that the two are in suitable proximity for D3 
products to interact with the ATPases. There are also reports that T3 can directly regulate 
hypothalamic Na+/K+ ATPase activity and hypothalamic ATP content to modulate energy 
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homeostasis (LuGuang Luoa, 2003). With this considered, it is possible that rAAV-D3 
treatment has somehow affected the action potential frequency of VMN neurones to influence 
the activity of SNS projections to BAT. The question of whether this effect is genomic or 
extragenomic could be answered with the use of chromatin immunoprecipitation (ChIP), 
whereby interactions between holoTR and the TRE could be colocalised using a specific 
antibody. The potential effect on axonal Na
+
/K
+
 ATPases could be measured using patch 
clamp studies to measure the action potential frequency in neurons in vitro following their 
transduction with rAAV-D3 in addition to the quantification of hypothalamic ATP content by 
ELISA. 
The data of this chapter support a growing concept that thyroid hormones can manipulate 
sympathetic nervous activity via the hypothalamus independent of peripheral thyroid 
hormone status (Klieverik et al., 2009, López et al., 2010, Sjögren et al., 2007). This is 
potentially a significant finding in appreciating the broad means by which T3 mediates its 
actions on the body‟s metabolic rate, which could also be characteristic of the neuroendocrine 
function of other hormones. 
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Chapter 6  
The Effect of rAAV-D3 Treatment iVMN in Rats 
Maintained on a High Fat Diet 
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6.1 Introduction 
The findings reported in chapter 5 highlighted a physiological response to D3 overexpression 
in the VMN, where the most significant findings were an increase in BAT UCP1 expression 
and a reduced level of body weight gain, despite unaltered food intake. It was hypothesised 
that the rAAV-D3 treated animals were expending more energy than their rAAV-GFP treated 
counterparts by virtue of increased BAT activity, which is used as a marker for increased 
energy expenditure in rodents. 
Models of elevated thermogenesis can be further investigated using techniques such as 
indirect calorimetry and response to an adrenergic challenge. These techniques are relatively 
expensive and limited by available resources. In this case, the level of resistance to diet-
induced obesity (DIO) has been investigated in rAAV-D3 treated animals by introducing a 
high fat diet (HFD) after administration of the virus. 
The regulation of food intake by hypothalamic thyroid hormone has recently received much 
attention, with the finding that several enzymes of fatty acid metabolism are modulated by T3 
administration to the VMN (López et al., 2010). The role of thyroid hormones in DIO and 
hypothalamic fatty acid metabolism are reviewed in this chapter introduction. 
6.1.1 Diet-Induced Obesity 
Obesity can be defined as an increase in adipose mass resulting from imbalance between 
energy intake and energy expenditure. A number of autosomal recessive mutations have been 
identified in rodents that give rise to the obese phenotype ob/ob and db/db mice (Halaas et al., 
1995, Zhang et al., 1994). The products of the ob and db genes represent the receptor-ligand 
pairing of leptin and LEPR, which form a hypothalamic negative feedback pathway of 
adipose homeostasis, as defined by adipose deposits and dietary fat consumption. 
It has been demonstrated in DIO mice that HFD increases hypothalamic expression of LEPR 
and NPY, whilst down-regulating POMC (Huang et al., 2004). Additionally, a direct 
relationship has been suggested between an ability to increase plasma leptin levels in 
response to a HFD and resistance to DIO (Surwit et al., 1997). However, it has been shown in 
humans that circulating leptin levels can be out of proportion to changing body fat stores 
(Havel et al., 1996). Hence, the involvement of other forms of hypothalamic fat „sensing‟ 
have been explored to improve our understanding of this disease. 
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6.1.2 Thyroid Hormone in Diet-Induced Obesity 
Plasma thyroid hormone tone positively correlates with nutritional status, particularly lipid 
availability, where fat stores and plasma leptin modulate the TRH set point to affect TRH, 
TSH and plasma thyroid hormone levels (Coppola et al., 2005, Germain, 1986). Furthermore, 
there have been studies demonstrating that food restriction and weight loss are accompanied 
by reduced plasma concentrations of thyroid hormone and decreased energy expenditure 
(Araujo et al., 2009, Kiortsis et al., 1999). These studies have shown that weight loss-induced 
reductions in plasma thyroid hormone and energy expenditure can be reversed by low dose 
administration of leptin in rodents and humans. Therefore, elevated plasma leptin levels in 
obese subjects would be expected to drive an increase in plasma thyroid hormone levels to 
raise the metabolic rate and combat weight gain. 
It has been demonstrated that HFD induced hyperactivation of the HPT axis in rats, 
characterised by 2.24, 1.6 and 3.7 fold elevations in hypothalamic TRH expression, thyroid 
iodide uptake and serum TSH, respectively (Araujo et al., 2010). Plasma thyroid hormone 
levels were within the normal range, despite D1 activity being increased in the thyroid gland, 
liver and kidneys, indicating that localised tissue thyroid hormone metabolism had been 
stimulated. Interestingly, D2 activity in the pituitary was reduced, which would trigger an 
increase in TSH synthesis and release. In addition, BAT D2 activity was reduced, indicating 
suppressed sympathetic tone and energy expenditure. 
6.1.3 Hypothalamic Fatty Acid Sensing 
Although fatty acids are not readily oxidised for energy production in the brain, the major 
enzymes of fatty acid metabolism are expressed within the hypothalamus, exhibiting some 
key roles. The multifunctional enzymes ACC and FAS are required for the de novo synthesis 
of fatty acids. ACC catalyzes the synthesis of malonyl-CoA from acetyl-CoA and hydrogen 
carbonate ions in the presence of ATP. FAS catalyzes the synthesis of long-chain fatty acids 
from acetyl- CoA and malonyl-CoA in the presence of NADPH. 
There is evidence to suggest that alterations in hypothalamic malonyl CoA concentration can 
modulate energy homeostasis in a physiological fat „sensing‟ mechanism. In the fasted state, 
hypothalamic malonyl CoA levels rapidly decrease to 0.1 to 0.2 µM, whereas this value 
increases to 1.2 – 1.8 µM in the refed state (Wolfgang and Lane, 2008, Hu et al., 2003). 
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Intra-ARC injection of rAAV overexpressing malonyl CoA decarboxylase (MCD), an 
enzyme that catalyzes conversion of malonyl CoA into acetyl CoA, thereby reducing 
hypothalamic malonyl CoA levels, induces hyperphagia (He et al., 2006). Thyroid hormone 
is known to modulate the transcription of ACC, AMPK and FAS in hepatic tissue both in 
vivo and in vitro (Roncari and Murthy, 1975, Volpe and Marasa, 1975). These three enzymes 
are thought to be key mediators of hypothalamic fatty acid sensing. 
 
Figure 6.1. The regulation of food intake in response to hypothalamic malonyl CoA content. 
In the refed state, the conversion of acetyl CoA to malonyl CoA is stimulated. The increased 
levels of malonyl CoA lead to the suppression of food intake. C75 inhibition of FAS 
potentiates this pathway by virtue of reduced malonyl CoA conversion to fatty acid. 
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6.1.3.1 Acetyl CoA Carboxylase 
Two isoforms of ACC exist, ACCα and ACCß, which derive from the Acca and Accb genes, 
respectively. It is hypothesised that ACCα, which is highly expressed in the liver, is 
important for lipid biosynthesis, whereas ACCß is predominantly involved in fatty acid 
oxidation. T3 regulates the transcriptional activity of the Acca gene in a mechanism that is 
potentiated by SREBP1. 
It has been shown that ICV leptin administration can activate ACC to increase ARC malonyl 
CoA levels and, consequentially, food intake (Gao et al., 2007), which is attenuated by 
subsequent administration of the ACC inhibitor, 5-tetradecyloxy-2-furoic acid (TOFA). This 
occurred despite leptin inhibition of ARC AMPK, suggesting that malonyl CoA may be a 
downstream mediator of AMPK signalling in hypothalamic regulation of appetite, although 
this is by no means conclusive evidence. Mice deficient in Accb have increased appetite, 
supporting its importance to the regulation of energy homeostasis. Genetic deficiency of Acca 
in mice is lethal to the embryo, which restricts understanding of its involvement in 
physiology. 
6.1.3.2 AMP-Activated Protein Kinase 
AMPK is a serine/threonine kinase that responds to metabolic stresses that deplete cellular 
adenylate charge. It is highly expressed in cells that exhibit a high level of oxidative capacity 
and those of a high lipogenic capacity. AMPK is a heterotrimeric protein consisting of a 
catalytic α subunit and regulatory ß and γ subunits (Kemp et al., 2007). A number of different 
isoforms of each subunit exists with varying tissue distribution (Stapleton et al., 1996). 
It is generally considered that AMPK acts as a „fuel sensor‟ that increases fatty acid ß-
oxidation during states of energy demand and decreases ß-oxidation when energy levels are 
sufficient. This modulation of fatty acid oxidation is due, in part, to the regulation of ACC 
activity, which is phosphorylated and inhibited by AMPK (Chen et al., 2000). 
In the hypothalamus, increasing glucose entry into the cell raises ATP levels and inhibits 
AMPK activity (Cota et al., 2006). However, there are several non-nucleotide modulators of 
AMPK activity. The orexigenic peptide ghrelin stimulates AMPK activation independent of 
adenylate charge (López et al., 2008). In addition, the adipokines leptin and adiponectin alter 
AMPK activity to affect appetite (Minokoshi et al., 2002, Kadowaki et al., 2008). 
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6.1.3.3 Fatty Acid Synthase 
Fatt acid synthase (FAS) is an important enzyme in de novo fatty acid biosynthesis, in which 
it converts malonyl CoA to malonyl ACP. This enzyme was first identified as an important 
player in appetite regulation when the FAS inhibitors C75 and cerulenin were shown to 
induce potent anorexigenic effects associated with a reduction in hypothalamic NPY 
expression and increased malonyl CoA concentrations. This is supported by the finding that 
mice with FAS deleted in the hypothalamus display a reduced appetite in addition to reduced 
body weight (Chakravarthy et al., 2007). Several studies have since demonstrated the 
involvement of FAS in appetite, such as the report that the anorexigenic effects of the 
oestrogen receptor antagonist, tamoxifen, were caused by its downregulation of FAS in the 
VMN, being completely independent of changes in AMPK or ACC activity. 
The role of hypothalamic FAS in the regulation of energy homeostasis appears to be rather 
complex, given the range of published causes and effects. It has recently been reported that 
FAS expression in the VMN of Sprague-Dawley rats is downregulated in response to a fast 
(López et al., 2008), which could be considered counterintuitive to previous findings. The 
mechanism for this effect was proposed as being mediated by the gut hormone ghrelin, which 
is heavily implicated in the hypothalamic regulation of energy homeostasis. It was reported 
that FAS was downregulated in the VMN as a direct response to AMPK activation by 
ghrelin, thus highlighting a mechanism of hormonal regulation of food intake via its 
modulation of fatty acid metabolism (López et al., 2008). Considering this controversy over 
the role of FAS in appetite pathways, the specific nature of its involvement remains to be 
elucidated. 
6.1.3.4 Thyroid Hormone Regulation of Hypothalamic Fatty Acid Metabolism 
T3-induced hyperphagia is associated with increased hypothalamic AMPK activity and 
inhibition of ACC (Ishii et al., 2008). The notion of hypothalamic fatty acid metabolism 
being affected by T3 in the regulation of energy homeostasis has recently been supported by 
further evidence. In this investigation, rats rendered hyperthyroid by chronic subcutaneous 
administration of T4 exhibited an increase in food intake marked by upregulation of 
hypothalamic Fasn and increased hypothalamic malonyl CoA content. Central administration 
of T3 to the 3
rd
 ventricle resulted in a rapid decrease in phosphorylated AMPK (pAMPK) and 
phosphorylated ACC (pACC), the active form of each molecule. Consistent with this, the 
hyperthyroid-associated weight loss was attenuated by 3
rd
 ventricular administration of 
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AICAR (aminoimidazole carboxamide ribonucleotide) and TOFA, which are inhibitors of 
AMPK and ACC, respectively (López et al., 2010). 
The role of AMPK in T3 signalling in the VMN was further explored in this investigation by 
employing an adenovirus encoding a constitutively active AMPKα, which was administered 
to the VMN of hyperthyroid Sprague-Dawley rats. The effect was a reduction in VMN 
malonyl CoA content, with body weight gained in the hyperthyroid, but not euthyroid rats. 
There were no reported effects on food intake despite an increase in markers of BAT 
activation (López et al., 2010). 
6.2 Aims of Study 
The aim of this study was to investigate the metabolic effects of Dio3 overexpression in the 
VMN of male Wistar rats, when they are maintained on a high fat diet. 
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6.3 Experimental Results 
6.3.1 Body Weight 
Male Wistar rats received either rAAV-D3 (n=10) or rAAV-GFP into the VMN (n=11). Both 
groups were maintained on a NCD until the 17
th
 day post-injection, at which time they were 
transferred to a HFD. After 72 days of the investigation, the rAAV-D3 group (314.8 +/- 
15.6g) had gained 19.1g more body weight than rAAV-GFP controls (295.7 +/- 10.0g) 
(figure 6.2A). 
Upon analysis of the data, it became evident that the rAAV-D3 began to gain more weight 
than rAAV-GFP controls following the introduction of HFD on day 17. During the 55 day 
period of high fat feeding, rAAV-D3 treated animals gained 27.2g more weight than their 
rAAV-GFP counterparts, which was approaching statistical significance (P=0.07) (figure 
6.2B). 
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Figure 6.2: The effect of HFD on cumulative body weight gain. Animals were injected with 
either rAAV-GFP (green line) N=11, or rAAV-D3 (black line) n=10. Cumulative body weight 
gain data were plotted for the 72 day investigation, where HFD was introduced at day 17 
(A). Cumulative data were also plotted for the period of HFD alone (B). Data are expressed 
as mean +/- SEM for both groups. 
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6.3.2 Body Weight Gain and Energy Consumption per Day of HFD 
The body weight gain and food intake data were reanalysed to determine the mean change in 
body weight per day post-injection relative to energy consumption. For this, food intake data 
were converted from weight in grams to kilojoules of energy, where NCD contains 
10.74kj/kg and HFD contains 21.914 kj/kg. 
The longitudinal presentation of this data highlighted a spiked increase in energy intake and 
body weight gain, upon the switch to HFD on day 17. However, there was no statistically 
significant trend in these data over the duration of the investigation, as calculated by the 
generalised estimated equation (GEE) (figure 6.3). 
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Figure 6.3: Body weight gain (triangles, right y-axis) and total energy intake (circles, left y-
axis) at each time-point following bilateral intra-VMN injection of rAAV-GFP (green line) 
N=11, or rAAV-D3 (black line) n=10. Data are expressed as mean +/- SEM for both groups. 
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6.3.2.1 Body Weight and Energy Intake on HFD v NCD 
Body weight and energy intake during HFD feeding were compared with NCD data from 
chapter 5. For this, NCD food intake data were converted from weight to kilojoules of 
energy. 
The mean weight gained per day by the rAAV-D3 group when fed a NCD (4.6 +/- 0.2g) was 
not significantly lower than that of rAAV-GFP controls (6.1 +/- 0.3g) (P = 0.2). However, the 
mean weight gained per day on a HFD was significantly higher (P = 0.006) in the rAAV-D3 
treated group (4.1 +/- 0.2g) than the rAAV-GFP controls (3.5 +/- 0.1g) (P = 0.01) (figure 
6.4A). 
The mean energy consumed per day during the period of normal chow feeding was not 
affected by rAAV treatment, which is consistent with the findings noted in Chapter 5. 
However, whilst the animals were maintained on a HFD, there was a significant increase in 
the amount of energy consumed by the rAAV-D3 group (439.42 +/- 4.8kj) compared to the 
rAAV-GFP group (415.69 +/- 4.0kj) (P <0.001) (figure 6.4B). 
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Figure 6.4: Energy parameters on HFD vs NCD. Body weight (A) and energy intake (B) 
during the 55 days of high fat feeding (HFD)  n=21, compared to the cohorts that were 
maintained on 78 days of normal chow feeding (NCD – chapter 4) n=24, following 
administration of either rAAV- GFP (green bars) N=11, or rAAV-D3 (black bars). Data are 
expressed as mean +/- SEM. ** P<0.01, *** P<0.001. 
A 
B 
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6.3.3 Body Composition Analysis 
Body fat percentage was calculated for each group and compared to the results obtained from 
chapter 5 (section 5.3.5). Body composition analysis indicated an 8.6% increase in fat mass 
as a percentage of total carcass mass in the rAAV-D3 group (29.2 +/- 5.0%) compared to the 
rAAV-GFP group (20.6 +/- 1.3%), which was a significant difference (P=0.05). Comparing 
these data from those obtained in chapter 5 (figure 5.7)  highlighted that rAAV-D3 treatment 
brought about a 10.2% higher body fat percentage when animals were fed HFD rather than 
NCD P=0.006) (Figure 6.5). 
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Figure 6.5: Body compostion on HFD vs NCD. Whole body composition was analysed 
following carcass dissolution. Body composition data from rAAV-D3 treated and rAAV-GFP 
control rats maintained on a HFD, n=16, were compared to the cohorts maintained on a 
normal chow diet (see figure 5.7) n=24. Data are expressed as fat mass (black shading) and 
lean mass (grey shading) as percentages of total body mass +/- SEM. * P<0.5) ** P<0.01. 
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6.3.4 Effect on Plasma HPT Axis Parameters 
No change was seen in plasma fT4 levels between rAAV-D3 (11.40 +/- 1.3 pmol/L) and 
rAAV-GFP (11.04 +/- 1.4 pmol/L). In addition, there was no change in plasma fT3 levels 
between rAAV-D3 (1.63 +/- 0.7 pmol/L) and rAAV-GFP (1.7 +/- 0.1 pmol/L) (Figure 6.6). 
 
Figure 6.6: Plasma levels of fT4 and fT3 were measured by RIA 72 days after bilateral iVMN 
injection of either rAAV-GFP (green bars) n=10, or rAAV-D3 (black  bars) n=11. fT4 and 
fT3 values are expressed as mean pmol/L +/- SEM. 
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6.3.4.1 Plasma free thyroxine on HFD v NCD 
Plasma thyroid hormone measurements taken from HFD-maintained rats were compared with 
those from NCD-maintained rats to assessthe effect of diet on systemic thyroid hormone 
homeostasis. Plasma fT3 measurements were not significantly affected by diet (data not 
shown). However, a difference was detected in plasma fT4 measurements whereby HFD 
appeared to reduce plasma free T4 levels, despite them remaining within the reference range 
for this hormone (figure 5.7). 
 
Figure 6.7: Plasma levels of fT4 in HFD-maintained animals. rAAV-GFP – green bars 
(n=10), rAAV-D3 – black bars (n=11)) were compared with plasma fT4 levels in NCD-
maintained animals (rAAV-GFP – green bars (n=11), rAAV-D3 – black bars (n=13)). Data 
are expressed as mean pmol/L +/- SEM). *** P<0.001 
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6.3.6 Effect on Plasma Leptin 
Plasma leptin levels were also measured by RIA. The rAAV-D3 group was not statistically 
higher plasma leptin (26.17 +/- 3.3ng/ml) than the rAAV-GFP group (23.04 +/- 3.4ng/ml) 
(P=0.4) (Figure 6.8). 
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Figure 6.8: Plasma leptin levels were measured by RIA 72 days after bilateral intra-VMN 
injection of rAAV-GFP (green bar) n=10 or rAAV-D3 (black bar) n=11. Values are shown as 
ng/ml +/- SEM. 
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6.3.7 Effect on Interscapular BAT 
BAT tissue mass (mg) from the interscapular pad was analysed according to rat body weight 
(g). The mass of this BAT pad in the rAAV-D3 group (1.14 +/- 0.1 mg/g) was not 
significantly different to that of the rAAV-GFP group (1.23 +/- 0.09 mg/g) (P=0.38) (Figure 
6.9). 
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Figure 6.9: Interscapular BAT mass. Interscapular BAT pad was dissected and weighed 72 
days after bilateral intra-VMN injection of 1µl rAAV-GFP (green bar) N=10, or 1µl rAAV-
D3 (black bar) n=11. Data are expressed as mean +/- SEM for both groups. 
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The mRNA levels of markers of adrenergic stimulation were quantified in the dissected BAT 
pads. UCP1 expression was 1.17 (+/- 0.09) fold higher in the rAAV-D3 treated group 
(P=0.12). Dio2 expression was 1.42 (+/-0.17) fold higher in the rAAV-D3 treated group 
(P=0.07). However, neither of these changes were statistically significant (figure 6.10). 
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Figure 6.10: BAT UCP1 and Dio2 mRNA levels. Ucp1 and Dio2 mRNA were quantified in 
100mg dissected interscapular BAT, 72 days after injection of either rAAV-GFP (green bars) 
n=10 or rAAV-D3 (black bars) n=11. 
184 
 
6.3.8 Hypothalamic Expression Profile on HFD 
Dissected hypothalami were analysed by qPCR for the expression of several genes that are 
important for hypothalamic function. Fasn mRNA was detected as being expressed higher in 
rAAV-D3 treated animals compared rAAV-GFP controls (5.5 fold +/- 1.8 AU), which was 
significant by 1-way ANOVA (P=<0.001) (figure 6.11). 
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Figure 6.11: Hypothalamic mRNA levels for Npy, Pomc, Agrp, Acca, Fasn, Ampkα and Ucp2 
were quantified by qPCR 72 days after bilateral injection of rAAV-GFP (green bars) n=11 or 
rAAV-D3 (black bars) n=10. Data are expressed as fold change +/- SEM. *** P<0.001 
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6.3.9 Hypothalamic Fatty Acid Metabolism on HFD versus NCD 
The mRNA levels of hypothalamic Acca and Fasn in rAAV-GFP and rAAV-D3-treated 
animals were compared between studies on HFD and NCD. Acca mRNA was significantly 
upregulated on a HFD in both rAAV groups compared to both groups on a NCD (P=<0.001), 
but was not significantly affected by rAAV-D3 treatment (Figure 6.11A). 
Fasn mRNA was significantly upregulated (7.6 fold +/- 2.4 AU) in rAAV-D3 treated rats fed 
a HFD compared to rAAV-D3 treated rats fed a NCD (P=0.009). This upregulation of 
hypothalamic Fasn in rAAV-D3 treated rats maintained on a HFD (5.8 fold +/- 1.9 AU) was 
significantly greater than the upregulation of hypothalamic Fasn in rAAV-GFP controls 
maintained on a HFD (1.1 +/- 0.2 AU) (P=0.01) (Figure 6.11B). 
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Figure 6.12: A comparison of Acca and Fasn mRNA levels in the NCD cohorts (RNA samples 
from Chapter 5) n=24 versus rats fed a HFD n=21, following administration of rAAV-GFP 
(green bars) or rAAV-D3 (black bars). Data are expressed as mean +/- SEM for both groups. 
* P<0.05, ** P<0.01, *** P<0.001. 
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6.4 Discussion 
Work in this chapter was designed to examine the response of rAAV-D3 treated rats to the 
challenge of a HFD. Data presented in Chapter 5 (sections 5.3.2 and 5.3.3) demonstrated that 
rAAV-D3 treatment on a normal chow diet causes a reduced rate of body weight gain without 
any noticeable difference in food intake. Assuming that the principal effect of rAAV-D3 
treatment is a hypermetabolic one, the introduction of a HFD would have been expected to 
accentuate any significant metabolic parameters, such as cumulative body weight gain and 
food intake. 
The initial stage of the experiment saw a similar phenotypical presentation to cohorts of 
chapter 5. During the initial 17 days post injection of rAAV, whilst maintained on a NCD, 
body weight gain was beginning to show a trend for reduction in the rAAV-D3 treated group, 
an effect independent of food intake. After the introduction of HFD, these animals 
instantaneously gained more weight than rAAV-GFP controls and consistently consumed a 
higher energy intake throughout the course of the investigation. This reversal of the body 
weight trend is clearly visible in figure 6.2, which shows a crossing-over of the body weight 
curves following the replacement of NCD with HFD. 
When the energy intake and body weight gain data were analysed per day of high fat feeding, 
it was witnessed that rAAV-D3 treatment significantly increased both parameters in 
comparison to rAAV-GFP controls. Furthermore, both parameters were significantly 
increased in rAAV-D3 treated animals on a HFD compared to rAAV-D3 treated animals on a 
NCD, an effect not observed in the control (rAAV-GFP) group. Following termination of the 
experiment, body composition analysis of the rat carcasses highlighted a similar presentation 
to that of the body weight and food intake data when compared to the data from the NCD 
study in chapter 5. There was a significant increase in the body fat percentage of rAAV-D3 
treated animals both when compared to controls and when compared to rAAV-D3 treated 
animals on a NCD. These data all suggest that rAAV-D3 treatment modulates the 
consumption and deposition of food, but only when maintained on a HFD. 
The phenotype of BAT dissected from rats in this chapter was investigated by weighing the 
interscapular pads and quantifying Ucp1 and Dio2 mRNA by qPCR. The interscapular BAT 
mass was not significantly increased by rAAV-D3 treatment on a HFD, unlike rAAV-D3 
treatment on a NCD. It is unclear why this effect was not witnessed in this experimental 
cohort; however, a common feature of obesity in lab rodents is white adipose infiltration of 
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BAT pads, which may have varied between the two treatment groups. This could be 
investigated histologically, whereby white and brown adipocytes could be readily 
distinguished, with a relative percentage estimated. The mRNA levels of Ucp1 and Dio2 in 
BAT demonstrated a trend towards upregulation following rAAV-D3 treatment, however 
neither was significant. This may too have been affected by differential white adipose 
infiltration of the interscapular BAT pad, which could have skewed the relative mRNA 
levels. 
Alternatively, there may be additional disparity in these mRNA levels due to modulation of 
UCP1 and D2 expression by the HFD, which reportedly downregulates these enzymes in 
BAT (Araujo et al., 2010). This may have suppressed the increases in the expression of these 
enzymes which were previously witnessed on a NCD. Additionally, this effect of rAAV-D3 
on energy expenditure could have been affected by the change in diet at a transcriptional 
level, given the finding that the potency of a selective TR agonist is attenuated by HFD 
(Castillo et al., 2010). In this case, the effects of unliganded TR in the VMN could have been 
disrupted by HFD, thus abolishing the previously witnessed activation of BAT UCP1. 
Plasma fT3 and fT4 measurements once again demonstrated that rAAV-D3 treatment in the 
VMN does not affect systemic thyroid hormone homeostasis. Plasma hormone data collected 
from the cohort mainatained on a HFD were compared with those from animals maintained 
on a NCD. There was no significant difference in plasma fT3 concentrations. fT4 levels were 
found to be reduced by HFD, despite operating within the normal range. This could help 
explain the loss of effect of rAAV-D3 on BAT UCP1 expression, given that reduced fT4 
levels would decrease local T4 to T3 conversion (Bianco et al., 2002) which is important for 
UCP1 upregulation. 
Plasma leptin was measured by RIA and, despite the significant increase in body fat 
composition, the plasma concentration of leptin was not significantly affected. It has been 
shown that circulating leptin correlates with fat mass, and the ability to increase plasma leptin 
allows resistance to DIO (Surwit et al., 1997). The lack of a leptin response in the rAAV-D3 
treated group, despite weight gain, suggests that this treatment interferes with plasma leptin 
levels. An explanation could be found in a putative pathway of systemic leptin homeostasis in 
which sympathetic pathways are known to descend from the hypothalamus to white adipose 
tissue (Bartness et al., 2010, Buettner et al., 2008). At the level of the hypothalamus, LEPR is 
regulated by T3 in chicks (Byerly et al., 2009), whilst leptin exerts effects on hypothalamic 
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D2 expression (Coppola et al., 2005). Thus, rAAV-D3 treatment could have perturbed these 
pathways by dysregulating LEPR expression in the VMN and also by reducing the effects of 
leptin-induced T3 production, owing to chronic inactivation of T3. Over a long-term study, 
this may have influenced the sympathetic pathways descending to white adipocytes, thus 
rAAV-D3 could have perturbed chronic leptin secretion in these animals. 
qPCR analysis of the dissected hypothalami did not detect any changes in the mRNA levels 
of the neuropeptides Npy, Pomc or Agrp. Given the well established effect of T3 on the 
regulation of enzymes of fatty acid metabolism, in addition to the pronounced effect on food 
intake and body weight after the introduction of HFD, the expression of some key fatty acid 
metabolic enzymes was analysed. There were no differences detected in the hypothalamic 
mRNA levels of Acca or Ampkα (α-subunit), however a 5.8 fold increase in Fasn mRNA was 
observed in rAAV-D3 treated animals. 
In order to compare this with the chapter 5 cohort, cDNA libraries from the HFD-fed animals 
were assayed alongside cDNA libraries from the NCD-fed animals for Acca and Fasn mRNA 
levels. It was found that Acca mRNA was significantly increased in the hypothalami of both 
experimental groups on a HFD compared to on a NCD. This could be a physiological 
response to the increased exposure to circulating metabolic substrates, such as triglycerides, 
which would require processing by fatty acid metabolic pathways in hypothalamic neurones. 
The systemic status of both cohorts could be compared by measuring fasting plasma 
triglyceride and cholesterol levels in each group, using an automated enzymatic procedure. 
In order to ascertain whether FAS had been activated on a proteomic scale, the activities and 
protein levels of ACC and FAS would need to be measured. Following iVMN administration 
of rAAV-GFP or rAAV-D3, hypothalami would be dissected following cardiac perfusion 
with formaldehyde. In half of the cohorts, ACC and FAS protein levels could be measured by 
western blot, using specific antibodies for each enzyme. In the other half, ACC and FAS 
activity could be measured, according to cited protocols (Lopaschuk et al., 1994, Nepokroeff 
et al., 1975). 
The involvement of FAS would need to be scrutinised for it to be considered a key 
mechanistic player. There are well characterised inhibitors of FAS and ACC, such as C75 and 
TOFA, which have been used to investigate the role of FAS in the regulation of hypothalamic 
malonl CoA levels (Hu et al., 2003). This model could be applied to the findings of this 
chapter to analyse the effect of FAS on food intake. rAAV-D3 would be administered iVMN 
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to rats maintained on a HFD, before injecting C75 either centrally or peripherally to 
pharmacologically block FAS activation and monitor how this affects acute HFD 
consumption. This could then be repeated using TOFA (ACC inhibitor), to confirm that the 
effect is restricted to FAS. Finally, C75 and TOFA would be administered simultaneously 
under the assumption that any effect derived from the activation of FAS could be interrupted 
by inactivation of ACC (see figure 6.1). 
The data presented in this chapter, rather than substantiate the findings of the previous 
chapter, have inadvertently added weight to an emerging concept that T3 influences 
hypothalamic control of appetite and energy expenditure via its modulation of neuronal fatty 
acid metabolism. It is logical that T3, which exerts potent effects on metabolic cycles, would 
affect the enzymes involved in fatty acid metabolism when its activity is altered. However, 
the mode by which these neuronal metabolic cycles influence affect behavioural aspects such 
as food intake and energy expenditure are still largely unknown. It is likely that this mode 
involves an interaction between many players in the metabolic pathways web, rather than an 
isolated enzyme, although this chapter suggests that if key metabolic enzymes are important 
in the neuronal control of appetite, FAS should be included as one of them. 
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Chapter 7 
Final Discussion and Conclusions 
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Thyroid hormones are potent stimulators of the metabolic rate, although some symptoms of 
hypothyroidism and hyperthyroidism are not explained by their direct effects on peripheral 
issues. There is growing evidence that T3 plays a prominent role in the hypothalamus in 
addition to its well defined effects on the HPT axis. Recent findings have identified that 
thyroid hormone regulates appetite, autonomic stimulation of hepatic glucose production and 
BAT thermogenesis, in part, via the hypothalamus without affecting systemic thyroid 
hormone levels (Klieverik et al., 2009, Kong et al., 2004, Sjögren et al., 2007). 
In this work the key deiodinases D2 and D3 have been exploited in conjunction rAAV to 
generate an experimental tool for the modulation of thyroid hormone activity. Using 
stereotaxic techniques, these deiodinases have been overxpressed in the VMN of male Wistar 
rats, which has never been attempted until now. The most significant findings in this work are 
that D3 overexpression in the VMN increases interscapular BAT mass and reduces body 
weight gain on a NCD, whereas it stimulates hypothalamic FAS expression and consumption 
of energy on a HFD. D2 overexpression was without a pronounced physiological effect, 
which may have been a product of its associated regulatory pathways. 
AAV was employed as a research tool in these investigations, despite the availability of a 
range of techniques for the manipulation of thyroid hormone levels, given its ability to 
provide prolonged periods of safe gene expression following a single neurosurgical session. 
The effects of rAAV-D3 treatment became apparent after a 21 day period, during which time 
the ssAAV vector was presumably being converted into a dsDNA expression cassette. This 
latency could have been avoided with the use of self-complementary AAV (scAAV), which 
is known to express more rapidly than ssAAV vectors. 
However, the apparent lack of a physiological effect during this 21 day period cannot be 
attributed to rAAV latency with absolute certainty, as it could simply be a reflection of the 
kinetics of this hypothalamic system, as opposed to the rAAV design. For example, rT3 is a 
product of D3 metabolism, known to exert effects on neuronal plasticity. It is possible that 
increased levels of rT3 were taking effect much sooner, and the 21 day period of „latency‟ 
was actually due to the slow development of neuronal rewiring at the site of rAAV-D3 
injection. 
This could be ascertained by generating and administering a scAAV-D3 vector, which should 
theoretically increase D3 activity more rapidly. Alternatively, D3 enzyme activity could be 
measured and compared in hypothalamic samples that had been dissected at various time 
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points from the first week up to the third week post-injection of rAAV-D3. This would help 
determine the potency of the effect and kinetics of the vectors used. 
The rAAV vectors used in the investigations contained a CMV promoter and a downstream 
WPRE element to maximise mRNA accumulation. There is a range of constitutive promoters 
that can be used in expression cassettes, which has been extensively reviewed (Fitzsimons et 
al., 2002). However, the precise location of where the rAAV vectors have transduced and 
expressed their transgenes is not known. The use of an endogenous promoter, such as 
neurone-specific enolase (NSE) would have ensured that rAAV expression was confined to 
neuronal cells without additional expression in astrogial cells. This would have augmented 
the neurone-specificity of the AAV serotype 2, thus providing a useful model for 
characterising the role of T3 within neuronal networks of the hypothalamus. 
The two plasmid transfection system utilised in production of the AAV vectors is a reliable 
method of producing research-grade and clinical-grade vector stocks with minimal 
contamination by adenovirus (Grimm et al., 1998). The dot-blot method for quantifying the 
viral particle number highlighted that a high yield was obtained for each vector utilised, of 
which the infectious titre is estimated to be greater than sixty-five percent. However, the fact 
that the infectious titre is unknown means that it is also impossible to know the exact number 
of transducing particles that have been administered to the rat VMN. Injecting more 
infectious particles per neurone into one rAAV treatment group than another may have 
experimental implications in terms of the neuronal response to the infectious load. Therefore, 
the effect of this disparity in infectious titre cannot be ignored when analysing the data. 
The evaluation of deiodinase enzyme activity data gave some interesting conclusions as to 
the efficacy of each treatment. In the case of rAAV-D2, it was shown that this vector was 
efficient in increasing D2 activity, which was approximately ten-fold higher than that of 
control (rAAV-GFP) samples. This was comparable with a transgenic approach to 
overexpressing D2, which achieved an increase by 3 orders of magnitude (Pachucki et al., 
2001). However this study also failed to produce physiologically significant effects. The 
ability to stimulate D2 activity by viral gene transfer is an important finding in itself, given 
that this could be readily used in other lines of thyroid research. However, the rAAV-D2 
virus would need further characterising for efficacy, in terms of its ability to increase the 
local T3 pool in vivo, before confirming this. The lack of physiological effects in iVMN 
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rAAV-D2 treated animals could be attributed to the level of D3 activity detected in these 
samples, which would have had a neutralising action. 
In the case of rAAV-D3, a number of analyses were carried out, each with different 
outcomes. Initially, the ability of the pTR-CGW-D3 packaging construct to increase D3 
activity in vitro was investigated in JEG3 cells, which were transfected with the plasmid. This 
investigation showed that D3 activity was stimulated approximately ten-fold by pTR-CGW-
D3 treatment which indicated that the construct was effective. 
The ability of rAAV-D3 to increase D3 activity in vivo was investigated by administering a 
dose of this vector into rat VMN before analysing enzyme activity in whole hypothalamic 
blocks. In this case, mean D3 activity in rAAV-D3 treated samples was not significantly 
greater than the control treatment (rAAV-GFP), with both detected at around 10 – 12 
fmol/min/mg. A subsequent investigation saw a repeat of the treatment procress, although in 
this case MBH punch biopsies were taken to determine the level of D3 activity within a more 
discrete location, to rule out the influence of „extra-VMN‟ hypothalamic structures. In this 
case, D3 activity was detected at the same level (around 20 fmol/min/mg) in all three 
treatment groups (rAAV-GFP, rAAV-D2, rAAV-D3), which was approximately double that 
of a non-transduced control sample. With D3 activity being much higher in MBH biopsies, it 
could be concluded that the source of this inflammation was within this hypothalamic region, 
which indicates that it was a direct response to the treatment. 
It was hypothesised that the induction of D3 enzyme activity in all three groups was the result 
of an inflammatory pathway, stimulated by the rAAV particles and/or the stereotaxic 
injection process (Boelen et al., 2005, Li et al., 2001). This would require investigation before 
proceeding with any repeats of this study. This investigation would involve iVMN stereotaxic 
surgery on rats with treatment groups of saline, rAAV-GFP, rAAV-D3, sham-injection or 
non-injection. MBH punch biopsies would then be taken from these animals and analysed for 
D3 enzyme activity. A comparison could then be made to determine the cause of elevated D3 
activity, or if it has been elevated at all. 
The CNS is an essential target of endocrine and humoral factors that regulate metabolic 
function. Hormones such as insulin, glucagon-like peptide 1 and corticosterone are known to 
modulate energy homeostasis through direct effects on their respective target tissues. The 
indirect effects of these hormones on metabolism via hypothalamic feedback pathways are 
well established, although their direct innervation of targets via the hypothalamus is now 
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receiving closer attention. This dual mechanism of hormonal regulation in energy 
homeostasis provides a new perspective from which we can approach neuroendocrinology 
and underlines the complexity of these processes. 
D3 overexpresion by the rAAV cassette resulted in a clear increase in Dio3 mRNA several 
weeks after surgery. This precipitated a reduction in body weight gained by the rAAV-D3 
treatment group, despite their food intake matching that of the control group. This 
presentation is indicative of increased energy expenditure. A marker of sympathetic activity 
and energy expenditure in laboratory rodents is UCP1 expression in BAT. The interscapular 
BAT pads of rAAV-D3-treated animals were significantly larger complete with increased 
levels of Ucp1 mRNA. This suggests that D3 upregulation in the VMN stimulates 
sympathetic stimulation of interscapular BAT. 
The mechanism of how rAAV-D3 influences rat physiology is some way from being 
determined and further investigations would begin at the source of the effect, in the 
hypothalamus. Primarily, the hypothalamic concentrations of T3 and T4 would need to be 
measured following iVMN rAAV-D3 treatment, in order to have an accurate profile of local 
thyroid hormone status. However, more important questions arise, such as; is the primary 
effect a genomic one and, if so, where exactly in the genome is this effect taking place? Both 
of these questions could be addressed with the use of „ChIP-seq‟, which has been reported 
(Schmidt et al., 2008). In such an experiment, antibodies raised to TRα and TRβ would be 
used to immunoprecipitate genomic DNA from hypothalamic tissue. These TR-DNA 
precipitates would then be analysed by high-throughput sequencing to enable a genome-scale 
analysis of the effects of the TR system in the rAAV-D3 iVMN model. This would provide 
data on how rAAV-D3 treatment affects the number of TR-DNA events, in addition to a 
comprehensive analysis of the genomic loci involved in any effects. 
As the next mediator downstream of the hypothalamus in the putative pathway, the level of 
SNS drive to BAT would need to be examined. This could be achieved through disruption of 
BAT sympathetic innervations, either surgically or chemically, using 6-OHDA (6-
hydroxydopamine). The concept of impaired T3 availability leading to increased BAT 
activity fits in line with work employing a mutant TRα, which blocks T3 signalling (Sjögren 
et al., 2007, Pelletier et al., 2008). However, conclusions are complicated by recent findings 
that T3 administration induces the same response in Sprague Dawley rats (López et al., 
2010), suggesting that some species variation may exist in the effects of T3 in this pathway. 
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The intriguing effect witnessed in chapter 6 asks the question of why rAAV-D3 treatment 
only increased energy intake and Fasn mRNA levels when animals were maintained on a 
HFD. There are a number of potential explanations for this which could be investigated. 
It is possible that rAAV-D3 treatment in the VMN interferes with hypothalamic fatty acid 
sensing thus leading to the inappropriate increase in HFD consumption. This could be 
examined by repeating the investigation, up to the point of HFD introduction, and instead 
looking at how the animals respond to either peripheral injection or oral gavage of fatty acids 
in terms of refeeding following a fast. Alternatively, HFD could be supplied at varying 
percentages of cholesterol and fats, which would provide a means of developing a „dose-
response‟ profile of rAAV-D3-mediated lipo-hyperphagia. 
An alternative explanation could be that rAAV-D3 treatment induces a hedonic preference 
for high energy foods. This would require a more simple investigation whereby rAAV-D3 
treated animals are provided with a choice between NCD and HFD during the study, with the 
resulting profile compared to rAAV-GFP controls. However, most animal models would 
demonstrate an overriding preference for the HFD, which would complicate the detection and 
interpretation of any noticeable effects. 
The pronounced upregulation of ACC on HFD is a novel and potentially important finding. 
Studies involving DIO mice have shown that levels ACC and FAS mRNA in adipose tissue 
and the liver are not significantly affected by HFD treatment (Kohsaka et al., 2007). Mice fed 
a 55% fat diet displayed basal activity of ACC in muscle tissue with an attenuated response 
of hypothalamic AMPKα to leptin administration (Martin et al., 2006). This reduced activity 
of AMPKα could potentially have a disinhibitory effect on hypothalamic ACC, which goes 
some way to supporting the effect observed in this thesis. 
The upregulation of FAS on a HFD is an interesting point of discussion. The notion of FAS 
stimulating food intake is supported by several investigations, whereby the mechanism is 
thought to be based on its net reduction of hypothalamic malonyl CoA levels, which then 
leads to appetite stimulation (Hu et al., 2003). It was recently reported that peripheral T3 
administration to Sprague Dawley rats stimulates FAS expression 1.3 fold to increase food 
intake on a normal chow diet (López et al., 2010). rAAV-D3 treatment would be expected to 
reduce local levels of T3, therefore some disparity occurs between the findings of this chapter 
and those of Lopez et al. However, there a number of differences between the studies, such as 
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the strains of Wistar rat used in the experiments, the method of hormone manipulation, the 
diets used in the investigations and the duration of their chronic investigations. 
The role of FAS in the regulation of food intake has not been fully characterised, as 
demonstrated by some findings that contradict the notion that this enzyme stimulates food 
intake. It has been demonstrated that FAS is downregulated in the hypothalamus in response 
to a fast (López et al., 2008). Additionally, the orexigenic gut hormone, ghrelin, was found to 
increase food intake by reducing FAS mRNA levels in the VMN as a direct effect of AMPK 
activation. Furthermore, the regulation of FAS by T3 is generally thought to be stimulatory 
(Sul and Wang, 1998), although it has also been reported that it can be inhibitory (Kameda, 
1995). Therefore, the role and regulation of FAS in the hypothalamus are not completely 
understood and further work is required to develop our understanding. 
In order to bring the findings of this thesis together to a unifying mechanism, the question 
needs to be asked whether or not the effects observed in chapter 5 can be married with those 
of chapter 6. Are the effects on appetite and energy expenditure acting simultaneously on a 
HFD or is there a molecular pathway that is affected by HFD? However, there are at least two 
potential mechanisms which link the effects witnessed in these studies, which include an 
interference with central leptin signalling and crosstalk between the TR and other nuclear 
hormone receptors. 
Leptin sensitivity depends on the expression of LEPR on the neurones of hypothalamic 
nuclei, where it is down-regulated by T3 (Byerly et al., 2009). Therefore, D3 overexpression 
would be expected to have a positive effect on LEPR expression which could explain the 
perceived stimulation of energy expenditure in chapter 5. It has been reported that HFD 
disrupts the nutritional regulation of LEPR expression in rodents (Sahu et al., 2002). With 
this considered, it is possible that the introduction of a HFD in chapter 6 was responsible for 
the lack of effect on BAT activity. This then raises the question of why these animals then eat 
more on a HFD. 
It is generally accepted that, whether via direct hypothalamic stimulation or secondary to its 
effects on metabolism, T3 leads to appetite stimulation, although the roles of other thyroid 
hormone molecules may also be relevant to physiology. It has recently been reported that the 
central administration of the thyroid hormone derivative 3-iodothyronamine (T1AM) 
stimulates food intake (Dhillo et al., 2009). It has also been shown that rT3 can induce 
changes in brain function by affecting neuronal plasticity (Bassett et al., 2003). The findings 
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of this chapter may highlight a role for D3-generated thyroid hormone metabolites whose 
concentrations affect HFD intake and sympathetic outflow to BAT. It could be hypothesised 
that D3-generated thyroid hormone derivatives have stimulated feeding whilst the 
transcriptional effects on LEPR have been blocked by the state of DIO. This could be 
investigated in further studies by iVMN administration of rT3 in diet-induced obese models. 
A molecular endocrinological explanation for the observed effect could involve the 
phenomenon of TR crosstalk with other nuclear receptors. It is recognised that TR interacts 
with transcription factors which respond to nutrient signals, such as the PPARs, SREBPs, 
LXRs and more (Liu and Brent, 2010). Furthermore, dysregulation of lipid metabolism by the 
unliganded form of TR, which would theoretically be increased by D3 overexpression, has 
been reported (Araki et al., 2009). The mechanisms for these interactions are diverse and 
involve competition for the common RXR heterodimer, response-regions on the target gene 
and recruitment of transcription factors. 
The SREBP-1c isoform is regulated by TR and is known to direct fatty acid synthesis, owing 
to the presence of a SRE on the Fasn and Acca genes. SREBP1c has been directly linked to 
the stimulation of FAS in primary culture of hypothalamic neurones as a response to insulin 
signalling (Kim et al., 2007). Given that SREBP1c is less active when lipid and sterol 
concentrations are increased, rats on a HFD would be expected to have FAS either 
downregulated or expressed at a basal level. However, on a HFD, FAS was expressed at a 
basal level in rAAV-GFP controls and significantly increased by rAAV-D3 treatment. This 
could indicate that alterations in TR signalling, brought about by D3 overexpression, 
somehow restore SREBP activation of the Fasn gene, in an environment of increased lipid 
availability, through nuclear crosstalk. 
In addition to SREBP signalling, PPARs have also been implicated in the regulation of genes 
in combination with TRs. Glucose-stimulated insulin secretion (GSIS) is affected by both 
PPARα signalling and TR signalling. Both PPARs and TRs compete for their common RXR 
heterodimer prior to their interactions with glycolytic enzymes in pancreatic islets, to regulate 
insulin secretion (Sugden et al., 2001, Garcia-Flores et al., 2001). It has been reported that 
PPARα signalling, induced by a HFD, stimulates GSIS in euthyroid rats, but inhibits GSIS in 
hyperthyroid rats (Holness et al., 2008). This suggests that the reversal of the rAAV-D3 
phenotype by HFD could be due to a molecular interaction between PPAR and TR signalling. 
199 
 
There are other nuclear receptors that are affected by both HFD and TR. The regulation of 
energy homeostasis by photoperiod in rodents is dependent on the expression of the „clock‟ 
genes, such as Clock and Bmal1 in the hypothalamic suprachiasmatic nucleus (SCN). The 
SCN conveys signals to hypothalamic nuclei and the pineal gland to induce changes in 
energy homeostasis. A well characterised pathway involves photoperiodic stimulation of 
melatonin signalling which regulates hypothalamic Dio2 expression (Revel et al., 2006, 
Yasuo et al., 2007). It has been reported that HFD disrupts circadian rhythms due to 
dysregulation of the „clock‟ genes, which alters melatonin signalling and hypothalamic 
energy circuits (Kohsaka et al., 2007). Therefore, it is possible that the effect of rAAV-D3 is 
perturbed by HFD due to these interactions with rodent circadian rhythms. It has been 
reported that melatonin administration can attenuate body weight gain on a HFD (Puchalski 
et al., 2003). Therefore, if the effects of rAAV-D3 on NCD and HFD are attenuated by 
melatonin administration, this could highlight circadian disruption as a potential mechanism 
for the effects of this recombinant virus. 
The findings of this thesis help further our understanding of the neuroendocrine role of 
thyroid hormones. For this, a tool was developed for the manipulation of local thyroid 
hormone homeostasis through viral gene transfer of the iodothyronine deiodinases. 
Furthermore, rAAV-D2 treatment produced a convincing increase in D2 activity, which has 
previously proved an arduous challenge. It has long been known that T3 plays an important 
role in the CNS, particularly in the hypothalamic pathways that influence the metabolic rate, 
although the specific mechanisms remain largely unclear. The key findings of this thesis are 
twofold: thyroid hormone influences the sympathetic nervous system through direct 
interactions with the hypothalamus, independent of systemic thyroid hormone tone; and 
stimulates the consumption of a high fat diet via transcriptional regulation of neuronal fatty 
acid metabolism. 
With respect to the controversy surrounding the role of T3 in hypothalamic energy circuits, 
these key findings fall into some key points of discussion. 
In relation to the effect highlighted in chapter 5, in which D3 stimulated BAT activity, this 
supports the findings which suggest that negative T3 signalling increases the BMR (Sjögren 
et al., 2007, Pelletier et al., 2008). However, as highlighted in chapter 1.7.5, this contradicts 
findings which state that positive T3 signalling stimulate the BMR (López et al., 2010). 
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Regarding the effect of T3 on appetite, it has previously been demonstrated that T3 promotes 
feeding (Kong et al., 2004, López et al., 2010, Ishii et al., 2008) although a uniform view on 
how this comes about could not be made. The findings of chapter 6 indicate that T3 
inactivation promotes consumption of a HFD which, along with other reports (Klieverik et 
al., 2009, López et al., 2010), contradicts those findings that suggest that T3 stimulates 
appetite.  
The findings in chapter 6, which suggest that FAS expression is increased by D3 in the VMN, 
further contradict the findings of Lopez et al who report that T3 stimulates FAS expression. 
Furthermore, Lopez et al reported that T3-induced FAS mediate effects on energy 
homeostasis by modulating the BMR, without effects on appetite, which is the exact opposite 
phenotype to that presented in chapter 6. 
This controversy of findings in the area further increases the opacity of our understanding of 
these processes and necessitates further investigations. The common finding is that T3 
influences the function of the hypothalamus, both in terms of appetite regulation and the 
setting of the body‟s metabolic rate, and this thesis supports new evidence that neuronal fatty 
acid metabolism is involved. The disparities between publications in how T3 achieves this 
could be products of the various species of animal models used for these investigations. 
Alternativey, it could suggest that the regulation of energy homeostasis by T3 is an extremely 
complex process, affected significantly a number of temporal and environmental factors, such 
as husbandry techniques, dietary sources, housing conditions etc which may differ 
significantly across research institutions. Given the range of physiological pathways that T3 
influences and is influenced by, it is unlikely that this hormone transmits a single, uniform 
effect in a system as complex as the hypothalamic energy circuits, let alone systemic 
metabolism. 
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Appendix I: List of Solutions 
3M Alcoholic KOH solution:  Add 39 g KOH pastels to 200 ml 65 % ethanol. 
Amasino wash buffer: Mix 250 ml 1M Na phosphate buffer, 2 ml 500 mM EDTA, and 100 
ml 20 % SDS with 650 ml GDW. 
Denaturing solution (RNA) (Denat):  Add 300μl of 40% formaldehyde and 100μl of 
20XMOPS to 1ml of formamide. 
0.5M ethylenediaminetetra-acetic acid (EDTA):  In 800ml autoclaved GDW, dissolve 
186.1g C10H14H2O8Na2.2H2O and adjust to pH 8.0 with 1M NaOH. Make up to 1L with 
GDW. 
4% Formaldehyde solution: Dissolve 100ml 40% formaldehyde in 1L GDW. 
Gel loading buffer: mix 3.125 ml 80 % glycerol, 50 ul 0.5 M C10H14H2O8Na2.2H2O and 
6.075 ml GDW, add 10 mg orange G. 
10% glycerol in GDW: Add 1ml glycerol to 9ml of GDW 
GTE: Mix 2.5ml 1M Tris-HCl, pH 8.0, 2ml 0.5M C10H14H2O8Na2.2H2O and 5ml 18% 
glucose and top up to 100ml. Sterilise by passing through a 0.2μm filter. 
Hybridisation buffer: dissolve 0.5 g dried milk powder in 48 ml GDW and 0.5 ml 500 mM 
EDTA. Add 25 ml 1 M Na phosphate, 25 ml 20 % SDS, 1 ml 2.5 mM ATA. 
Hybridisation buffer for oligo dT probing: dissolve 0.2 g milk powder in 75 ml GDW and 
25 ml 20X SSPE at 37 ºC. Add 200 ul nonidet and put on ice to allow Nonidet to dissolve. 
HBS Buffer: 1.36M NaCl, 0.05M KCl, 0.007M Na2HPO4.2H20, 0.2M HEPES, 0.125M 
glucose passed through a sterile filter unit. 
1x HEBS buffer: 1.36M NaCl, 0.05M KCl, 0.007M Na2HPO4.2H20, 0.2M HEPES, 0.125M 
glucose 
Kemteck Buffer: 22.4g Na2HPO4, 9.96g NaH2PO4, EDTA 14.8g, Thimersol 1g, 30% BSA 
26.6ml. Made up to 4L. 
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LB (amp): Dissolve; 10 g Bacto-tryptone, 5 g Bacto-Yeast Extract, 5 g NaCl in 800ml GDW. 
Add 200µL 5N NaOH to achieve pH 7.5 and make up to 1L before autoclaving. When LB 
has cooled to room temperature, add 2ml of 50mg/ml sterile ampicillin solution per litre of 
LB. 
LB(amp) plates: Take 1L of prepared LB, pH 7.5, and add 30g bacto-agar per litre of LB. Mix 
the contents and autoclave. When LB has cooled to ~40°C, add 2ml of 50mg/ml sterile 
ampicillin solution per litre of LB and mix. Pour ~20ml LB-agar into each petri dish before 
flaming each one to remove bubbles. 
SOB: Dissolve; 20g Bacto-tryptone, 5g Bacto-yeast extract, 0.5g NaCl in 800ml GDW. 
Adjust to pH 7.0 with 5M NaOH. Before use, add 5ml of 2M MgCl2. 
20x MOPS: Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g sodium 
acetate, 7.4g C10H14H2O8Na2.2H2O and 2.5ml formaldehyde to 800ml GDW. Add 833µL 
3M KC. Adjust to pH 7.0 with 10M sodium hydroxide and make up to 1L before autoclaving.  
1x PBS: In 800ml deionised water, dissolve: 8g of NaCl, 0.2g of KCl, 1.44g of Na2HPO4, 
0.24g of KH2PO4. Adjust pH to 7.4 before making up to 1L volume. 
PE Buffer: 100 mM phosphate buffer containing 2 mM EDTA and 50mM DTT. Adjust to 
pH 8.0. 
Phosphate Buffer (RIA buffer): 48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g 
C10H14H2O8Na2.2H2O, 2.5g NaN3 were dissolved in 5L GDW, that had been boiled and 
allowed to cool, the pH was measured to confirm it was 7.6 ± 0.1 and the buffer was stored at 
4˚C. 
3M potassium acetate: Dissolve 294.4g CH3COOK in 500 ml GDW, add 115 ml glacial 
acetic acid and GDW up to 1 L. 
20mg/ml proteinase K: Dissolve 20mg for every 1ml GDW and store at -20°C. 
Sephadex G50: Add 8g fine grade Sephadex G-50 beads (diameter: 20-80μm) (Sigma), 2ml 
100x TE and 0.1ml 20% SDS to 200ml GDW and autoclave to expand beads. 
3M sodium acetate, pH 5.2: Dissolve 246.1g CH3COONa in 800ml a/c GDW, adjust to pH 
5.2 with glacial acetic acid and make up to 1L with GDW   
220 
 
5M sodium chloride: dissolve 292.2 g NaCl in 1 L GDW. 
20% sodium dodecyl sulphate (SDS): Add 200g SDS to 800ml a/c GDW, heat to 60˚C 
while stirring. Allow to cool and make up to 1L with GDW. 
Solution A: 10mM Tris/HCl pH8.0, 10mM MgCl2, 10µg/ml DNaseI 
Solution B: 10mM Tris/HCl pH8.0 100mM NaCl 10mM EDTA 0.5% SDS 
20x SSC:  Dissolve 1.753g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 700ml 
GDW, adjust to pH 7.7 with 10M NaOH and make up to 1L with GDW. 
20x SSPE: Dissolve 210.4g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in  
700mls GDW, adjust to pH 7.7 with 10M NaOH and make up to 1L with GDW. 
30% sucrose solution:  Dissolve 300g sucrose in 1L GDW. 
50x TAE: Dissolve 242g Trizma base in 843ml GDW and mix in 57ml glacial acetic acid 
and 100ml 0.5M C10H14H2O8Na2.2H2O. 
100x TE: Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml and 
adjust pH 7.5 with hydrochloric acid. Make up to 1L. 
TES: 50mM Tris-HCl, pH 8.0, 50mM sodium chloride, 5 mM EDTA 
Universal wash buffer: mix 10 ml 20 % SDS and 10 ml 20X SSPE with 980 ml GDW. 
Buffer R: Contains; 40mM Pipes buffer pH 7.6, 1.5mM DCHBS, 17.5mM magnesium-ions. 
Reagent R: Contains; 0.4mM aminophenazonel, 1mM ATP, glycerol-kinase  > 0.4 U/ml, 
glycerol-3-phosphate oxidase > 1.5 U/ml, peroxidase > 0.5 U/ml. ascorbic acid oxidase > 7.0 
KU/l. 
Dio2 Oligos:  NCBI Ref: NM_172119.2; Location: 5‟  - 106 – 1060 - 3‟ 
5‟AGCTACCGGTGAGGCAATGGGATTCAGTTG 
  3‟AGCTGGATCCTGACTGGGGAAGCAGAGTGC 
Dio3 Oligos: NCBI Ref: NM_017210.3; Location: 5‟ - 28 – 1518 - 3‟ 
5‟GCTGGATCCTGGTGGTCGGAGAAGGTGAA 
  3‟GCTTGTACATACTTTAGGCGCTGTTTCGA 
SECIS Oligos: NCBI Ref: NM_172119.2; Location: 5‟ - 5051 - 5651 - 3‟ 
5‟AGCTACCGGTAACAAGACTGCTCACGCAAG 
  3‟AGCTTGTACATGGACACACGTGTTCTCAGT 
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Appendix II: List of Suppliers 
Advanced Biotechnology Centre, Imperial College, London, UK 
Animalcare Limited, Dunnington, York, UK 
Applied Biosystems, Warrington, UK 
ATCC, Middlesex, UK 
Bright Instrument Company, Huntingdon, Cambridgeshire, UK 
Campden Instruments, Lougborough, UK 
Charles River, Bicester, UK 
Clark electromedical instruments, Pangbourne, UK 
Crystal Chem Inc, Illinois, USA 
Eppendorf, Hamburg, Germany 
Fisher Scientific UK, Loughborough, Leicestershire, UK 
GE Healthcare, Little Chalfont, Buckinghamshire, UK 
Harvard Appuratus, Kent, UK 
Helena Biosciences, Sunderland, Tyne and Wear, UK 
Invitrogen Life Technologies, Paisley, UK 
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